Methods for improving nucleic acid sequencing quality by eliminating nucleic acids with deaminated bases from a library, and sequencing methods for complex and concatemer binding of primer polymerase and labeled probes

CN123036388APending Publication Date: 2026-11-03ELEMENT BIOSCIENCES INC
View PDF 11 Cites 0 Cited by

Patent Information

Application Number
CN202580022151.3
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-06-20
Filing Date
2025-01-29
Publication Date
2026-11-03

AI Technical Summary

Technical Problem

Existing multinucleotide sequencing technologies suffer from problems such as poor base interpretation and low signal-to-noise ratio, leading to increased sequencing costs.

Method used

By using a clamp to capture primers and contact them with linear library molecules, immobilized open-circular library molecules are generated. Deaminated nucleotide bases are then treated with glycosylation enzymes and lyases, followed by rolling circle amplification and sequencing, which reduces the number of deaminated nucleotide bases and improves sequencing quality.

Benefits of technology

It improved sequencing quality scores, reduced base interpretation errors, and enhanced the signal-to-noise ratio and overall sequencing efficiency of sequencing data.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123036388A_ABST
    Figure CN123036388A_ABST
Patent Text Reader

Abstract

The present disclosure provides methods for reducing sequencing errors, comprising one or any combination of: (i) removing deaminated bases in any nucleic acid molecule throughout a library preparation workflow, including immobilized splints bound to the library, use of compression oligonucleotides, optionally with intervening sequences, forming a closed circular nucleic acid, use of glycosylase and lyase activity to create a gap at a location with a deaminated base. The library can be sequenced using paired sequencing, such as dark sequencing and / or sequencing using multivalent labeling probes for forming affinity molecules and soluble primers and polymerase. Methods for sequencing concatemers, wherein the concatemer is contacted with a polymerase, a soluble primer, and a multivalent labeling molecule that forms a complex with the polymerase. Detecting a polymerase position and a nucleobase bound to the polymerase in the complex. These methods generate higher quality base calls during downstream sequencing workflows.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] Related applications

[0002] This application claims priority to and benefits from U.S. Provisional Application No. 63 / 626,912, filed January 30, 2024, and U.S. Provisional Application No. 63 / 661,989, filed June 20, 2024, the disclosures of which are incorporated herein by reference in their entirety.

[0003] Reference to electronic sequence listing

[0004] The contents of the electronic sequence list (ELEM-029_001WO_SeqList_ST26.xml; size: 108,120 bytes; and creation date: January 29, 2025) are incorporated herein by reference in their entirety. Technical Field

[0005] This disclosure provides compositions and methods for reducing C:G to T:A nucleotide base transitions in nucleic acid molecules, resulting in improved sequencing quality scores. Such compositions and methods can be applied to nucleic acid molecules to deaminate nucleotide bases and / or reduce erroneously introduced nucleotide bases in a nucleic acid manipulation workflow, wherein the workflow includes one or more of the following: fragmentation of the input nucleic acid; end repair of the double-stranded fragmented nucleic acid; non-template tailing of the double-stranded fragmented nucleic acid; attachment of adapters by ligation or PCR; PCR amplification; denaturation to generate single-stranded library molecules; circularization of the single-stranded library molecules; and / or immobilization of linear or circularized library molecules. Background Technology

[0006] Polynucleotide sequencing technology has applications in biomedical research and healthcare settings. Improved polynucleotide methods require enhanced surface chemistry, support-based polynucleotide amplification, and base interpretation. Currently, these elements create barriers in existing sequencing technologies, leading to throughput limitations, poor signal-to-noise ratios, and ultimately, increased costs associated with polynucleotide sequencing.

[0007] There is a need for novel multinucleotide sequencing methods with improved surface chemistry, support-based amplification, and base interpretation. This disclosure provides methods and compositions for improving multinucleotide sequencing by improving base interpretation and subsequently enhancing sequencing quality, such as sequencing quality scores. Summary of the Invention

[0008] In some aspects, this disclosure provides a method for reducing the number of nucleic acid library molecules carrying at least one deaminonucleotide base in a plurality of library molecules, the method comprising: providing a plurality of clip-on trap primers immobilized to a support, wherein each clip-on trap primer comprises a first portion and a second portion, wherein the plurality of clip-on trap primers have the same sequence, and wherein the density of the plurality of clip-on trap primers is 10. 2 Up to 10 15 / mm 2Between; the plurality of clip-capture primers are contacted with a plurality of linear nucleic acid libraries comprising a first subgroup and a second subgroup of linear library molecules, wherein the linear library molecules of the first subgroup carry at least one deaminated nucleotide base, and wherein the linear library molecules of the second subgroup lack deaminated bases, and wherein each of the plurality of library molecules is single-stranded and comprises: a universal adaptor sequence having a binding sequence for a first portion of a given clip-capture primer, a universal adaptor sequence having a binding sequence for a forward sequencing primer, a target sequence, a universal adaptor sequence having a binding sequence for a reverse sequencing primer, and a binding sequence for a compressed oligonucleotide. The universal adaptor sequence and a universal adaptor sequence having a second portion of the binding sequence targeting the same given clip-on capture primer; wherein the contact is performed under conditions suitable for generating a plurality of fixed open-loop libraries from the linear library molecule, wherein each fixed open-loop library molecule contains a nick between the 5' and 3' ends of the respective library molecule, wherein the nick is enzymatically ligated, and wherein each fixed open-loop library molecule contains a first portion of the clip-on capture primer and a second portion of the same clip-on capture primer, the first portion hybridizing with a universal adaptor sequence having a binding sequence targeting the first portion of the clip-on capture primer, and the second portion hybridizing with a second portion of the clip-on capture primer. Hybridization with a universal adaptor sequence of the binding sequence, wherein the plurality of fixed open-loop library molecules comprises a first subgroup and a second subgroup, the first subgroup comprising fixed open-loop library molecules having at least one deaminated base, and the second subgroup comprising fixed open-loop library molecules lacking a deaminated base; contacting the plurality of fixed open-loop library molecules with a ligase to generate a plurality of fixed covalently closed circular library molecules, wherein each covalently closed circular library molecule hybridizes with a fixed clip-on trap primer; contacting the plurality of fixed covalently closed circular library molecules with a deamination reagent comprising: (i) at least one enzyme having glycosylation activity, which generates one or more in the covalently closed circular library molecules. (ii) an enzyme with lysin activity that releases an abase-free site to create one or more gaps in a covalently closed circular library molecule, thereby generating a first subgroup of fixed covalently closed circular library molecules carrying one or more gaps and a second subgroup of fixed covalently closed circular library molecules having complete covalently closed circular library molecules, thereby generating a plurality of fixed linearized library molecules from the second subgroup of fixed covalently closed circular library molecules, and retaining the second subgroup of fixed covalently closed circular library molecules having complete covalently closed circular library molecules, thereby reducing the number of nucleic acid library molecules carrying at least one deaminated nucleotide base in the plurality of library molecules.

[0009] In some embodiments, the method further includes (e) contacting the plurality of immobilized covalently closed circular library molecules with rolling circle amplification reagent to generate a plurality of immobilized nucleic acid multiply template molecules immobilized to a support.

[0010] In some embodiments, the method further includes (f) sequencing the plurality of fixed nucleic acid multiply template molecules to determine the sequence of at least a portion of the fixed nucleic acid multiply template molecules.

[0011] In some embodiments, the sequencing in step (f) includes performing pairwise sequencing, which includes: sequencing the plurality of fixed polyp template molecules to generate a plurality of first-strand reads (R1); replacing the plurality of fixed polyp molecules with primer extension to generate a plurality of second polyp strands, each second polyp strand having a sequence complementary to the sequence of the fixed polyp template molecules; removing the plurality of fixed polyp template molecules while retaining the plurality of second polyp strands; and sequencing the plurality of second polyp strands to generate a plurality of second-strand reads (R2).

[0012] In some embodiments, sequencing the plurality of second multiply strands includes dark sequencing using a plurality of reverse sequencing primers, a plurality of unlabeled nucleotide reagents, and a plurality of sequencing polymerases, wherein the unlabeled nucleotide reagents may be incorporated into the 3' end of the reverse sequencing primers, thereby extending the reverse sequencing primers, and wherein the incorporation of the unlabeled nucleotide reagents is not detected.

[0013] In some embodiments, dark sequencing is performed for 2 to 30 consecutive cycles.

[0014] In some embodiments, sequencing the plurality of second polysynthetic strands includes dark sequencing of the initial portion of the second polysynthetic strand for 2 to 30 consecutive sequencing cycles.

[0015] In some embodiments, the at least one enzyme having glycosylation activity includes any one or any combination of the following: formamidopyrimidine DNA glycosylation enzyme (fpg); uracil N-glycosylation enzyme (UNG); uracil DNA glycosylation enzyme (UDG); 8-oxoguanine glycosylation enzyme (OGG, including thermostable OGG); DNA (purine-free) lyase; DNA (pyrimidine-free) lyase; and / or endonuclease III.

[0016] In some embodiments, the at least one enzyme with lysin activity includes any one or any combination of the following: AP lyase, Endo IV endonuclease, FPG glycosylation enzyme / AP lyase (formamidopyrimidine DNA glycosylation enzyme), endonuclease VIII glycosylation enzyme / AP lyase and / or endonuclease III.

[0017] In some embodiments, the rolling circle amplification reagent in step (e) includes a chain displacement polymerase and a plurality of nucleotides, including dATP, dGTP, dCTP, dTTP, and dUTP.

[0018] In some embodiments, the rolling circle amplification reagent generates multiple fixed polymers carrying at least one uracil.

[0019] In some embodiments, the at least one uracil is distributed at random positions along the plurality of fixed polymolecules.

[0020] In some embodiments, the rolling circle amplification reagent in step (e) comprises a plurality of compressed oligonucleotides, wherein each compressed oligonucleotide contains a 5' region and a 3' region, and wherein the 5' and 3' regions of a given compressed oligonucleotide are hybridized to binding sites in a given fixed nucleic acid multiply template molecule to pull together the distal portions of the given fixed nucleic acid multiply template molecule, thereby causing compression of the fixed nucleic acid multiply template molecule to form DNA nanospheres.

[0021] In some embodiments, each compressed oligonucleotide is contained in an inner region between the 5' and 3' regions.

[0022] In some embodiments, sequencing the plurality of immobilized nucleic acid polymer template molecules includes: contacting the plurality of immobilized nucleic acid polymer template molecules with (i) a plurality of sequencing polymerases and (ii) a plurality of soluble sequencing primers, wherein the contact is performed under conditions suitable for forming a plurality of complex sequencing polymerases, each complex sequencing polymerase comprising a sequencing polymerase that binds to a nucleic acid duplex, wherein the nucleic acid duplex comprises an immobilized nucleic acid polymer template molecule, the immobilized nucleic acid polymer template molecule hybridizing with the soluble sequencing primers to provide hybridized sequencing primers; contacting the plurality of complex sequencing polymerases with a plurality of nucleotides under conditions suitable for binding at least one nucleotide to the complex sequencing polymerases, wherein the plurality of nucleotides comprises at least one nucleotide analog labeled with a fluorescent group and having a removable chain termination portion at the 3' position of the sugar; incorporating at least one nucleotide into the 3' end of the hybridized sequencing primers to generate a plurality of newly formed extended sequencing primers; and detecting the incorporated nucleotide and identifying the nucleobases of the incorporated nucleotide, wherein the identification of nucleobases includes base reading.

[0023] In some embodiments, each nucleotide in the plurality of nucleotides includes a removable chain termination portion at the 3' sugar group, optionally wherein the removable chain termination portion includes an alkyl group, an alkenyl group, an alkynyl group, an allyl group, an aryl group, a benzyl group, an azide group, an azidoyl group, an O-azidomethyl group, an amine group, an amide group, a ketone group, an isocyanate group, a phosphate group, a thio group, a disulfide group, a carbonate group, a urea group, an acetal group, or a silyl group, and wherein the removable chain termination portion may be cleaved using a chemical compound to generate an extendable 3'OH moiety on the sugar group.

[0024] In some embodiments, the plurality of nucleotides includes a type of nucleotide selected from the group consisting of dATP, dGTP, dCTP, dTTP, and dUTP.

[0025] In some embodiments, the plurality of nucleotides comprises a mixture of two or more types of nucleotides selected from the group consisting of dATP, dGTP, dCTP, dTTP, and dUTP.

[0026] In some embodiments, sequencing the plurality of immobilized nucleic acid multiply template molecules includes: contacting the plurality of immobilized nucleic acid multiply template molecules with (i) a plurality of sequencing polymerases and (ii) a plurality of soluble sequencing primers, wherein the contact is performed under conditions suitable for forming a plurality of first complex sequencing polymerases, each of the first complex sequencing polymerases comprising a sequencing polymerase that binds to a nucleic acid duplex, wherein the nucleic acid duplex comprises an immobilized nucleic acid multiply molecule that hybridizes to the soluble sequencing primers; and, under conditions suitable for binding complementary nucleotide portions of the multivalent molecule to at least two of the plurality of first complex sequencing polymerases, sequencing the plurality of first complex sequencing polymerases. The synthase is contacted with a plurality of detectably labeled multivalent molecules to form a plurality of multivalent complex polymerases, thereby forming a plurality of multivalent complex polymerases, wherein suitable conditions inhibit the incorporation of the complementary nucleotide moiety into the soluble sequencing primer of the plurality of multivalent complex polymerases, wherein each of the plurality of multivalent molecules contains a core attached to a plurality of nucleotide arms, and each nucleotide arm is attached to a nucleotide moiety; the plurality of multivalent complex polymerases are detected; and the nucleobases of the complementary nucleotide moiety bound to the plurality of first complex sequencing polymerases in the plurality of multivalent complex polymerases are identified, thereby determining the sequence of the nucleic acid template, wherein the identification of the nucleobases includes base interpretation.

[0027] In some embodiments, the method further includes: dissociating a plurality of multivalent complex polymerases, and removing a plurality of first sequencing polymerases and their bound multivalent molecules, while retaining a plurality of nucleic acid duplexes; contacting the plurality of nucleic acid duplexes retained in step (e) with a plurality of second sequencing polymerases, wherein the contact is performed under conditions suitable for binding the plurality of second sequencing polymerases with the plurality of nucleic acid duplexes, thereby forming a plurality of second complex sequencing polymerases, each second complex sequencing polymerase comprising a second sequencing polymerase bound to a nucleic acid duplex; contacting the plurality of second complex sequencing polymerases with a plurality of nucleotides, the plurality of nucleotides comprising at least one unlabeled nucleotide analog having a removable chain termination portion at a sugar 3' position, wherein the contact is performed under conditions suitable for: i. binding complementary nucleotides from the plurality of nucleotides to at least two of the second complex polymerases from step (f), thereby forming a plurality of nucleotide complex polymerases; and ii. promoting the incorporation of the bound complementary nucleotides into the sequencing primers of the nucleotide complex polymerases.

[0028] In some embodiments, soluble sequencing primers include soluble universal sequencing primers.

[0029] In some aspects, this document provides a method for sequencing by forming at least one affinity complex, comprising: binding a first universal sequencing primer, a first sequencing polymerase, and a first detectably labeled multivalent molecule to a first portion of a fixed nucleic acid multivalent template molecule generated by the method according to claim 19, thereby forming a first binding complex, wherein a first nucleotide portion of the first multivalent molecule is bound to the first sequencing polymerase; and binding a second universal sequencing primer, a second sequencing polymerase, and the first detectably labeled multivalent molecule to a second portion of the same fixed nucleic acid multivalent template molecule, thereby forming a second binding complex, wherein a second nucleotide portion of the first multivalent molecule is bound to the second sequencing polymerase, wherein the first binding complex and the second binding complex bound to the same multivalent molecule form an affinity complex, wherein the first detectably labeled multivalent molecule comprises a nucleus attached to a plurality of nucleotide arms. The fixed nucleic acid multiplex template molecule contains two or more tandem repeat sequences of the target sequence (110) and universal primer binding sites for binding the first universal sequencing primer and the second universal sequencing primer, and the contact is performed under conditions suitable for inhibiting polymerase-catalyzed incorporation of the first and second nucleotide portions bound in the first and second binding complexes; the first and second binding complexes on the same fixed nucleic acid multiplex template molecule are detected, and the first nucleotide portion in the first binding complex is identified, thereby determining the sequence of the first portion of the fixed multiplex template molecule, and the second nucleotide portion in the second binding complex is identified, thereby determining the sequence of the second portion of the fixed multiplex template molecule, wherein the identification of the first nucleotide portion and the identification of the second nucleotide portion include base interpretation.

[0030] In some embodiments, multiple nucleotide arms attached to the core of each multivalent molecule have the same type of nucleotide moiety, wherein the type of the nucleotide moiety is selected from the group consisting of dATP, dGTP, dCTP, dTTP, and dUTP.

[0031] In some embodiments, the plurality of multivalent molecules comprises a mixture of any combination of two or more types of multivalent molecules, each type having a nucleotide moiety selected from the group consisting of dATP, dGTP, dCTP, dTTP, and dUTP.

[0032] In some embodiments, each nucleotide in the plurality of nucleotides includes a removable chain termination portion at the 3' sugar group, wherein the removable chain termination portion includes an alkyl group, an alkenyl group, an alkynyl group, an allyl group, an aryl group, a benzyl group, an azide group, an azidoyl group, an O-azidomethyl group, an amine group, an amide group, a ketone group, an isocyanate group, a phosphate group, a thio group, a disulfide group, a carbonate group, a urea group, or a silyl group, and wherein the removable chain termination portion may be cleaved using a chemical compound to generate an extendable 3'OH moiety on the sugar group.

[0033] In some embodiments, the plurality of nucleotides includes a type of nucleotide selected from the group consisting of dATP, dGTP, dCTP, dTTP, and dUTP.

[0034] In some embodiments, the plurality of nucleotides comprises a mixture of any combination of two or more types of nucleotides selected from the group consisting of dATP, dGTP, dCTP, dTTP, and dUTP.

[0035] In some embodiments, the support includes a glass or plastic substrate.

[0036] In some embodiments, the support is passivated with at least one hydrophilic polymer coating having a water contact angle of no more than 45 degrees.

[0037] In some embodiments, at least one hydrophilic polymer coating comprises molecules selected from the group consisting of: polyethylene glycol (PEG), poly(vinyl alcohol) (PVA), poly(vinylpyridine), poly(vinylpyrrolidone) (PVP), poly(acrylic acid) (PAA), polyacrylamide, poly(N-isopropylacrylamide) (PNIPAM), poly(methyl methacrylate) (PMA), poly(2-hydroxyethyl methacrylate) (PHEMA), poly(oligomeric (ethylene glycol) methyl ether methacrylate) (POEGMA), polyglutamic acid (PGA), polylysine, polyglucosides, streptavidin, and dextran.

[0038] In some embodiments, the plurality of fixed clamps capture primers at predetermined positions on a polymer-coated support.

[0039] In some embodiments, the plurality of fixed clamps capture primers at random locations on a polymer-coated support.

[0040] In some embodiments, the plurality of immobilized nucleic acid multiply template molecules on the support are fluidly connected to each other to allow reagent solutions to flow onto the support, such that the plurality of immobilized nucleic acid multiply template molecules can react with the reagents substantially simultaneously in a large-scale parallel manner.

[0041] In some embodiments, the reagent comprises one or more enzymes, nucleotides, divalent cations, or combinations thereof.

[0042] In some embodiments, the method further includes determining the percentage of base misreadings based on the sequencing in step (f).

[0043] In some embodiments, the method further includes determining a quality score for the sequencing data based on the percentage of base misreading errors.

[0044] In some embodiments, when a deamination reagent is used in step (c), the quality score increases from Q30 to Q40 or Q50 compared to a method in which no deamination reagent is used in step (c).

[0045] In some embodiments, when a deamination reagent is used in step (c), the quality score of the first chain read (R1) increases from Q30 to Q40 or Q50, compared to the same method without a deamination reagent in step (c).

[0046] In some embodiments, when a deamination reagent is used in step (c), the quality score of the second chain read (R2) increases from Q30 to Q40 or Q50, compared to the same method without a deamination reagent in step (c). Attached Figure Description

[0047] The features of this disclosure are set forth in the appended claims. A better understanding of the features and advantages of this disclosure will be obtained by referring to the following detailed description, in which the principles of this disclosure are utilized and illustrated in the accompanying drawings:

[0048] Figure 1 This is a schematic diagram of an exemplary low-binding support comprising a glass substrate and alternating hydrophilic coatings covalently or non-covalently adhered to the glass, and further comprising chemically reactive functional groups that act as attachment sites for oligonucleotide primers (e.g., capturing oligonucleotides). The support may be made of any material such as glass, plastic, or polymeric materials.

[0049] Figure 2 Schematic diagrams of various exemplary configurations of multivalent molecules. Left (Class I): Schematic diagram of multivalent molecules with a "starburst" or "helter-skelter" configuration. Middle (Class II): Schematic diagram of multivalent molecules with a dendritic macromolecular configuration. Right (Class III): Schematic diagram of multiple multivalent molecules formed by the reaction of streptavidin with a 4-arm or 8-arm PEG-NHS containing biotin and dNTPs. The nucleotide moiety is designated as 'N', biotin is designated as 'B', and streptavidin is designated as 'SA'.

[0050] Figure 3 A schematic diagram of an exemplary multivalent molecule comprising a universal core attached to multiple nucleotide arms.

[0051] Figure 4 This is a schematic diagram of an exemplary multivalent molecule comprising a dendritic core attached to multiple nucleotide arms.

[0052] Figure 5 A schematic diagram of an exemplary multivalent molecule is shown, comprising a core attached to multiple nucleotide arms, wherein the nucleotide arms include biotin, spacers, linkers, and nucleotide portions.

[0053] Figure 6 This is a schematic diagram of an exemplary nucleotide arm that includes a core attachment portion, a spacer, a linker, and a nucleotide portion.

[0054] Figure 7 The chemical structures of exemplary spacers (top) and various exemplary connectors, including 11-atom connectors, 16-atom connectors, 23-atom connectors and N3 connectors (bottom), are shown.

[0055] Figure 8 The chemical structures of various exemplary connectors (including connectors 1 to 9) are shown.

[0056] Figure 9 The chemical structures of various exemplary connectors that join / attach to nucleotide moieties are shown.

[0057] Figure 10 The chemical structures of various exemplary connectors that join / attach to nucleotide moieties are shown.

[0058] Figure 11 The chemical structures of various exemplary connectors that join / attach to nucleotide moieties are shown.

[0059] Figure 12 The chemical structure of an exemplary linker that joins / attaches to a nucleotide moiety is shown.

[0060] Figure 13 The chemical structure of an exemplary biotinylated nucleotide arm is shown. In this example, the nucleotide portion is attached to the linker via a propargylamine attachment at the 5-position of the pyrimidine base or the 7-position of the purine base.

[0061] Figure 14 The chemical structures of various nucleotide bases and their corresponding deamination bases are shown, including: cytosine deamination to uracil; adenine deamination to hypoxanthine; guanine deamination to xanthine; and 5-methylcytosine deamination to thymine.

[0062] Figure 15A schematic diagram illustrating the hybridization of an exemplary linear single-stranded library molecule (100) with a double-stranded splint molecule (200), thereby circularizing the library molecule to form a library-sponge complex (500) with two nicks. The library molecule (100) comprises: a first left universal adaptor sequence (120); a first left unique identifier sequence (180); a first left index sequence (160); a second left universal adaptor sequence (140); a target sequence (110); a second right universal adaptor sequence (150); a first right index sequence (170); and a first right universal adaptor sequence (130). The double-stranded splint molecule comprises a first splint chain (long chain (300)) that hybridizes with a second splint chain (short chain (400)). The first splint chain includes a first region (320) that hybridizes with a sequence at one end of the linear single-stranded library molecule and a second region (330) that hybridizes with a sequence at the other end of the linear single-stranded library molecule. The inner region (310) of the first splint chain hybridizes with the second splint chain (400). The second splint chain (400) comprises three subregions, wherein the first subregion contains a universal binding sequence for a third surface primer, the second subregion contains a universal binding sequence for a fourth surface primer, and the third subregion contains a sample index sequence having 5 to 20 bases and / or a unique identification sequence (e.g., NN) having 2 to 10 or more bases. The inner region (310) of the first splint chain (300) comprises three subregions, wherein the fourth subregion hybridizes with the first subregion of the second splint chain (400), the fifth subregion hybridizes with the second subregion of the second splint chain (400), and the sixth subregion hybridizes with the third subregion of the second splint chain (400).

[0063] Figure 16 This diagram illustrates an exemplary library-sandwich complex (500) undergoing a ligation reaction to close a nick and form a covalently closed circular library molecule (600), which hybridizes with a first sandwich chain (300), which can be used as an amplification primer for rolling circle amplification. Dashed lines represent newly formed extension products.

[0064] Figure 17The nucleotide sequence of an exemplary double-stranded splint molecule (200) is shown, having a first splint chain (300; (SEQ ID NO: 1)) and a second splint chain (400; (SEQ ID NO: 2)). The exemplary first splint chain includes a first region (320; SEQ ID NO: 3), a second region (330; SEQ ID NO: 4), and an inner region (310) having a fourth sub-region (SEQ ID NO: 5) and a fifth sub-region (SEQ ID NO: 6). The first splint chain (300) includes the first region (320), the second region (330), and the inner region (310) (SEQ ID NO: 7). The exemplary second splint chain (400) includes a first sub-region (SEQ ID NO: 8) and a second sub-region (SEQ ID NO: 9). The second splint chain (400; SEQ ID NO: 2) includes the first and second sub-regions (SEQ ID NO: 8 and 9, respectively).

[0065] Figure 18 This is a schematic diagram illustrating the hybridization of an exemplary linear single-stranded library molecule (700) with a single-stranded splint molecule / chain (800), thereby circularizing the library molecule to form a library-sliplin complex (900) with a nick. The exemplary library molecule (700) comprises: a first left universal adaptor sequence (720); an optional first left unique identifier sequence (780); a first left index sequence (760); a second left universal adaptor sequence (740); a target sequence (710); a second right universal adaptor sequence (750); a first right index sequence (770); and a first right universal adaptor sequence (730). The single-stranded splint chain (800) includes a first region (810) that hybridizes with a sequence at one end of the linear single-stranded library molecule and a second region (820) that hybridizes with a sequence at the other end of the linear single-stranded library molecule.

[0066] Figure 19 This diagram illustrates an exemplary library-splice complex (900) undergoing a ligation reaction to close the nick and form a covalently closed circular library molecule (1000), which hybridizes with a single-stranded splint chain (800), which is used as an amplification primer for rolling circle amplification. Dashed lines represent newly formed extension products.

[0067] Figure 20 The nucleotide sequence (800; SEQ ID NO: 10) of an exemplary single-stranded splint molecule / chain is shown. The exemplary single-stranded splint chain includes a first region (810; SEQ ID NO: 11) and a second region (820; SEQ ID NO: 12).

[0068] Figure 21A schematic diagram is provided to illustrate an exemplary support having a first surface primer (e.g., a clip-on trap primer) fixed thereon, which can be used for support-on-support ligation reactions in a pairwise sequencing workflow. Figures 21 to 28 , Figures 31A to 31B An exemplary workflow for connecting on a support is shown. Figure 32 An exemplary workflow for rolling circle amplification reaction on a support is shown. Figures 33 to 45 An exemplary workflow for pairwise sequencing is shown.

[0069] Figure 22 This schematic diagram illustrates an exemplary single-stranded linear library molecule comprising a target sequence and various universal adaptor sequences targeting primer binding sites. The arrangement of the various universal adaptor sequences in this schematic diagram is for illustrative purposes. Those skilled in the art will understand that many other arrangements and combinations of universal adaptor sequences are possible.

[0070] Figure 23 This is a schematic diagram illustrating an exemplary single-stranded linear library molecule hybridizing with a fixed first surface primer (e.g., a fixed clip-on trap primer) to form a cyclized library molecule with asymmetrically positioned gaps or nicks.

[0071] Figure 24 This is a schematic diagram illustrating an exemplary single-stranded linear library molecule hybridizing with a fixed first surface primer (e.g., a fixed clip-on trap primer) to form a cyclized library molecule with asymmetrically positioned gaps or nicks.

[0072] Figure 25 This is a schematic diagram illustrating an exemplary single-stranded linear library molecule hybridizing with a fixed first surface primer (e.g., a fixed clip-on trap primer) to form a cyclic library molecule with symmetrically positioned gaps or slits. Figure 23 , Figure 24 and Figure 25 The schematic diagrams shown illustrate several embodiments of cyclized library molecules comprising single-stranded linear library molecules that hybridize with fixed first surface primers.

[0073] Figure 26 This is a schematic diagram illustrating an exemplary covalently closed cyclic library molecule generated through a covalently closed gap or slit.

[0074] Figure 27 This is a schematic diagram illustrating an exemplary covalently closed cyclic library molecule generated through a covalently closed gap or slit.

[0075] Figure 28 This is a schematic diagram illustrating an exemplary covalently closed cyclic library molecule generated through a covalently closed gap or slit. Figure 26 , Figure 27 and Figure 28 The schematic diagrams shown illustrate several embodiments of covalently closed circular library molecules hybridized with a fixed first surface primer (e.g., a fixed clip-on trap primer).

[0076] Figure 29 To illustrate various embodiments of a linear library molecule (e.g., (A) to (D)), the linear library molecule comprises (i) a target sequence (e.g., an insert region (15)) and at least one adaptor sequence, wherein the adaptor sequence comprises: (ii) a universal binding site (25) (or its complementary sequence) for a first portion of a clip-on capture primer, (iii) at least one sample index sequence (e.g., (65) and / or (75) which can be used to distinguish the target sequence obtained from different sample sources in multiplex assays, (iv) a universal binding site (45) (or its complementary sequence) for a forward sequencing primer, and (v) a universal binding site (55) (or its complementary sequence) for a reverse sequencing primer. (vi) at least one unique molecular index sequence (UMI) (e.g., (85) and / or (86)) which can be used to uniquely identify nucleic acid molecules (e.g., those with a target sequence) to which the unique molecular index sequence is attached, and (vii) a universal binding site (35) (or its complementary sequence) for a second part of the fixed clip trap. For example, the at least one sample index sequence (e.g., (65) and / or (75)) comprises a sample index sequence that is conjugated to a short random sequence (e.g., NNN), wherein the short random sequence provides nucleotide sequence diversity and is about 3 to 20 nucleotides in length. Either the target sequence (15) or the adaptor sequence can be arranged in any order.

[0077] Figure 30To illustrate various embodiments of a linear library molecule (e.g., (A) through (F)), the linear library molecule comprises (i) a target sequence (e.g., an insert region (15)) and at least one adaptor sequence, wherein the adaptor sequence comprises: (ii) a universal binding site (25) (or its complementary sequence) for a first portion of a clip-on capture primer, (iii) at least one sample index sequence (e.g., (65) and / or (75)) which can be used to distinguish the target sequence obtained from different sample sources in multiplex assays, (iv) a universal binding site (45) (or its complementary sequence) for a forward sequencing primer, (v) a universal binding site (55) (or its complementary sequence) for a reverse sequencing primer, and (vi) a universal binding site (35) (or its complementary sequence) for a second portion of a fixed clip-on capture. For example, the at least one sample index sequence (e.g., (65) and / or (75)) comprises a sample index sequence that binds to a short random sequence (e.g., NNN), wherein the short random sequence provides nucleotide sequence diversity and is about 3 to 20 nucleotides in length. Either the target sequence (15) or the adaptor sequence can be arranged in any order. A linear library molecule may contain one sample index sequence (e.g., (65) or (75)), or it may contain two sample index sequences (e.g., (65) and (75)). A linear library molecule may further contain a universal binding site (45) (or its complement) for forward sequencing primers and lack a universal binding site (55) (or its complement) for reverse sequencing primers. A linear library molecule may contain a universal binding site (45) (or its complement) for forward sequencing primers and a universal binding site (55) (or its complement) for reverse sequencing primers. Alternatively or additionally, a linear library molecule may contain at least one unique molecular index sequence (UMI) (e.g., see [link to original document]). Figure 29 (85) and / or (86)), which can be used to uniquely identify nucleic acid molecules (e.g., those with a target sequence) with the attached unique molecular index sequence. The at least one unique molecular index sequence (UMI) can be located at any position in the linear library molecule.

[0078] Figure 31AA schematic diagram illustrating an exemplary clip-on capture primer (92) fixed to a support is provided, wherein the clip-on capture primer hybridizes with a linear library molecule to form an open-loop library (91) with nicks or gaps. For example, the clip-on capture primer (91) comprises a first portion (93) (e.g., SP1-A) and a second portion (94) (e.g., SP1-B). The linear library molecule may contain (i) a target sequence (e.g., an insert region (15)) arranged in any order and two or more universal linker sequences. The linear library molecule may further include (i) a universal binding site (25) (or its complementary sequence) for a first portion of the clip-capture primer, (ii) at least one sample index sequence (e.g., (65) and / or (75)) which can be used to distinguish the target sequence obtained from different sample sources in multiplex assays, (iii) a universal binding site (45) (or its complementary sequence) for forward sequencing primers, (iv) a universal binding site (55) (or its complementary sequence) for reverse sequencing primers, and (v) a universal binding site (35) (or its complementary sequence) for a second portion of the immobilized clip-capture. The linear library molecule may further include at least one unique molecular index sequence (UMI) (e.g., (85) and / or (86)) which can be used to uniquely identify nucleic acid molecules (e.g., those with the target sequence) to which the unique molecular index sequence is attached. For example, and not limited to, the linear library molecule may include Figure 29 and Figure 30 Any of the linear library molecules shown.

[0079] Figure 31B To illustrate the covalent closure Figure 31A A schematic diagram of an exemplary covalently closed cyclic library molecule (95) generated by the gaps or cuts in the open-ring library molecule (91) shown. Figure 31B The covalently closed circular library molecules (95) can be used to perform workflows including rolling circle amplification and sequencing, wherein the workflow is in Figures 32 to 45 As shown in the image.

[0080] Figure 32 To illustrate an exemplary rolling circle amplification reaction on a support, this exemplary rolling circle amplification reaction uses... Figure 21 The diagram illustrates a covalently closed circular library molecule hybridized to a fixed first surface primer (e.g., a clip-on trap primer) and a nucleotide mixture comprising a nucleotide having a cleavable portion that can be cleaved to generate a base-free site. Rolling circle amplification generates a fixed single-stranded nucleic acid multiplicand template molecule having at least one nucleotide with a cleavable portion that can be cleaved to generate a base-free site within the fixed multiplicand template molecule.

[0081] Figure 33This is a schematic diagram illustrating an exemplary support having first surface primers fixed thereon, which can be used for rolling circle amplification reactions and pairwise sequencing workflows on the support. Figure 33 In this context, the first surface primer can be a clip-on trap primer (e.g., see [reference]). Figure 31A and Figure 31B (or surface capture primers.)

[0082] Figure 34 To illustrate an exemplary rolling circle amplification reaction on a support, this exemplary rolling circle amplification reaction uses... Figure 33 The diagram illustrates a covalently closed circular library molecule hybridized with a fixed first surface primer and a nucleotide mixture comprising a nucleotide having a cleavable portion that can be cleaved to generate a base-free site. Rolling circle amplification generates a fixed single-stranded nucleic acid multiplicand template molecule having at least one nucleotide with a cleavable portion that can be cleaved to generate a base-free site within the fixed multiplicand template molecule. The various primer-binding sequences arranged in the nucleic acid circular library molecule are for illustrative purposes. Those skilled in the art will understand that many other arrangements are possible. Figures 36 to 45 Showing the Figure 34 and Figure 35 The workflow for pair sequencing of fixed multiply template molecules described in the paper.

[0083] Figure 35 This is a schematic diagram illustrating an exemplary single-stranded nucleic acid multiplicative template molecule immobilized to a first surface primer. The immobilized multiplicative template molecule contains at least one nucleotide having a cleavable portion that can be cleaved to generate a base-free site within the immobilized multiplicative template molecule. The immobilized multiplicative template molecule can be generated by performing a rolling circle amplification reaction on a support. The various primer binding sequences are arranged for illustrative purposes. Those skilled in the art will understand that many other arrangements are possible. Figures 36 to 45 It shows the Figure 35 The workflow for pair sequencing of fixed multiply template molecules described in the paper.

[0084] Figure 36 To show the Figure 35 The diagram illustrates an exemplary forward sequencing reaction performed using a fixed multiply template molecule. The forward sequencing reaction can be performed using multiple soluble forward sequencing primers to generate multiple extended forward sequencing primer chains. The fixed multiply template molecule may have two or more extended forward sequencing primer chains hybridized thereon.

[0085] Figure 37The diagram illustrates an exemplary method for using a primer extension reaction performed with a chain-displacement polymerase in the absence of soluble primers, thereby generating a forward extension strand to replace the extended forward sequencing primer strand.

[0086] Figure 38 The diagram illustrates an exemplary method for replacing extended forward sequencing primer strands by generating forward extension strands through a primer extension reaction using soluble forward sequencing primers.

[0087] Figure 39 The diagram illustrates an exemplary method for replacing extended forward sequencing primers with a forward extension strand generated by performing a primer extension reaction using soluble amplification primers.

[0088] Figure 40 The diagram illustrates an exemplary method for generating a base-free site at a nucleotide with a cleavable portion in a fixed single-stranded multiplex template molecule, and creating a gap at the base-free site to generate a plurality of multiplex template molecules containing gaps, while retaining the plurality of forward extension strands and the plurality of fixed first surface primers. The forward extension strands can be... Figure 37 or Figure 38 The method described in the document is used to generate it.

[0089] Figure 41 To illustrate the removal of, such as Figure 40 The diagram shows an exemplary retained forward-extended chain following a multi-linked template molecule containing gaps.

[0090] Figure 42 The diagram illustrates an exemplary method for generating a base-free site at a nucleotide with a cleavable portion in a fixed single-stranded multiplex template molecule, and creating a gap at the base-free site to generate a plurality of multiplex template molecules containing gaps, while retaining the plurality of forward extension strands and the plurality of fixed first surface primers. The forward extension strands can be... Figure 39 The method described in the document is used to generate it.

[0091] Figure 43 To illustrate the removal of, such as Figure 42 The diagram shows an exemplary retained forward-extended chain following a multi-linked template molecule containing gaps.

[0092] Figure 44 To show the Figure 41The diagram illustrates an exemplary reverse sequencing reaction performed with the retained forward extension strand. The reverse sequencing reaction can be performed using multiple soluble reverse sequencing primers. The retained forward extension strand may have two or more extended reverse sequencing primer strands hybridized thereon. The extended reverse sequencing primer strands are not hybridized to or covalently bound to the first surface primer. Therefore, the extended reverse sequencing primer strands are not fixed to the support. For simplicity, Figures 35 to 44 An exemplary fixed multiply molecule with two copies of the target sequence and various universal primer binding sites is shown. Those skilled in the art will understand that a fixed multiply molecule may contain two or more tandem copies containing the target sequence and various universal primer binding sites.

[0093] Figure 45 To show the Figure 43 The diagram illustrates an exemplary reverse sequencing reaction performed with the retained forward extension strand. The retained forward extension strand may have two or more extended reverse sequencing primer strands hybridized thereon. The extended reverse sequencing primer strands are not hybridized to or covalently bound to the first surface primer. Therefore, the extended reverse sequencing primer strands are not fixed to the support. For simplicity, Figures 35 to 45 An exemplary fixed multiply molecule with two copies of the target sequence and various universal primer binding sites is shown. Those skilled in the art will understand that a fixed multiply molecule may contain two or more tandem copies containing the target sequence and various universal primer binding sites.

[0094] Figure 46 This is a schematic diagram illustrating an exemplary support having a first surface primer and a second surface primer attached thereto. The first surface primer may include a surface-capturing primer or a clip-capturing primer. The second surface primer may include a surface-stapled primer. Figure 35 A portion of the fixed multiply template molecule shown hybridizes with a fixed second surface primer (e.g., a surface-stapled primer). The fixed multiply template molecule has two or more copies of a universal binding sequence for the fixed second surface primer. A portion of the fixed multiply template molecule containing the universal binding sequence for the fixed second surface primer can hybridize with the fixed second surface primer.

[0095] Figure 47ATo illustrate an exemplary rolling circle amplification reaction in solution, this exemplary reaction uses a circular library molecule, a soluble first amplification primer, and a mixture of nucleotides including cleavable moieties having cleavable portions that can be cleaved to produce base-free sites. The rolling circle amplification reaction generates nascent single-stranded nucleic acid multiplexes in solution having at least one nucleotide with a cleavable portion that can be cleaved to produce base-free sites in the multiplexe molecule. The various primer binding sequences arranged in the circular library molecule are for illustrative purposes only. Those skilled in the art will understand that many other arrangements are possible.

[0096] Figure 47B To illustrate an exemplary method including the following: Figure 47A The rolling circle amplification reaction described herein is distributed onto a support having a first surface primer (e.g., a surface capture primer) immobilized thereon. The multiply molecule can hybridize with the immobilized first surface primer. The rolling circle amplification reaction can continue on the support, thereby generating an immobilized multiply template molecule containing at least one nucleotide with a cleavable moiety, which can be cleaved to generate a base-free site in the immobilized multiply template molecule.

[0097] Figure 47C This is a schematic diagram illustrating an exemplary support including a first surface primer and a second surface primer attached thereto. The first surface primer includes a surface-capturing primer. The second surface primer includes a surface-stapled primer. Figure 47B A portion of the fixed multiply template molecule shown hybridizes with a fixed second surface primer. The fixed multiply template molecule has two or more copies of a universal binding sequence for the fixed second surface primer. A portion of the fixed multiply template molecule containing the universal binding sequence for the fixed second surface primer can hybridize with the fixed second surface primer.

[0098] Figure 48 The amino acid sequence of the wild-type DNA polymerase having the main strand sequence from RLF 89458.1 (SEQ ID NO: 13).

[0099] Figure 49 The amino acid sequence of the wild-type DNA polymerase having the main strand sequence from RLF 78286.1 (SEQ ID NO: 14).

[0100] Figure 50 The amino acid sequence of the wild-type DNA polymerase having the main strand sequence from NOZ 58130.1 (SEQ ID NO: 15).

[0101] Figure 51The amino acid sequence of the wild-type DNA polymerase having the main strand sequence from RMF 90817.1 (SEQ ID NO: 16).

[0102] Figure 52 The amino acid sequence of a wild-type DNA polymerase having the main strand sequence from MBC 7218772.1 (SEQ ID NO: 17).

[0103] Figure 53 The amino acid sequence of a wild-type DNA polymerase having the main strand sequence from WP 175059460.1 (SEQ ID NO: 18).

[0104] Figure 54 The amino acid sequence of the wild-type DNA polymerase having the main strand sequence from KUO 42443.1 (SEQ ID NO: 19).

[0105] Figure 55 The amino acid sequence of the wild-type DNA polymerase having the main strand sequence from NOZ 77387.1 (SEQ ID NO: 20).

[0106] Figure 56 The amino acid sequence of a wild-type DNA polymerase having the main strand sequence of Geobacillus stearothermophilus (Bst polymerase) (SEQ ID NO: 21).

[0107] Figure 57 The amino acid sequence is that of 9 °N polymerase (SEQ ID NO: 22).

[0108] Figure 58 The amino acid sequence is that of 9 °N polymerase UniProt Q56366 (SEQ ID NO: 23).

[0109] Figure 59 The amino acid sequence is that of THERMINATOR polymerase (SEQ ID NO: 24).

[0110] Figure 60 The amino acid sequence of VENT polymerase UniProt P30317 (SEQ ID NO: 25).

[0111] Figure 61 The amino acid sequence is that of DEEP VENT polymerase UniProt Q51334 (SEQ ID NO: 26).

[0112] Figure 62The amino acid sequence is that of Pfu polymerase UniProt P61875 (SEQ ID NO: 27).

[0113] Figure 63 The amino acid sequence of UniProt P0CL77 (SEQ ID NO:28), a polymerase of Pyrococcus abyssi.

[0114] Figure 64 The amino acid sequence is that of RB69 polymerase (SEQ ID NO: 29).

[0115] Figure 65 The two figures illustrate the sequencing quality scores of multiply template molecules generated through a workflow that includes: using double-stranded splice adapters (e.g., see...). Figures 15 to 17 The linear library molecules are circularized, with or without USER treatment, and subjected to rolling circle amplification on the support to generate multiplicative template molecules immobilized to the coated support. The left-hand control plot shows the sequencing quality scores for base reads (T, C, A, and G) of multiplicative template molecules generated without USER treatment during the library preparation workflow. The control plot shows a quality score of approximately 39 for T base reads. The right-hand plot, after USER treatment, shows the sequencing quality scores for base reads (T, C, A, and G) of multiplicative template molecules generated with USER treatment during the library preparation workflow. The USER-treated plot shows an increase in the quality score for T base reads to approximately 43. The linear library molecules are treated prior to hybridization with the double-stranded splice adaptor (see Examples 1, 2, and 3).

[0116] Figure 66 Two figures illustrate sequencing quality scores for multiply template molecules generated via a workflow including the following: using double-stranded splice adapters with or without USER processing (e.g., see...). Figures 15 to 17 The linear library molecules were circularized, and rolling circle amplification on the support was performed to generate multiply template molecules immobilized on the coated support. The left-hand control plot shows the sequencing quality scores of the bases T, C, A, and G for multiply template molecules generated without USER treatment during the library preparation workflow. The control plot shows a quality score of approximately 39 for the T bases. The right-hand plot, after USER treatment, shows the sequencing quality scores of the bases T, C, A, and G for multiply template molecules generated with USER treatment during the library preparation workflow. The USER-treated plot shows that the quality score of the T bases increased to approximately 45. The linear library molecules were processed after digestion of the first splint strand (300) with T7 exonuclease and a thermosensitive exonuclease (see Examples 1, 2, and 4).

[0117] Figure 67A To illustrate the sequencing quality score of the C-base readout of the first-strand multiply template molecule, which was generated via a workflow including the following: using a double-stranded splice adapter with or without heat (e.g., see...). Figures 15 to 17 However, there were no unique identifying sequences (180) and (190) to circularize the linear library molecules and to perform rolling circle amplification on the support to generate multiply template molecules immobilized to the coated support. The library preparation workflow compared the effects of heat, NaOH, HEPES buffer, or a premix of a complex enzyme that generates and removes base-free sites. The X-axis represents the sequencing cycle number. The Y-axis represents the quality score.

[0118] Figure 67B To illustrate the sequencing quality score of the A-base readout of the first-strand multiply template molecule, which is generated via a workflow including the following: using a double-stranded clip adaptor with or without heat (e.g., see...). Figures 15 to 17 However, there were no unique identifying sequences (180) and (190) to circularize the linear library molecules and to perform rolling circle amplification on the support to generate multiply template molecules immobilized to the coated support. The library preparation workflow compared the effects of heat, NaOH, HEPES buffer, or a premix of a complex enzyme that generates and removes base-free sites. The X-axis represents the sequencing cycle number. The Y-axis represents the quality score.

[0119] Figure 67C To illustrate the sequencing quality score of the G-base interpretation of the first-strand multiply template molecule, which was generated via a workflow including the following: using a double-stranded clamp adapter with or without heat (e.g., see...). Figures 15 to 17 However, there were no unique identifying sequences (180) and (190) to circularize the linear library molecules and to perform rolling circle amplification on the support to generate multiply template molecules immobilized to the coated support. The library preparation workflow compared the effects of heat, NaOH, HEPES buffer, or a premix of a complex enzyme that generates and removes base-free sites. The X-axis represents the sequencing cycle number. The Y-axis represents the quality score.

[0120] Figure 67D To illustrate the sequencing quality score of the T-base readout of the first-strand multiply template molecule, which was generated via a workflow including the following: using a double-stranded splice adapter with or without heat (e.g., see...). Figures 15 to 17However, there were no unique identifying sequences (180) and (190) to circularize the linear library molecules and to perform rolling circle amplification on the support to generate multiply template molecules immobilized to the coated support. The library preparation workflow compared the effects of heat, NaOH, HEPES buffer, or a premix of a complex enzyme that generates and removes base-free sites. The X-axis represents the sequencing cycle number. The Y-axis represents the quality score.

[0121] Figure 68A To illustrate the sequencing quality score of the C-base readout of the second-stranded multiply template molecule, which was generated via a workflow including the following: using a double-stranded clamp adapter with or without heat (e.g., see...). Figures 15 to 17 However, there were no unique identifying sequences (180) and (190) to circularize the linear library molecules and to perform rolling circle amplification on the support to generate multiply template molecules immobilized to the coated support. The library preparation workflow compared the effects of heat, NaOH, HEPES buffer, or a premix of a complex enzyme that generates and removes base-free sites. The X-axis represents the sequencing cycle number. The Y-axis represents the quality score.

[0122] Figure 68B To illustrate the sequencing quality score of the A-base readout of the second-stranded multiply template molecule, which was generated via a workflow including the following: using a double-stranded clamp adapter with or without heat (e.g., see...). Figures 15 to 17 However, there were no unique identifying sequences (180) and (190) to circularize the linear library molecules and to perform rolling circle amplification on the support to generate multiply template molecules immobilized to the coated support. The library preparation workflow compared the effects of heat, NaOH, HEPES buffer, or a premix of a complex enzyme that generates and removes base-free sites. The X-axis represents the sequencing cycle number. The Y-axis represents the quality score.

[0123] Figure 68C To illustrate the sequencing quality score of the G-base interpretation of the second-stranded multiplex template molecule, which was generated via a workflow including the following: using a double-stranded clip adaptor with or without heat (e.g., see...). Figures 15 to 17 However, there were no unique identifying sequences (180) and (190) to circularize the linear library molecules and to perform rolling circle amplification on the support to generate multiply template molecules immobilized to the coated support. The library preparation workflow compared the effects of heat, NaOH, HEPES buffer, or a premix of a complex enzyme that generates and removes base-free sites. The X-axis represents the sequencing cycle number. The Y-axis represents the quality score.

[0124] Figure 68DTo illustrate the sequencing quality score of the T-base readout of the second-stranded multiply template molecule, which was generated via a workflow including the following: using a double-stranded splice adapter with or without heat (e.g., see...). Figures 15 to 17 However, there were no unique identifying sequences (180) and (190) to circularize the linear library molecules and to perform rolling circle amplification on the support to generate multiply template molecules immobilized to the coated support. The library preparation workflow compared the effects of heat, NaOH, HEPES buffer, or a premix of a complex enzyme that generates and removes base-free sites. The X-axis represents the sequencing cycle number. The Y-axis represents the quality score.

[0125] Figure 69 To illustrate a series of three graphs showing the sequencing quality scores for the A, G, C, and T base interpretations of the first-strand multiply template molecule (read 1), this first-strand multiply template molecule was generated via a workflow including: using a double-stranded clip adaptor with ligase inactivation (e.g., see...). Figures 15 to 17 However, there were no unique identifying sequences (180) and (190) to circularize the linear library molecules and to perform rolling circle amplification on the support to generate multiply template molecules immobilized on the coated support. The library preparation workflow compared the effects of high heat sterilization control, low heat sterilization, and NaOH inactivation of ligase. The X-axis represents the sequencing cycle number. The Y-axis represents the quality score.

[0126] Figure 70 To illustrate a series of three graphs showing the sequencing quality scores for the A, G, C, and T base interpretations of the second-stranded multiply template molecule (read 2), this second-stranded multiply template molecule was generated via a workflow including: using a double-stranded clip adaptor with ligase inactivation (e.g., see...). Figures 15 to 17 However, there were no unique identifying sequences (180) and (190) to circularize the linear library molecules and to perform rolling circle amplification on the support to generate multiply template molecules immobilized on the coated support. The library preparation workflow compared the effects of high heat sterilization control, low heat sterilization, and NaOH inactivation of ligase. The X-axis represents the sequencing cycle number. The Y-axis represents the quality score.

[0127] Figure 71The bar graph shows the average percentage recovery of covalently closed circular libraries of input DNA from different species, as determined by qPCR. Lane 1: Haemophilus influenzae (38% GC); Lane 2: Escherichia coli (51% GC); Lane 3: Rhodopseudomonas palustris (65% GC); Lane 4: PhiX; Lane 5: Human; Lane 6: Human exome; Lane 7: Human mRNA.

[0128] Figure 72 The bar chart illustrating the average polymerase clonal density was obtained by distributing covalently closed circular library molecules onto a support and performing rolling circle amplification on the support. The covalently closed circular library molecules were prepared from input DNA from different species. Lane 1: Cell-free DNA; Lane 2: *E. coli*; Lane 3: Human; Lane 4: Metagenomic DNA; Lane 5: PhiX.

[0129] Figure 73 Two tables are shown, each listing the conditions used for library preparation and flow-through processing with or without reagents for reducing or removing deaminated bases from library molecules, and the corresponding sequencing quality scores for R1 and R2 reads in paired sequencing runs. Table A lists data from sequencing E. coli samples. Table B lists data from sequencing human samples.

[0130] Figure 74 A graph illustrating the nucleotide base diversity of the left sample index sequence lacking the trimeric random sequence (NNN). The graph shows that the nucleotide diversity for A and T bases is approximately 40%, for C bases approximately 15%, and for G bases approximately 5%.

[0131] Figure 75 A graph illustrating the nucleotide base diversity of the right sample index sequence, including the trimeric random sequence (NNN). The graph shows that the nucleotide diversity of the trimeric random sequence (NNN) with A and T bases is approximately 30%, and the nucleotide diversity with C and G bases is approximately 20%. Detailed Implementation

[0132] definition:

[0133] The headings provided herein are not intended to limit any aspect of this disclosure, which is to be understood by referring to the entire specification.

[0134] Unless otherwise defined, the technical and scientific terms used herein have the meanings commonly understood by one of ordinary skill in the art. Generally, terms related to the techniques of molecular biology, nucleic acid chemistry, protein chemistry, genetics, microbiology, transgenic cell production, and hybridization described herein are those well-known and commonly used in the art. The techniques and procedures described herein are generally performed according to conventional methods well-known in the art and as described in the various general and more specific references cited and discussed throughout this specification. For example, see Sambrook et al., Molecular Cloning: A Laboratory Manual (3rd edition, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY2000). See also Ausubel et al., Current Protocols in Molecular Biology, Greene Publishing Associates (1992). The nomenclature used in conjunction with the laboratory procedures and techniques described herein is that which is well-known and commonly used in the art.

[0135] Unless the context otherwise requires, singular terms shall include plural forms, and plural terms shall include singular forms. Unless explicitly and definitively limited to one referent, the singular forms “a” and “the”, and any singular use of the word, shall include multiple referents.

[0136] It should be understood that the use of alternative terms (e.g., "or") is considered to refer to one or both of the alternatives or any combination thereof.

[0137] As used herein, the term “and / or” will be considered to mean that each of the specified features or components is explicitly disclosed with or without the other. For example, the term “and / or” as used in phrases such as “A and / or B” herein is intended to include: “A and B”; “A or B”; “A” (A alone); and “B” (B alone). Similarly, the term “and / or” as used herein, such as “A, B and / or C”, is intended to cover each of the following aspects: “A, B and C”; “A, B or C”; “A or C”; “A or B”; “B or C”; “A and B”; “B and C”; “A and C”; “A” (A alone); “B” (B alone); and “C” (C alone).

[0138] As used herein and in the appended claims, the terms “comprising,” “including,” “having,” and “containing,” and their grammatical variations, are intended to be non-limiting, such that one or more items in the list do not exclude other items that may be substituted for or added to the listed items. It should be understood that whenever an aspect is described herein with the language “comprising,” other similar aspects described as “consisting of” and / or “substantially consisting of” are also provided.

[0139] As used herein, the terms “about” and “approximately” mean a value or composition within an acceptable error range for a particular value or composition, as determined by one of ordinary skill in the art, which will depend in part on how the value or composition is measured or determined, i.e., the limitations of the measurement system. For example, according to practice in the art, “about” or “approximately” may mean within one or more standard deviations. Alternatively, “about” or “approximately” may mean a range of up to 10% (i.e., ±10%) or greater, depending on the limitations of the measurement system. For example, about 5 mg may include any number between 4.5 mg and 5.5 mg. Furthermore, particularly for biological systems or processes, the term may mean a value of up to one order of magnitude or up to five times. When a particular value or composition is provided in this disclosure, unless otherwise stated, the meaning of “about” or “approximately” should be assumed to be within an acceptable error range for that particular value or composition. Furthermore, in the case of providing ranges and / or subranges of values, the range and / or subrange may include the endpoints of the range and / or subrange.

[0140] The terms “peptide,” “polypeptide,” and “protein,” as used herein, and other related terms, are used interchangeably and refer to polymers of amino acids and are not limited to any particular length. Polypeptides can contain both natural and non-natural amino acids. Polypeptides include recombinant or chemically synthesized forms. Polypeptides also include precursor molecules that have not undergone post-translational modifications, such as proteolytic cleavage, cleavage due to ribosome jumping, hydroxylation, methylation, esterification, acetylation, SUMOylation, ubiquitination, glycosylation, phosphorylation, and / or disulfide bond formation. These terms encompass natural and artificial proteins, protein fragments and polypeptide analogues (such as mutant proteins, variants, chimeric proteins, and fusion proteins), and proteins that are post-translationally or otherwise covalently or non-covalently modified.

[0141] The term "cellular biological sample" refers to a section of a single cell, multiple cells, tissue, organ, organism, or any of these cellular biological samples. Cellular biological samples can be extracted from an organism (e.g., by biopsy) or obtained from cell cultures grown in liquid or in petri dishes. Cellular biological samples can comprise fresh, frozen, fresh-frozen, or archived samples (e.g., formalin-fixed paraffin-embedded; FFPE). Cellular biological samples can be embedded in wax, resin, epoxy resin, or agar. Cellular biological samples can be fixed in any one or more of, such as acetone, ethanol, methanol, formaldehyde, paraformaldehyde-triton, or glutaraldehyde. Cellular biological samples can be sectioned or unsectioned. Cellular biological samples can be stained, destained, or unstained.

[0142] Desired nucleic acids can be extracted from cells or cellular biological samples using any of a variety of techniques known to those skilled in the art. For example, a typical DNA extraction procedure includes: (i) collecting a cell or tissue sample from which DNA is to be extracted; (ii) disrupting the cell membrane (i.e., cell lysis) to release DNA and other cytoplasmic components; (iii) treating the dissolved sample with a concentrated salt solution to precipitate proteins, lipids, and RNA, followed by centrifugation to separate the precipitated proteins, lipids, and RNA; and (iv) purifying the DNA from the supernatant to remove detergents, proteins, salts, or other reagents used during cell membrane lysis. A variety of suitable commercial nucleic acid extraction and purification kits are consistent with the disclosure herein. Examples include, but are not limited to: the QIAamp kit (for isolating genomic DNA from human samples) and DNAeasy kit (for isolating genomic DNA from animal or plant samples) from Qiagen (Germantown, MD), or the Maxwell® and ReliaPrep™ series kits from Promega (Madison, WI).

[0143] As used herein, the term "polymerase" and its variants include enzymes comprising a domain that binds a nucleotide (or nucleoside), wherein the polymerase can form a complex having a template nucleic acid and a complementary nucleotide. Polymerases may have one or more activities, including but not limited to: base analog detection activity, DNA polymerization activity, reverse transcriptase activity, DNA binding, strand substitution activity, and nucleotide binding and recognition. A polymerase can be any enzyme capable of catalyzing the polymerization of nucleotides (including their analogs) into a nucleic acid chain. Typically, but not necessarily, such nucleotide polymerization can occur in a template-dependent manner. Typically, a polymerase includes one or more active sites at which nucleotide binding and / or nucleotide polymerization catalysis can occur. In some embodiments, the polymerase contains other enzymatic activities, such as 3' to 5' exonuclease activity or 5' to 3' exonuclease activity. In some embodiments, the polymerase has strand substitution activity. Polymerases may include, but are not limited to: naturally occurring polymerases and any subunits and truncated forms thereof, mutant polymerases, variant polymerases, recombinant, fusion, or otherwise engineered polymerases, chemically modified polymerases, synthetic molecules or assemblies, and any analogs, derivatives, or fragments thereof (e.g., catalytically active fragments) that retain the ability to catalyze nucleotide polymerization. Polymerases include catalytically inactive polymerases, catalytically active polymerases, reverse transcriptases, and other enzymes containing nucleotide-binding domains. In some embodiments, polymerases may be isolated from cells or generated using recombinant DNA technology or chemical synthesis methods. In some embodiments, polymerases may be expressed in prokaryotes, eukaryotes, viruses, or bacteriophages. In some embodiments, polymerases may be post-translational modified proteins or fragments thereof. Polymerases may be derived from prokaryotes, eukaryotes, viruses, or bacteriophages. Polymerases include DNA-guided DNA polymerases and RNA-guided DNA polymerases.

[0144] The term "strand displacement" refers to the ability of a polymerase to locally separate double-stranded nucleic acid strands and synthesize a new strand in a template-based manner. Strand displacement polymerases replace the complementary strand from the template strand and catalyze the synthesis of the new strand. Strand displacement polymerases include mesophilic and thermophilic polymerases. Strand displacement polymerases include wild-type enzymes and variants (including exonuclease subtraction mutants, mutant versions, chimeric enzymes, and truncated enzymes). Examples of strand displacement polymerases include: phi29 DNA polymerase, large fragment of Bst DNA polymerase, large fragment of Bsu DNA polymerase (exo-), Bca DNA polymerase (exo-), Klenow fragment of E. coli DNA polymerase, T5 polymerase, M-MuLV reverse transcriptase, HIV reverse transcriptase, Deep Vent DNA polymerase, and KOD DNA polymerase. The phi29 DNA polymerase can be a wild-type phi29 DNA polymerase (e.g., MagniPhi from Expedeon), a variant EquiPhi29 DNA polymerase (e.g., from Thermo Fisher Scientific), or a chimeric QualiPhi DNA polymerase (e.g., from 4basebio).

[0145] The terms “nucleic acid,” “polynucleotide,” “oligonucleotide,” and other related terms used herein are used interchangeably and refer to nucleotide polymers and are not limited to any particular length. Nucleic acids include recombinant and chemically synthesized forms. Nucleic acids can be isolated. Nucleic acids include DNA molecules (e.g., cDNA or genomic DNA), RNA molecules (e.g., mRNA), DNA or RNA analogs produced using nucleotide analogs (e.g., peptide nucleic acids and non-naturally occurring nucleotide analogs), and chimeric forms containing DNA and RNA. Nucleic acids can be single-stranded or double-stranded. Nucleic acids comprise polymers of nucleotides, wherein the nucleotides comprise natural or non-natural bases and / or sugars. Nucleic acids contain naturally occurring nucleoside bonds, such as phosphodiester bonds. Nucleic acids contain non-natural nucleoside bonds, including thiophosphate, sulfur-containing phosphate, or peptide nucleic acid (PNA) bonds. In some embodiments, nucleic acids comprise one type of polynucleotide or a mixture of two or more different types of polynucleotides.

[0146] As used herein, the terms “operably linked” and “operably conjugated” or related terms refer to the juxtaposition of components. The juxtaposed components may be covalently linked together. For example, two nucleic acid components may be enzymatically linked together, wherein the bond conjugating the two components includes a phosphodiester bond. A first nucleic acid component and a second nucleic acid component may be linked together, wherein the first nucleic acid component can conjugate function to the second nucleic acid component. For example, a bond between a primer-binding sequence and a target sequence forms a nucleic acid library molecule having a primer-binding portion. In another example, a transgene (e.g., a nucleic acid encoding a polypeptide or a target nucleic acid sequence) may be linked to a vector, wherein the bond allows the transgene sequence contained in the vector to be expressed or function. In some embodiments, the transgene is operably linked to a host cell regulatory sequence (e.g., a promoter sequence) that affects transgene expression. In some embodiments, the vector includes at least one host cell regulatory sequence comprising a promoter sequence, an enhancer, a transcription and / or translation initiation sequence, a transcription and / or translation termination sequence, a polypeptide secretion signaling sequence, etc. In some embodiments, the host cell regulatory sequence controls the level, timing, and / or location of transgene expression.

[0147] The terms “linked,” “joined,” “attached,” “additional,” and variations thereof encompass any type of fusion, binding, attachment, or association between any combination of compounds or molecules that possesses sufficient stability to withstand use in a particular procedure. This procedure may include, but is not limited to: nucleotide binding; nucleotide incorporation; deblocking (e.g., removal of chain terminations); washing; removal; flow; detection; imaging and / or identification. Such bonds may include, for example, covalent bonds, ionic bonds, hydrogen bonds, dipole-dipole bonds, hydrophilic bonds, hydrophobic bonds, or affinity bonds, bonds or associations involving van der Waals forces, mechanical bonds, and so on. In some embodiments, such bonds occur intramolecularly, for example, linking the ends of single-stranded or double-stranded linear nucleic acid molecules together to form a cyclic molecule. In some embodiments, such bonds may occur between combinations of different molecules or between molecules and non-molecules, including, but not limited to: bonds between nucleic acid molecules and solid surfaces; bonds between proteins and detectable reporter moieties; bonds between nucleotides and detectable reporter moieties; and so on. Some examples of the key can be found in Hermanson, G., “Bioconjugate Techniques”, 2nd edition (2008); Aslam, M., Dent, A., “Bioconjugation: Protein Coupling Techniques for the Biomedical Sciences”, London: Macmillan (1998); Aslam, M., Dent, A., “Bioconjugation: Protein Coupling Techniques for the Biomedical Sciences”, London: Macmillan (1998).

[0148] As used herein, the term "primer" and related terms refer to oligonucleotides capable of hybridizing with DNA and / or RNA polynucleotide templates to form double-stranded molecules. Primers may be single-stranded along their entire length or have both single-stranded and double-stranded portions. Primers include natural nucleotides and / or nucleotide analogs. Primers may be recombinant nucleic acid molecules. Primers may have any length, but typically range from 4 to 50 nucleotides. Typical primers include a 5' end and a 3' end. The 3' end of a primer may contain a 3' OH portion that acts as the initiation site for nucleotide polymerization in a polymerase-catalyzed primer extension reaction. Alternatively, the 3' end of a primer may lack a 3' OH portion or may contain a terminal 3' blocking group that inhibits nucleotide polymerization in a polymerase-catalyzed reaction. Any nucleotide or more along the length of the primer may be labeled with a detectable reporter portion. Primers may be in solution (e.g., soluble primers) or may be immobilized to a support (e.g., capture primers).

[0149] The terms “template nucleic acid,” “template polynucleotide,” “target nucleic acid,” “target polynucleotide,” “template strand,” and other variations refer to the nucleic acid strand used as the base nucleic acid molecule in any amplification and / or sequencing method described herein. The template nucleic acid can be single-stranded or double-stranded, or may have single-stranded or double-stranded portions. The template nucleic acid can be obtained from naturally occurring sources, in recombinant forms, or chemically synthesized to include any type of nucleic acid analogue. The template nucleic acid can be linear, multiplicative, circular, or other forms.

[0150] The term "adaptor" and related terms refer to an oligonucleotide that can be operatively linked (added) to a target polynucleotide, wherein the adaptor confers function on the co-conjugated adaptor-target molecule. Adaptors include DNA, RNA, chimeric DNA / RNA, or analogs thereof. An adaptor may contain at least one ribonucleoside residue. An adaptor may be single-stranded, double-stranded, or have single-stranded and / or double-stranded portions. Adaptors may be configured in linear, stem-loop, hairpin, or Y-shaped forms. Adaptors can be of any length, including 4 to 100 nucleotides or longer. Adaptors may have blunt ends, overhanging ends, or a combination of both. Overhanging ends include 5' and 3' overhangs. The 5' end of a single-stranded adaptor or one strand of a double-stranded adaptor may have a 5' phosphate group or lack a 5' phosphate group. An adaptor may contain a 5' tail that has not hybridized to the target polynucleotide (e.g., a tailed adaptor), or the adaptor may be tailless. At least a portion of the adaptor contains a known and predetermined sequence. The adaptor may contain a sequence complementary to at least a portion of a primer (such as an amplification primer, sequencing primer, or capture primer (e.g., a soluble or immobilized capture primer)). The adaptor may contain a random or degenerate sequence. The adaptor may contain at least one inosine residue. The adaptor may contain at least one thiophosphate, thiophosphate, and / or phosphoramide bond. The adaptor may contain at least one barcode sequence that can be used to distinguish polynucleotides (e.g., insert sequences) from different sample sources in multiplex assays. The adaptor may contain at least one unique identification sequence (e.g., a molecular identifier) ​​that can be used to uniquely identify the nucleic acid molecule to which the adaptor is appended. In some embodiments, the unique identification sequence comprises 2 to 12 or more nucleotides having a known sequence. For example, the unique identification sequence comprises a known random sequence, wherein the nucleotides at each position are randomly selected from nucleotides having bases A, G, C, T, or U. The adaptor may contain at least one restriction enzyme recognition sequence, including any combination of any one or more of the group consisting of types I, II, III, IV, Hs, or IIB.

[0151] The term "universal sequence" and related terms refer to a sequence common to two or more polynucleotide molecules in a nucleic acid molecule. For example, an adaptor with a universal sequence can operatively bind to multiple polynucleotides such that a population of co-conjugated molecules carries the same universal adaptor sequence. Examples of universal adaptor sequences include amplification primer sequences, sequencing primer sequences, or capture primer sequences (e.g., soluble or immobilized capture primers).

[0152] When used to refer to nucleic acid molecules, the terms "hybridize," "hybridizing," "hybridization," or other related terms refer to the hydrogen bonding between two different nucleic acids to form a double-stranded nucleic acid. Hybridization also includes the hydrogen bonding between two different regions of a single nucleic acid molecule to form a self-hybridized molecule with double-stranded regions. Hybridization may involve Watson-Crick or Hoogstein binding to form a double-stranded nucleic acid or a double-stranded region within a nucleic acid molecule. The two different regions of a double-stranded nucleic acid or a single nucleic acid can be completely complementary or partially complementary. Complementary nucleic acid strands do not need to hybridize to each other across their entire length. Complementary base pairing can be standard AT or CG base pairing, or it can be other forms of base pairing interaction. Double-stranded nucleic acids may contain mismatched base-paired nucleotides.

[0153] When used to refer to nucleic acids, the terms "extend," "extending," "extension," and other variations refer to the incorporation of one or more nucleotides into a nucleic acid molecule. Nucleotide incorporation involves the polymerization of one or more nucleotides into the 3' OH terminus of the nucleic acid chain, resulting in the extension of the nucleic acid chain. Nucleotide incorporation can be performed using native nucleotides and / or nucleotide analogs. Typically, but not always, nucleotide incorporation occurs in a template-dependent manner. Any suitable method for extending nucleic acid molecules can be used, including primer extension catalyzed by DNA polymerase or RNA polymerase.

[0154] The term "nucleotide" and related terms refer to a molecule comprising an aromatic base, a pentose sugar (e.g., ribose or deoxyribose), and at least one phosphate ester group. Canonical or non-canonical nucleotides are used in accordance with this terminology. In some embodiments, a nucleotide comprises a monophosphate, diphosphate, triphosphate, or a corresponding phosphate analog. The term "nucleoside" refers to a molecule comprising an aromatic base and a sugar. Nucleotides and nucleosides may be unlabeled or partially labeled with a detectable reporter substance.

[0155] Nucleotides (and nucleosides) typically contain heterocyclic bases, including substituted or unsubstituted nitrogen-containing parent heteroaromatic rings, commonly found in nucleic acids, including naturally occurring, substituted, modified, or engineered variants or analogues thereof. The bases of nucleotides (or nucleosides) are capable of forming Watson-Crick and / or Husstein hydrogen bonds with suitable complementary bases. Exemplary bases include, but are not limited to, purines and pyrimidines, such as: 2-aminopurine, 2,6-diaminopurine, adenine (A), ethylene adenine, N... 6 -Δ 2 -Isopentenyladenine (6iA), N 6 -Δ 2 -Isopentenyl-2-methylthioadenine (2ms6iA), N 6 -Methyladenine, guanine (G), isoguanine, N 2 -Dimethylguanine (dmG), 7-methylguanine (7mG), 2-thiopyrimidine, 6-thioguanine (6sG), hypoxanthine and O 6 -Methylguanine; 7-denitro-purine, such as 7-denitro-adenine (7-denitro-A) and 7-denitro-guanine (7-denitro-G); pyrimidine, such as cytosine (C), 5-propynylcytosine, isocytosine, thymine (T), 4-thiothymine (4sT), 5,6-dihydrothymine, O 4 -Methylthymine, uracil (U), 4-thiouracil (4sU), and 5,6-dihydrouracil (dihydrouracil; D); indole, such as nitroindole and 4-methylindole; pyrrole, such as nitropyrrole; muscarin; inosine; hydroxymethylcytosine; 5-methylcytosine; base (Y); and methylated, glycosylated, and acylated base moieties; etc. Further exemplary bases can be found in Fasman, 1989, in “Practical Handbook of Biochemistry and Molecular Biology”, pp. 385–394, CRC Press, Boca Raton, Fla.

[0156] Nucleotides (and nucleosides) typically contain sugar moieties such as carbocyclic moieties (Ferraro and Gotor 2000 Chem. Rev. 100: 4319-48), acyclic moieties (Martinez et al., 1999 Nucleic Acids Research 27: 1271-1274; Martinez et al., 1997 Bioorganic & Medicinal Chemistry Letters Vol. 7: 3013-3016), and other sugar moieties (Joeng et al., 1993 J. Med. Chem. 36: 2627-2638; Kim et al., 1993 J. Med. Chem. 36: 30-7; Eschenmosser 1999 Science 284: 2118-2124; and U.S. Patent No. 5,558,991). The sugar moiety includes: ribosyl; 2'-deoxyribosyl; 3'-deoxyribosyl; 2',3'-dideoxyribosyl; 2',3'-didehydrodideoxyribosyl; 2'-alkoxyribosyl; 2'-azidoribosyl; 2'-aminoribosyl; 2'-fluororibosyl; 2'-mercaptoribosyl; 2'-alkylthioribosyl; 3'-alkoxyribosyl; 3'-azidoribosyl; 3'-aminoribosyl; 3'-fluororibosyl; 3'-mercaptoribosyl; 3'-alkylthioribosyl carbocyclic; acyclic or other modified sugars.

[0157] In some embodiments, the nucleotide comprises a chain of one, two, or three phosphorus atoms, wherein the chain is typically attached to the 5' carbon of the sugar moiety via an ester or phosphoramide bond. In some embodiments, the nucleotide is an analogue having a phosphorus chain, wherein the phosphorus atoms are linked together by an intermediate O, S, NH, methylene, or ethylene group. In some embodiments, the phosphorus atom in the chain comprises a substituted side group, which includes O, S, or BH3. In some embodiments, the chain comprises a phosphate ester group substituted with an analogue, which includes phosphoramide, thiophosphate, dithiophosphate, and O-methylphosphoramide groups.

[0158] The term "rolling circle amplification" generally refers to an amplification method that employs a circularized nucleic acid template molecule containing a target sequence, an amplification primer-binding sequence, and optionally one or more adaptor sequences, such as sequencing primer-binding sequences and / or sample index sequences. Rolling circle amplification reactions can be performed under isothermal amplification conditions and include a circularized nucleic acid template molecule, amplification primers, a strand displacement polymerase, and multiple nucleotides to generate multiplexes containing tandem repeat sequences of the circular template molecule, as well as any adaptor sequences present in the original circularized nucleic acid template molecule. The multiplexes can self-collapse to form nucleic acid nanospheres. The shape and size of the nanospheres can be further compressed by including a pair of inverted repeat sequences in the circular template molecule, or by performing rolling circle amplification with one or more compressed oligonucleotides. One advantage of using rolling circle amplification to generate clonal amplicones for sequencing workflows is that repetitive copies of the target sequence in the nanospheres can be sequenced simultaneously to increase signal strength. In some embodiments, rolling circle amplification reactions can be performed in the presence of multiple compressed oligonucleotides having at least four consecutive guanines. The rolling circle amplification reaction generates multiplexes containing repetitive copies of a universal binding sequence for the compressed oligonucleotides. At least one compressed oligonucleotide can form a guanine tetramer and hybridize with a universal binding sequence for the compressed oligonucleotide, and the resulting polymer can fold to form an intramolecular G-quadruplex structure. The polymer can self-collapse to form a compressed nanosphere. The formation of the guanine tetramer and G-quadruplex within the nanosphere increases the stability of the nanosphere to maintain its compact size and shape, thus withstanding repeated flows of reagents used in any sequencing workflow described herein.

[0159] When used to refer to nucleic acids, the terms "amplify," "amplifying," and other related terms include generating multiple copies of the original polynucleotide template molecule, wherein the copies contain sequences complementary to the template sequence, and / or the copies contain sequences identical to the template sequence. In some embodiments, the copies contain sequences substantially identical to the template sequence, and / or sequences substantially identical to sequences complementary to the template sequence.

[0160] The terms "reporter moiety," "reporter moieties," or related terms refer to compounds that produce or cause a detectable signal. A reporter moiety is sometimes referred to as a "tag." Any suitable reporter moiety can be used, including luminescence, photoluminescence, electroluminescence, bioluminescence, chemiluminescence, fluorescence, phosphorescence, chromophores, radioisotopes, electrochemical, mass spectrometry, Raman spectroscopy, haptens, affinity tags, atoms, or enzymes. A reporter moiety produces a detectable signal caused by a chemical or physical change, such as heat, light, electricity, pH, salt concentration, enzyme activity, or proximity events. Proximity events include two reporter moieties coming close to each other, associating with each other, or binding together. Those skilled in the art are well aware of selecting reporter moieties such that each reporter moiety absorbs excitation radiation and / or emits fluorescence at a wavelength distinguishable from other reporter moieties, allowing for the monitoring of the presence of different reporter moieties in the same or different reactions. Two or more different reporter moieties with spectrally distinct emission profiles or with minimal overlap spectral emission profiles can be selected. The reporter portion may be linked (e.g., operably linked) to nucleotides, nucleosides, nucleic acids, enzymes (e.g., polymerases or reverse transcriptases) or supports (e.g., surfaces).

[0161] The report portion (or labeling) includes fluorescent labels or fluorophores. Exemplary fluorescent portions that can be used as fluorescent markers or fluorophores include, but are not limited to, fluoresceins and fluorescein derivatives, such as carboxyfluorescein, tetrachlorofluorescein, hexachlorofluorescein, carboxynaphthol fluorescein, isothiocyanate fluorescein, NHS-fluorescein, iodoacetamide-fluorescein, maleimide fluorescein, SAMSA-fluorescein, aminothiourea fluorescein, hydrazine methylthioacetamide-fluorescein; rhodamine and rhodamine derivatives, such as TRITC, TMR, lissamine rhodamine, Texas red, rhodamine B, rhodamine 6G, rhodamine 10, NHS-rhodamine, TMR-iodoacetamide, lissamine rhodamine B sulfonyl chloride, lissamine rhodamine B sulfonyl hydrazine, Texas red sulfonyl chloride, Texas red hydrazine; coumarins and coumarin derivatives, such as AMCA, AMCA-NHS, AMCA-sulfonyl-NHS, AMCA-HPDP, DCIA, AMCE-hydrazine; BODIPY® and derivatives such as BODIPY. FL C3-SE, BODIPY 530 / 550 C3, BODIPY 530 / 550 C3-SE, BODIPY 530 / 550 C3 hydrazide, BODIPY 493 / 503 C3 hydrazide, BODIPY FL C3 hydrazide, BODIPYFL IA, BODIPY 530 / 551 IA, Br-BODIPY 493 / 503, Cascade Blue and its derivatives, such as Cascade Blue acetylazide, Cascade Blue cadaverine, Cascade Blue ethylenediamine, Cascade Blue hydrazide, Lucifer Yellow and its derivatives, such as Lucifer Yellow iodoacetamide, Lucifer Yellow CH, cyanines and their derivatives, such as indolonyl cyanine dyes, benzoindolonyl cyanine dyes, pyridinium cyanine dyes, thiazolonyl cyanine dyes, quinolinelonyl cyanine dyes, imidazolonyl cyanine dyes, Cy3, Cy5, lanthanide chelates and their derivatives, such as BCPDA, TBP, TMT, BHHCT, BCOT, europium chelates, terbium chelates, Alexa Fluor® dyes, DyLight® dyes, Atto TM Dyes, LightCycler® Red dyes, CAL Flour dyes, JOE and its derivatives, Oregon Green TMDyes, WellRED dyes, IRD dyes, phycoerythrin and phycobilin dyes, malachite green, diphenylethylene, DEG dyes, NR dyes, near-infrared dyes, and other dyes known in the art, such as the fluorescent moieties described in Haugland, Molecular Probes Handbook, (Eugene, Oreg.) 6th edition; Lakowicz, Principles of Fluorescence Spectroscopy, 2nd edition, Plenum Press New York (1999) or Hermanson, Bioconjugate Techniques, 2nd edition, or derivatives thereof; or any combination thereof. Anthocyanin dyes may be present in sulfonated or non-sulfonated forms and consist of two pseudoindole, benzoindoline, pyridinium, thiazoline, and / or quinolinium groups separated by a polymethystylene bridge between two nitrogen atoms.Commercially available anthocyanin fluorophores include, for example, Cy3 (which may contain 1-[6-(2,5-dioxopyrrolidone-1-yloxy)-6-oxohexyl]-2-(3-{1-[6-(2,5-dioxopyrrolidone-1-yloxy)-6-oxohexyl]-3,3-dimethyl-1,3-dihydro-2H-indol-2-ylidene}prop-1-en-1-yl)-3,3-dimethyl-3H-indolium or 1-[6-(2,5-dioxopyrrolidone-1-yloxy)-6-oxohexyl]-2-(3-{ ...3,3-dimethyl-1,3-dihydro-2H-indol-2-ylidene}prop-1-en-1-yl)-3,3-dimethyl-3H-indolium or 1-[6-(2,5-dioxopyrrolidone-1-yloxy)-6-oxohexyl]-2-(3-{1-[6-(2,5-dioxopyrrolidone-1-yloxy)-6-oxohexyl]-2-(3-{1-[6-(2,5-dioxopyrrolidone-1-yloxy)-6-oxohexyl]-2- [[1-(6-((2,5-dioxopyrrolidone-1-yl)oxy)-6-oxohexyl]-3,3-dimethyl-5-sulfonyl-1,3-dihydro-2H-indol-2-ylide]prop-1-en-1-yl)-3,3-dimethyl-3H-indolon-5-sulfonate], Cy5 (which may contain 1-(6-((2,5-dioxopyrrolidone-1-yl)oxy)-6-oxohexyl)-2-((1E,3E)-5-((E)-1-(6-((2,5-dioxopyrrolidone-1-yl)oxy)-6-oxohexyl)-3,3-dimethyl-5-indololin-2-ylide) )pent-1,3-dien-1-yl)-3,3-dimethyl-3H-indole-1-onium or 1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-2-((1E,3E)-5-((E)-1-(6-((2,5-dioxopyrrolidin-1-yl)oxy)-6-oxohexyl)-3,3-dimethyl-5-sulfonoindoline-2-ylidene)pent-1,3-dien-1-yl)-3,3-dimethyl-3H-indole-1-onium-5-sulfonate) and Cy7 (which may contain 1-(5-carboxypentyl) Cy2 is an oxazole derivative rather than a pseudoindole, and the benzo[Cy]-2-[(1E,3E,5E,7Z)-7-(1-ethyl-1,3-dihydro-2H-indole-2-ylidene)hept-1,3,5-trien-1-yl]-3H-indole-5-sulfonate, where “Cy” stands for 'cyanine' and the first number indicates the number of carbon atoms between the two pseudoindole groups. Cy2 is an oxazole derivative rather than a pseudoindole, and the benzo[Cy]-derived Cy3.5, Cy5.5, and Cy7.5 are exceptions to this rule.

[0162] In some embodiments, the report portion may be a FRET pair, allowing multiple classifications to be performed in a single excitation and imaging step. As used herein, FRET may include excitation exchange (Forster) transfer or electron exchange (Dexter) transfer.

[0163] As used herein, the term "support" refers to a substrate designed for the deposition of biological molecules or biological samples for assays and / or analyses. Examples of biological molecules to be deposited onto a support include nucleic acids (e.g., DNA, RNA), peptides, carbohydrates, lipids, single cells, or multiple cells. Examples of biological samples include, but are not limited to, saliva, sputum, mucus, blood, plasma, serum, urine, feces, sweat, tears, and fluids from tissues or organs.

[0164] In some embodiments, the support is solid, semi-solid, or a combination of both. In some embodiments, the support is any combination of porous, semi-porous, non-porous, or porous. In some embodiments, the support can be substantially planar, concave, convex, or any combination thereof. In some embodiments, the support can be cylindrical, for example, including a capillary or the inner surface of a capillary.

[0165] In some embodiments, the surface of the support may be substantially smooth. In some embodiments, the support may have a regular or irregular texture, which includes bumps, etching, holes, three-dimensional supports, or any combination thereof.

[0166] In some embodiments, the support comprises beads of any shape, including spherical, hemispherical, cylindrical, barrel-shaped, ring-shaped, disc-shaped, rod-shaped, conical, triangular, cubic, polygonal, tubular, or linear.

[0167] The support can be made of any material, including but not limited to: glass, fused silica, silicon, polymers (e.g., polystyrene (PS), macroporous polystyrene (MPPS), polymethyl methacrylate (PMMA), polycarbonate (PC), polypropylene (PP), polyethylene (PE), high-density polyethylene (HDPE), cyclic olefin polymers (COP), cyclic olefin copolymers (COC), polyethylene terephthalate (PET)) or any combination thereof. Various combinations of both glass and plastic substrates are envisioned.

[0168] This disclosure provides a plurality (e.g., two or more) of nucleic acid template molecules immobilized to a support. In some embodiments, the immobilized plurality of nucleic acid template molecules have the same sequence or different sequences. In some embodiments, each of the plurality of nucleic acid template molecules is immobilized to a different site on the support. In some embodiments, two or more of the plurality of nucleic acid template molecules are immobilized to sites on the support.

[0169] The term "array" refers to a support containing a plurality of sites located at predetermined positions on a support to form an array of sites. The sites can be discrete and separated by interstitial space. In some embodiments, the predetermined sites on the support can be arranged in rows or columns in one dimension, or in rows and columns in two dimensions. In some embodiments, the plurality of predetermined sites are arranged in an organized manner on the support. In some embodiments, the plurality of predetermined sites are arranged in any organized pattern, including straight lines, hexagonal patterns, grid patterns, patterns with reflective symmetry, patterns with rotational symmetry, etc. The spacing between different pairs of sites can be the same or different. In some embodiments, the support includes at least 10 2 At least 10 sites 3 At least 10 sites 4 At least 10 sites 5 At least 10 sites 6 At least 10 sites 7 At least 10 sites 8 At least 10 sites 9 At least 10 sites 10 At least 10 sites 11 At least 10 sites 12 At least 10 sites 13 At least 10 sites 14 At least 10 sites 15 One or more sites, wherein the site is located at a predetermined position on the support. In some embodiments, a plurality of predetermined sites on the support (e.g., 10 sites) 2 Up to 10 15 Nucleic acid template molecules are immobilized at multiple sites (one or more) to form a nucleic acid template array. In some embodiments, nucleic acid template molecules are immobilized at multiple predetermined sites by hybridization with immobilized surface capture primers, or by covalently attaching nucleic acid template molecules to surface capture primers. In some embodiments, nucleic acid template molecules are immobilized at multiple predetermined sites, for example, at 10 sites. 2 Up to 10 15 At one or more predetermined sites. In some embodiments, a fixed nucleic acid template molecule is cloned and amplified to generate fixed nucleic acid clusters at the multiple predetermined sites. In some embodiments, each fixed nucleic acid cluster comprises a linear cluster, or comprises single-stranded or double-stranded multiples.

[0170] In some embodiments, a support including the plurality of sites located at random positions on a support is referred herein to as a support having randomly positioned sites thereon. The positions of the randomly positioned sites on the support are not predetermined. The plurality of randomly positioned sites are arranged on the support in a disordered and / or unpredictable manner. In some embodiments, the support comprises at least 10 2At least 10 sites 3 At least 10 sites 4 At least 10 sites 5 At least 10 sites 6 At least 10 sites 7 At least 10 sites 8 At least 10 sites 9 At least 10 sites 10 At least 10 sites 11 At least 10 sites 12 At least 10 sites 13 At least 10 sites 14 At least 10 sites 15 One or more sites, wherein the sites are randomly located on the support. In some embodiments, multiple randomly located sites on the support (e.g., 10 sites) 2 Up to 10 15 Nucleic acid template molecules are immobilized at multiple randomized sites (one or more). In some embodiments, the nucleic acid template molecules are immobilized at multiple randomly located sites by hybridization with immobilized surface capture primers, or by covalently attaching the nucleic acid template molecules to the surface capture primers. In some embodiments, the nucleic acid template is immobilized at multiple randomly located sites, for example, at 10 sites. 2 Up to 10 15 At one or more sites. In some embodiments, a fixed nucleic acid template is amplified in a clonal manner to generate fixed nucleic acid clusters at the plurality of randomly located sites. In some embodiments, each fixed nucleic acid cluster comprises a linear cluster, or comprises single-stranded or double-stranded multiples.

[0171] In some embodiments, the plurality of fixed surface capture primers on the support (e.g., positioned at predetermined or random locations on the support) are fluidly connected to each other to allow reagent solutions (e.g., nucleic acid template molecules, soluble primers, enzymes, nucleotides, divalent cations, buffers, etc.) to flow onto the support, such that the plurality of fixed surface capture primers on the support can react with the reagents substantially simultaneously in a large-scale parallel manner. In some embodiments, the fluid connectivity of the plurality of fixed surface capture primers can be used to perform nucleic acid amplification reactions (e.g., RCA, MDA, PCR, and bridge amplification) substantially simultaneously on the plurality of fixed surface capture primers.

[0172] In some embodiments, the plurality of immobilized nucleic acid clusters on the support are fluidly connected to each other to allow solutions of reagents (e.g., enzymes, nucleotides, divalent cations, etc.) to flow onto the support, such that the plurality of immobilized nucleic acid clusters on the support can react with the reagents substantially simultaneously in a massively parallel manner. In some embodiments, the fluid connectivity of the plurality of immobilized nucleic acid clusters can be used to perform nucleotide binding assays and / or nucleotide polymerization reactions (e.g., primer extension or sequencing) substantially simultaneously on the plurality of immobilized nucleic acid clusters, and optionally to perform detection and imaging of massively parallel sequencing.

[0173] The term "fixed" and related terms refer to nucleic acid molecules attached to a support, or to a coating on a support, or embedded within a matrix formed by a coating on a support via covalent bonds or non-covalent interactions, wherein the nucleic acid molecules include surface capture primers, nucleic acid template molecules, and extension products of the capture primers. Extension products of the capture primers may include nucleic acid multiplexes (e.g., nucleic acid clusters). Nucleic acid molecules may be fixed at predetermined or random locations on the support. Nucleic acid molecules may be fixed at predetermined or random locations on or within a passivated coating on the support.

[0174] The term "fixed" and related terms may also refer to an enzyme (e.g., a polymerase) attached to a support by covalent bonds or non-covalent interactions, or to a coating on a support, or embedded within a matrix formed by a coating on a support. The enzyme may be fixed at predetermined or random locations on the support. The enzyme may be fixed at predetermined or random locations on or within a passivated coating on the support.

[0175] In some embodiments, one or more nucleic acid template molecules are immobilized on a support, for example, at sites on the support. In some embodiments, one or more nucleic acid template molecules are cloned and amplified. In some embodiments, one or more nucleic acid template molecules are cloned and amplified from a support (e.g., in solution), then deposited onto the support and immobilized. In some embodiments, the clonal amplification reaction of one or more nucleic acid template molecules is performed on the support, resulting in immobilization on the support. In some embodiments, the one or more nucleic acid templates are amplified clonally using a nucleic acid amplification reaction (e.g., in solution or on a support), the nucleic acid amplification reaction including any one or any combination of the following: polymerase chain reaction (PCR), multiple displacement amplification (MDA), transcription-mediated amplification (TMA), nucleic acid sequence-based amplification (NASBA), strand displacement amplification (SDA), real-time SDA, bridging amplification, isothermal bridging amplification, rolling circle amplification (RCA), loop-to-loop amplification, helicase-dependent amplification, recombinase-dependent amplification, and / or single-strand binding (SSB) protein-dependent amplification.

[0176] The term "surface primer" and related terms herein refer to a single-stranded oligonucleotide immobilized to a support and containing a sequence capable of hybridizing with at least a portion of a nucleic acid template molecule. Surface capture primers can be used to immobilize template molecules to a support via hybridization. Surface capture primers can be immobilized to the support in a manner resistant to primer removal during flow, washing, aspiration, and changes in temperature, pH, salt, chemical, and / or enzymatic conditions. Typically, but not necessarily, the 5' end of the surface capture primer may be immobilized to the support or a coating on the support (or embedded in a coating on the support). Alternatively, the interior or 3' end of the surface capture primer may be immobilized to the support.

[0177] The sequence of the surface capture primer may be completely or partially complementary to at least a portion of the nucleic acid template molecule along its length. The support may include multiple fixed surface capture primers having the same sequence or having two or more different sequences. The surface capture primers may be of any length, such as 4 to 50 nucleotides, or 50 to 100 nucleotides, or 100 to 150 nucleotides, or longer.

[0178] Surface capture primers may have a terminal 3' nucleotide with a sugar 3' OH moiety that can extend for nucleotide polymerization (e.g., polymerase-catalyzed polymerization). Surface capture primers may also have a terminal 3' nucleotide with a 3' sugar position linked to a chain-terminating moiety that inhibits nucleotide polymerization. The 3' chain-terminating moiety can be removed (e.g., deblocked) using a deblocking agent to convert the 3' end into an extendable 3' OH end. Examples of chain-terminating moieties include alkyl groups, alkenyl groups, alkynyl groups, allyl groups, aryl groups, benzyl groups, azido groups, amine groups, amide groups, ketol groups, isocyanate groups, phosphate groups, thio groups, disulfide groups, carbonate groups, urea groups, acetal groups, or silyl groups. Azide-type chain-terminating moieties include azido, azidoyl, and azidomethyl groups. Examples of deblocking agents include phosphine compounds, such as tris(2-carboxyethyl)phosphine (TCEP) and bissulfotriphenylphosphine (BS-TPP), for the chain-terminating groups azido, azidoyl, and azidomethyl groups. Examples of deblocking agents include tetra(triphenylphosphine)palladium(O) (Pd(PPh3)4) with piperidine or with 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ), for the chain-terminating groups alkyl, alkenyl, alkynyl, and allyl. Examples of deblocking agents include Pd / C, for the chain-terminating groups aryl and benzyl. Examples of deblocking agents include phosphine, β-mercaptoethanol, or dithiothreitol (DTT), for the chain-terminating groups amine, amide, ketone, isocyanate, phosphate, thio, and disulfide. Examples of deblocking agents include potassium carbonate (K2CO3) in MeOH, triethylamine in pyridine, and Zn in acetic acid (AcOH), for the carbonate chain-terminating group. Examples of deblocking agents include tetrabutylammonium fluoride, pyridine-HF, and ammonium fluoride and triethylamine trihydrofluoride, used for chain-terminating groups urea and silyl groups.

[0179] The term "sequencing" and related terms refer to methods for obtaining nucleotide sequence information from nucleic acid molecules, typically by identifying at least some nucleotides (including their nucleobase composition) within the nucleic acid molecule. In some embodiments, sequence information for a given region of the nucleic acid molecule includes identifying each nucleotide within the sequenced region. In some embodiments, sequencing information identifies only some nucleotides in the region, while the identification of some nucleotides remains undetermined or incorrectly determined. Any suitable sequencing method can be used. In exemplary embodiments, sequencing may include label-free or ion-based sequencing methods. In some embodiments, sequencing may include labeled or dye-based or fluorescence-based nucleotide sequencing methods. In some embodiments, sequencing may include polymerase cloning-based sequencing or bridge sequencing methods. In some embodiments, sequencing employs polymerases and multivalent molecules to generate at least one affinity complex, wherein each multivalent molecule contains multiple nucleotide moieties tethered to a core. In some embodiments, sequencing employs polymerases and free nucleotides for sequencing-by-synthesis. In some embodiments, sequencing employs ligases and multiple sequence-specific oligonucleotides for sequencing-by-ligation.

[0180] introduction

[0181] High-quality sequencing errors have been observed in massively parallel pairwise sequencing workflows using detectably labeled multivalent molecules. These errors include bases assigned high-quality sequencing scores but not matching reference bases. Without being bound by theory, it is believed that these high-quality sequencing errors are caused by upstream or downstream processes in the sequencing portion of the workflow. Examples of upstream processes include library preparation and loading the prepared library onto a sequencing flow pool for fixation and sequencing, i.e., steps prior to sequencing.

[0182] Library preparation workflows include numerous steps, including but not limited to: fragmentation of input nucleic acids; end repair of double-stranded fragmented nucleic acids; template-free tailing of double-stranded fragmented nucleic acids; attachment of adapters by ligation or PCR; PCR amplification; denaturation to generate single-stranded library molecules; circularization of single-stranded library molecules; and / or immobilization of linear or circularized library molecules. In some embodiments, the library preparation workflow may be PCR-free. In some embodiments, the library preparation workflow includes the removal of deaminonucleotide bases and gap generation of nucleic acid molecules carrying at least one deaminonucleotide base. In some embodiments, a method for loading the prepared library onto a sequencing flow cell includes the removal of deaminonucleotide bases and gap generation of nucleic acid molecules carrying at least one deaminonucleotide base.

[0183] High-quality base misreading errors have been detected for T bases when sequencing the first strand (e.g., the R1 read) and for A bases when sequencing corresponding positions on the complementary second strand (e.g., the R2 read). Many of these high-quality T base misreading errors on the first strand sequence align with C bases in a known reference sequence. It is believed that some bases in the library molecule have been deaminated, leading to base substitutions, including C:G to T:A transitions.

[0184] Deamination typically involves removing an amino group from a molecule. Regarding nucleotide bases, cytosine (C) can be deaminated to produce uracil (U), where uracil can pair with an adenine (A) base; guanine (G) can be deaminated to produce xanthine, where xanthine can pair with a cytosine (C) base; and adenine (A) can be deaminated to produce hypoxanthine, where hypoxanthine can pair with a cytosine (C) base (e.g., Figure 14 ).

[0185] The workflow for preparing nucleic acid library molecules involves numerous steps, including conditions that can cause deamination of nucleotide bases. For example, and not limited to, deamination can be caused by the presence of deaminases at any stage of the library preparation workflow. As another non-limiting example, any library preparation buffer with a low pH value can lead to base deamination. In another non-limiting example, the high temperatures used in PCR can cause base deamination. In another non-limiting example, the mechanical shearing forces used to fragment the input nucleic acid can generate damaging free radicals that cause deamination. Exemplary mechanical forces may include ultrasonic forces, acoustic forces, atomizing forces, shearing forces, and cavitation forces. In another example, certain chemicals, such as bisulfites, can cause deamination. Those skilled in the art will recognize that nucleotide base deamination can be generated by many other conditions and any combination of the above conditions.

[0186] In some embodiments, the library preparation workflow can generate a plurality of library molecules, comprising a mixture of a first subgroup and a second subgroup of library molecules. In some embodiments, each library molecule in the first subgroup carries at least one deaminated nucleotide base. In some embodiments, each library molecule in the second subgroup lacks a deaminated nucleotide base.

[0187] This disclosure provides compositions and methods for improving sequencing quality scores, including removing deaminated bases from any nucleic acid molecules throughout the workflow, including, for example, fragmented input nucleic acid molecules. In some embodiments, fragmented input nucleic acid molecules carrying deaminated bases may be removed while fragmented input nucleic acid molecules lacking deaminated bases are retained. In some embodiments, the compositions and methods for removing deaminated bases from multiple fragmented input nucleic acid molecules employ at least one enzyme containing glycosylation enzyme activity and / or at least one enzyme containing lyase activity.

[0188] This disclosure also provides compositions and methods for improving sequencing quality scores, including removing deamination bases from multiple nucleic acid library molecules. In some embodiments, library molecules carrying deamination bases may be removed while library molecules lacking deamination bases are retained. In some embodiments, the compositions and methods for removing deamination bases from library molecules employ at least one enzyme containing glycosylation enzyme activity and / or at least one enzyme containing lyase activity. In some embodiments, the compositions and methods for removing deamination bases from library molecules can be applied to any type of nucleic acid library molecule, including, for example, linear or circularized library molecules, and library molecules for sequencing in a massively parallel manner. In some embodiments, the compositions and methods for removing deamination bases from library molecules may be applied to a support before or during rolling circle amplification reactions.

[0189] High-quality base-reading errors have also been detected near the ends of the insertion regions of library molecules. For example, G-to-T errors have been detected in early sequencing cycles of read 2 (R2), or C-to-A errors have been detected on the reverse strand. Without being bound by theory, these errors are believed to occur during the end-repair steps of the library preparation workflow, for example, but not limited to, before attaching the adaptor to the end-repaired nucleic acid molecule.

[0190] End-repair workflows are typically employed after fragmentation of the input double-stranded nucleic acid via mechanical shearing, which yields a mixture of fragmented nucleic acids with 5' overhanging ends, 3' overhanging ends, and / or blunt ends. End-repair workflows can generate double-stranded fragments with blunt ends at both ends. End-repair workflows can be performed by enzymatic exonuclease degradation of the 5' or 3' overhanging ends and / or by polymerase-catalyzed extension of the 3' overhanging ends. Exonuclease degradation reactions typically do not introduce base errors at the ends of nucleic acid fragments. In contrast, polymerase-catalyzed extension reactions can be relatively low-fidelity reactions that can introduce base errors, including G-to-T base errors, at the ends of nucleic acid fragments. In some embodiments, the end-repair workflow includes a polymerase-catalyzed extension reaction.

[0191] This disclosure also provides compositions and methods for improving sequencing quality scores, comprising reducing base errors on one strand, including G-to-T base errors, by performing an end-repair workflow on multiple fragmented input nucleic acids, wherein the end-repair workflow lacks polymerase-catalyzed extension of the 3' overhanging end, wherein the opposing strand contains a 5' overhanging end. For example, and not limited to, the end-repair workflow includes employing a nuclease to degrade the 5' overhanging end, thereby generating a blunt end. In some embodiments, the end-repair workflow may further include employing a nuclease to degrade the 3' overhanging end, thereby generating a blunt end.

[0192] This disclosure further provides compositions and methods for improving sequencing quality scores, comprising reducing base errors on a strand, including G-to-T base errors, by performing dark sequencing during the initial 2 to 30 bases (e.g., 5 to 30, 2 to 20, 10 to 30, 10 to 20, 15 to 30 bases, or any range thereof) of the second read (read 2 or R2) strand. In some embodiments, dark sequencing may be performed on 2 to 30 consecutive bases in the initial portion of the read 2 (R2) strand. As used herein, “dark sequencing” refers to a method that includes recursive sequencing cycles using unlabeled nucleotide reagents with extendable sequencing primers, but without detecting nucleotide incorporation. In some embodiments, the unlabeled nucleotide reagents comprise unlabeled canonical nucleotides and / or unlabeled chain terminator nucleotides.

[0193] This disclosure also provides compositions and methods for improving sequencing quality scores, comprising any combination of one or more of the following: (i) removing deaminated bases from any nucleic acid molecule throughout the library preparation workflow; (ii) performing a library preparation workflow including end-repair methods to reduce the introduction of erroneous nucleotide bases; (iii) inactivating ligase activity using an alkaline reagent instead of heat; (iv) inactivating exonuclease activity using an alkaline reagent instead of heat; (v) removing deaminated bases from any nucleic acid molecule loaded onto a sequencing flow cell; and / or (vi) dark sequencing. In some embodiments, any of these compositions and methods may reduce C:G to T:A base transitions, which may result in higher quality base interpretation during downstream sequencing workflows. In some embodiments, the sequencing quality score of Q30 may be increased to a sequencing quality score of Q40, Q45, Q50, Q55, Q60, or higher.

[0194] In some embodiments, the accuracy and quality of base interpretation from sequencing data can be assessed. The “Q score” is a measure of data quality. The Q score can be defined as the Phred quality score. The Q score is based on a logarithmic scale. It is generally defined as Q = -10log(P), where P is the error probability. For example, Q10 represents a 10% error, Q20 represents a 1% error, Q30 represents a 0.1% error, and Q40 represents a 0.01% error. In another instance, Q10 is a 1 / 10 error, Q20 is a 1 / 100 error, Q30 is a 1 / 1000 error, Q40 is a 1 / 10,000 error, Q50 is a 1 / 100,000 error, and Q60 is a 1 / 1,000,000 error.

[0195] Preparation of nucleic acid molecules with reduced deaminated nucleotide bases

[0196] In some aspects, this disclosure provides methods for improving sequencing quality scores, which include performing a library preparation workflow that includes at least one step for reducing / removing deaminonucleotide bases in fragmented input nucleic acids and / or in cyclized library molecules and / or in immobilized cyclized library molecules.

[0197] Remove deamino bases from fragmented input nucleic acid molecules

[0198] In some embodiments, a method for preparing fragmented input nucleic acid molecules having reduced deaminonucleotide bases includes the step (a): fragmenting the input nucleic acid to generate a plurality of fragmented input nucleic acids, comprising a first subgroup and a second subgroup of fragmented input nucleic acid molecules. In some embodiments, each fragmented input nucleic acid molecule in the first subgroup carries at least one deaminonucleotide base. In some embodiments, each fragmented input nucleic acid molecule in the second subgroup lacks a deaminonucleotide base. The input nucleic acid can be fragmented using any mechanical, enzymatic (e.g., restriction endonuclease), or chemical fragmentation method as described herein.

[0199] In some embodiments, a method for preparing fragmented input nucleic acid molecules with reduced deaminated nucleotide bases includes step (b): contacting the plurality of fragmented input nucleic acid molecules (including a first subgroup and a second subgroup of fragmented input nucleic acid molecules) with a deaminating reagent, thereby generating a plurality of reagent-treated fragmented input nucleic acid molecules, wherein each reagent-treated fragmented input nucleic acid molecule contains at least one base-free site. In some embodiments, the deaminating reagent comprises at least one enzyme having glycosylation activity, including any combination of any two or more of the following: formamidopyrimidine DNA glycosylation enzyme (fpg); uracil N-glycosylation enzyme (UNG); uracil DNA glycosylation enzyme (UDG); 8-oxoguanine glycosylation enzyme (OGG, including thermostable OGG); DNA (purine-free) lyase; DNA (pyrimidine-free) lyase; and / or endonuclease III. In some embodiments, the deaminating reagent may be washed away or inactivated after the glycosylation reaction is complete.

[0200] In some embodiments, in step (b), the reagent for removing deaminated bases from the plurality of fragmented input nucleic acids comprises at least one enzyme with lysin activity, capable of cleaving the phosphodiester backbone at the 5' and 3' sides of the base-free site to release base-free deoxyribose and create a gap, wherein the enzyme with lysin activity comprises any combination of any one or more of the following: AP lyase, Endo IV endonuclease, FPG glycosylase / AP lyase (formamidopyrimidine DNA glycosylase), endonuclease VIII glycosylase / AP lyase, and / or endonuclease III. In some embodiments, the reagent for removing deaminated bases may be washed away or inactivated after the lysin reaction is complete.

[0201] In some embodiments, in step (b), the reagent for removing deaminated bases from the plurality of fragmented input nucleic acids comprises at least one enzyme that generates base-free sites in the nucleic acid chain and at least one enzyme with lysin activity. In some embodiments, the reagent for removing deaminated bases comprises a mixture of uracil DNA glycosylase and DNA glycosylase-lysin endonuclease VIII, such as USER (uracil-specific excision reagent enzyme, such as from New England Biolabs®) or heat-sensitive USER (e.g., from New England Biolabs). In some embodiments, the reagent for removing deaminated bases may be washed away or inactivated after the glycosylase and lysin reaction is complete.

[0202] In some embodiments, a method for preparing fragmented input nucleic acid molecules with reduced deaminonucleotide bases includes optional step (c): attaching at least one adaptor to one or both ends of a plurality of reagent-treated fragmented input nucleic acid molecules, thereby generating a plurality of library molecules (e.g., a plurality of linear library molecules).

[0203] Removal of deamino bases from library molecules

[0204] In some embodiments, a method for preparing a plurality of library molecules having reduced deaminonucleotide bases includes step (a): attaching at least one adaptor to one or both ends of a fragmented input nucleic acid molecule, thereby generating a plurality of library molecules (e.g., a plurality of linear library molecules) comprising a mixture of a first subgroup and a second subgroup of library molecules. In some embodiments, each library molecule in the first subgroup carries at least one deaminonucleotide base. In some embodiments, each library molecule in the second subgroup lacks a deaminonucleotide base.

[0205] In some embodiments, a method for preparing a plurality of library molecules having reduced deamino nucleotide bases includes optional step (b): contacting the plurality of library molecules (including a first subgroup and a second subgroup of the library molecules) with a reagent for removing deamino bases, thereby generating a plurality of library molecules, wherein each library molecule contains at least one base-free site.

[0206] In some embodiments, a method for preparing a plurality of library molecules having reduced deaminonucleotide bases includes the optional step (c): cyclizing the plurality of linear library molecules, thereby generating a plurality of covalently closed cyclic library molecules having reduced deaminonucleotide bases. Any of the methods described herein for cyclizing linear library molecules can be used to generate a plurality of covalently closed cyclic library molecules, including, for example, using CIRCLIGASE, using telomerase TelN, cyclization using single-stranded clip-on chains, or cyclization using double-stranded clip-on adaptors. Exemplary, non-limiting single-stranded clip-on chains and double-stranded clip-on adaptors, and related methods, are described in WO 2023 / 168444, WO 2023 / 168443, WO 2024 / 011145, WO 2024 / 059550, and PCT / US2024 / 39186, the contents of which are incorporated herein by reference in their entirety. In some embodiments, linear library molecules can be circularized by hybridization with single-stranded trap primers fixed to a support.

[0207] In some embodiments, the plurality of cyclized library molecules comprises a mixture of a first subgroup and a second subgroup of cyclized library molecules. In some embodiments, each cyclized library molecule in the first subgroup carries at least one deaminated nucleotide base. In some embodiments, each cyclized library molecule in the second subgroup lacks a deaminated nucleotide base.

[0208] In some embodiments, a method for preparing a plurality of cyclized library molecules having reduced deamino nucleotide bases includes contacting the plurality of cyclized library molecules with a reagent for removing deamino bases, thereby generating a plurality of library molecules, wherein each cyclized library molecule contains at least one base-free site.

[0209] In some embodiments, a method for preparing a plurality of library molecules having reduced deaminonucleotide bases includes the optional step (d): distributing the plurality of cyclized library molecules onto a support comprising a plurality of fixed surface-capturing primers to generate a plurality of fixed cyclized library molecules, wherein each fixed cyclized library molecule comprises a cyclized library molecule that hybridizes to at least a portion of the fixed surface-capturing primers. In some embodiments, at least a portion of each fixed surface-capturing primer comprises a sequence capable of hybridizing to at least a portion of each cyclized library molecule. In some embodiments, the plurality of fixed cyclized library molecules may be contacted with rolling circle amplification reagent to perform a rolling circle amplification reaction to generate a plurality of fixed multiply molecules.

[0210] In some embodiments, prior to the rolling circle amplification reaction, the plurality of immobilized cyclized library molecules may be subjected to enzymatic removal of deaminated bases and gap generation.

[0211] In some embodiments, the plurality of immobilized cyclized library molecules comprises a mixture of a first subgroup and a second subgroup of immobilized cyclized library molecules. In some embodiments, each immobilized cyclized library molecule in the first subgroup carries at least one deaminated nucleotide base. In some embodiments, each immobilized cyclized library molecule in the second subgroup lacks a deaminated nucleotide base.

[0212] In some embodiments, a method for preparing a plurality of immobilized cyclized library molecules having reduced deaminated nucleotide bases includes contacting the plurality of immobilized cyclized library molecules with a reagent for removing deaminated bases, thereby generating a plurality of immobilized cyclized library molecules, wherein each immobilized cyclized library molecule contains at least one base-free site.

[0213] In some embodiments, in steps (b), (c), and (d), the reagent for removing deaminated bases comprises at least one enzyme with glycosylation activity, including any combination of any two or more of the following: formamidopyrimidine DNA glycosylation enzyme (fpg); uracil N-glycosylation enzyme (UNG); uracil DNA glycosylation enzyme (UDG); 8-oxoguanine glycosylation enzyme (OGG, including thermostable OGG); DNA (purine-free) lyase; DNA (pyrimidine-free) lyase; and / or endonuclease III. In some embodiments, the reagent for removing deaminated bases may be washed away or inactivated after the glycosylation enzyme reaction is complete.

[0214] In some embodiments, in steps (b), (c), and (d), the reagent for removing deaminated bases comprises at least one enzyme with lysin activity, capable of cleaving the phosphodiester backbone at the 5' and 3' sides of the base-free site to release the base-free deoxyribose and create a gap. The enzyme with lysin activity comprises any one or any combination of two or more of the following: AP lyase, Endo IV endonuclease, FPG glycosylase / AP lyase (formamidopyrimidine DNA glycosylase), endonuclease VIII glycosylase / AP lyase, and / or endonuclease III. In some embodiments, the reagent for removing deaminated bases may be washed away or inactivated after the lysin reaction is complete.

[0215] In some embodiments, in steps (b), (c), and (d), the reagent for removing deaminated bases comprises at least one enzyme that produces a base-free site in the nucleic acid chain and at least one enzyme with lysin activity. In some embodiments, the reagent for removing deaminated bases comprises a mixture of uracil DNA glycosylase and DNA glycosylase-lysin endonuclease VIII, such as, but not limited to, USER (uracil-specific excision reagent enzyme, such as from New England Biolabs) or heat-sensitive USER (e.g., from New England Biolabs). In some embodiments, the reagent for removing deaminated bases may be washed away or inactivated after the glycosylase and lysin reaction is complete.

[0216] In some embodiments, the multiple library molecules (e.g., multiple linear library molecules) generated in step (b) are not subjected to enzymatic removal of deaminated bases and gap generation.

[0217] In some embodiments, the multiple covalently closed cyclic library molecules generated in step (c) do not undergo enzymatic removal of deaminated bases and gap generation.

[0218] In some embodiments, the plurality of fixed cyclized library molecules generated in step (d) are not subjected to enzymatic removal of deaminated bases and gap generation.

[0219] In some embodiments, the method for enzymatic removal of deaminated bases and gap generation can be applied to any combination of multiple fragmented input nucleic acid molecules in step (a), and / or to multiple library molecules (e.g., multiple linear library molecules) generated in step (b), and / or to multiple cyclized library molecules generated in step (c), and / or to multiple fixed cyclized library molecules generated in step (d).

[0220] Preparation of nucleic acid molecules with reduced introduced nucleotide base errors

[0221] In some aspects, this disclosure provides methods for improving sequencing quality scores, comprising performing a library preparation workflow including at least one step for reducing introduced nucleotide base errors in fragmented input nucleic acids and / or in circularized library molecules and / or in immobilized circularized library molecules. In some embodiments, the reduction of introduced nucleotide base errors can be achieved by performing an end-repair workflow.

[0222] End repair of fragmented input nucleic acids

[0223] In some embodiments, a method for preparing fragmented input nucleic acids with reduced introduced nucleotide base errors includes step (a): fragmenting the input nucleic acid to generate a plurality of fragmented input nucleic acids comprising a mixture of fragmented nucleic acids having 5' overhanging ends, 3' overhanging ends, and / or blunt ends. In some embodiments, the input nucleic acid comprises a double-stranded input nucleic acid. In some embodiments, the input nucleic acid may be fragmented using any mechanical, enzymatic (e.g., restriction endonuclease), or chemical fragmentation methods as described herein.

[0224] In some embodiments, a method for preparing fragmented input nucleic acids with reduced introduced nucleotide base errors includes step (b): contacting the plurality of fragmented input nucleic acids with at least one nucleic acid end-repairing agent under conditions suitable for converting 5' and 3' overhanging ends to blunt ends. In some embodiments, the at least one nucleic acid end-repairing agent comprises an enzyme capable of degrading 5' or 3' overhanging ends, or capable of filling 3' underhanging ends (e.g., 5' overhanging ends). In some embodiments, one or both strands of the end-repaired double-stranded nucleic acid contain a 5' phosphorylated end.

[0225] In some embodiments, in step (b), the at least one nucleic acid end repair reagent comprises at least one nuclease. In some embodiments, the at least one nucleic acid end repair reagent comprises at least one single-stranded nuclease. In some embodiments, the at least one nucleic acid end repair reagent comprises any one or any combination of two or more nucleases, including mung bean nuclease, exonuclease I (from E. coli), thermostable exonuclease I, exonuclease T, exonuclease VII, exonuclease VIII and / or RecJf.

[0226] In some embodiments, in step (b), the at least one nucleic acid end repair reagent comprises an enzyme capable of degrading a 5' overhanging end, thereby generating a double-stranded fragmented input nucleic acid with blunt ends. In some embodiments, the at least one nucleic acid end repair reagent comprises an S1 nuclease.

[0227] In some embodiments, in step (b), the at least one nucleic acid end repair agent degrades the 3' overhanging end, thereby generating a double-stranded fragmented input nucleic acid with blunt ends. In some embodiments, the at least one nucleic acid end repair agent comprises any combination of any one or more of the following: DNA polymerase I, Klenow fragment, T4 DNA polymerase, and / or mung bean nuclease.

[0228] In some embodiments, in step (b), the at least one nucleic acid end repair reagent comprises a single-stranded specific endonuclease capable of removing 5' and 3' overhanging ends, wherein the single-stranded specific endonuclease comprises mung bean nuclease.

[0229] In some embodiments, in step (b), the at least one nucleic acid end repair reagent comprises a polymerase capable of catalyzing the filling of a 3' overhang (e.g., a 5' overhang). In some embodiments, step (b) comprises contacting the plurality of fragmented input nucleic acids with a polymerase and a plurality of nucleotides, wherein the polymerase comprises T4 DNA polymerase, Tfi DNA polymerase, Tli DNA polymerase, Taq DNA polymerase, Klenow fragment, phi29 DNA polymerase, polymerase β (polβ), Mako DNA polymerase, and / or Q5U hot-start high-fidelity DNA polymerase (e.g., catalog number M0515S, from New England Biolabs). Any of these polymerases may be a thermostable or thermostable enzyme.

[0230] In some embodiments, in step (b), the nucleic acid end repair reagent lacks a polymerase that can catalyze the filling of the 3' underhangt and lacks multiple nucleotides.

[0231] In some embodiments, step (b) optionally includes contacting the plurality of fragmented input nucleic acids with (i) at least one nucleic acid end-repair reagent to convert 5' overhanging ends and 3' overhanging ends into blunt ends, and (ii) a deamination-removing reagent, thereby generating a plurality of fragmented input nucleic acid molecules, wherein each fragmented input nucleic acid molecule contains at least one base-free site. In some embodiments, the deamination-removing reagent comprises at least one enzyme having glycosylation activity, including any combination of any two or more of the following: formamidopyrimidine DNA glycosylation enzyme (fpg); uracil N-glycosylation enzyme (UNG); uracil DNA glycosylation enzyme (UDG); 8-oxoguanine glycosylation enzyme (OGG, including thermostable OGG); DNA (purine-free) lyase; DNA (pyrimidine-free) lyase; and / or endonuclease III. In some embodiments, the deamination-removing reagent may be washed away or inactivated after the glycosylation enzyme reaction is complete.

[0232] In some embodiments, step (b) further comprises contacting the plurality of fragmented input nucleic acids with (iii) a reagent for removing deaminated bases from the plurality of fragmented input nucleic acids, the reagent comprising at least one enzyme with lysin activity capable of cleaving the phosphodiester backbone at the 5' and 3' sides of the baseless site to release baseless deoxyribose and create a gap, wherein the enzyme with lysin activity comprises any combination of any one or more of the following: AP lyase, Endo IV endonuclease, FPG glycosylase / AP lyase (formamidopyrimidine DNA glycosylase), endonuclease VIII glycosylase / AP lyase, and / or endonuclease III. In some embodiments, the deaminated base removal reagent may be washed away or inactivated after the lysin reaction is complete.

[0233] In some embodiments, in steps (b)(ii) and (b)(iii), the reagent for removing deaminated bases from the plurality of fragmented input nucleic acids comprises at least one enzyme that generates base-free sites in the nucleic acid chain and at least one enzyme having lysin activity. In some embodiments, the reagent for removing deaminated bases comprises a mixture of uracil DNA glycosylase and DNA glycosylase-lysin endonuclease VIII, for example, USER (uracil-specific excision reagent enzyme, such as from New England Biolabs) or heat-sensitive USER (e.g., from New England Biolabs). In some embodiments, the reagent for removing deaminated bases may be washed away or inactivated after the glycosylase and lysin reaction is complete.

[0234] Fragment the input nucleic acid

[0235] In some aspects, this disclosure provides methods for improving sequencing quality scores, including fragmenting input nucleic acids. In some embodiments, the input nucleic acid includes DNA, RNA, or cDNA. In some embodiments, the input nucleic acid includes nucleic acids having the same sequence or a mixture of different sequences. In some embodiments, the input nucleic acid includes single-stranded or double-stranded nucleic acids. In some embodiments, the input nucleic acid can be fragmented using mechanical force, enzymatic (e.g., restriction endonuclease), or chemical fragmentation methods. In some embodiments, the mechanical force includes ultrasonic force, acoustic force, atomizing force, shearing force, or cavitation force. In some embodiments, the mechanical force can generate free radicals that can deaminate nucleotide bases. In some embodiments, the mechanical force can generate a mixture of fragmented input nucleic acid molecules having 5' overhanging ends, 3' overhanging ends, and / or blunt ends. In some embodiments, reverse transcriptase can be used to generate fragmented input nucleic acids from RNA to produce RNA that hybridizes with cDNA. In some embodiments, double-stranded DNA can be prepared by reacting a DNA polymerase with RNA that hybridizes with cDNA. In some embodiments, DNA fragments can be generated by performing PCR using the input nucleic acid and a pair of PCR primers. In some embodiments, the input nucleic acid may be fragmented using an enzyme that generates single-stranded nicks and another enzyme that catalyzes double-stranded cleavage. Exemplary enzyme mixtures include FRAGMENTASE (e.g., from New England Biolabs). In yet another embodiment, the input nucleic acid fragment comprises circulating cell-free DNA (e.g., double-stranded cfDNA) that has not yet undergone a fragmentation process. The cell-free DNA may be 50 bp to 200 bp in length. In some embodiments, the fragmented input nucleic acid may be size-selective or size-independent. Those skilled in the art will recognize that any of these methods can be used to generate fragmented input nucleic acids, and the fragments may be about 50 bp to 1000 bp in length or greater than 1000 bp. In some embodiments, the fragmented input nucleic acid may be about 50 bp to 100 bp in length, or about 100 bp to 250 bp in length, or about 250 bp to 500 bp in length, or about 500 bp to 750 bp in length, or about 750 bp to 2000 bp in length. In some embodiments, one or both ends of the fragmented input nucleic acid contain 5' phosphorylated ends.

[0236] In some embodiments, the input nucleic acid can be extracted from any source, including biological samples (e.g., fresh or live samples), such as single cells, multiple cells, or tissues. The input nucleic acid can be isolated from healthy or diseased cells or tissues. The input nucleic acid can be obtained from archived samples (such as fresh frozen-embedded (FFPE) samples) or from needle biopsies, circulating tumor cells, or cell-free circulating DNA (e.g., from tumor cells or fetuses). Cells or tissues are typically treated with a lysis buffer to release their DNA and RNA and to separate the desired nucleic acid from undesirable macromolecules such as proteins.

[0237] In some embodiments, the input nucleic acid can be isolated in any form, including chromosomal, genomic (e.g., whole genome), organelle (e.g., mitochondrial, chloroplast, or ribosome), recombinant molecules, cloned, or amplified. The input nucleic acid can be methylated or unmethylated.

[0238] In some embodiments, the input nucleic acid can be isolated from any organism, including viruses, fungi, prokaryotes, or eukaryotes. The input nucleic acid can be isolated from any organism, including humans, apes, great apes, dogs, felines, cattle, horses, rats, pigs, goats, wolves, frogs, fish, plants, insects, or bacteria. The input nucleic acid can be isolated from organisms carried in the air, water, soil, or food.

[0239] In some embodiments, the input nucleic acid can be isolated from any biological fluid, including blood, urine, serum, lymph, tumor, saliva, anal secretions, vaginal secretions, amniotic membrane samples, sweat, semen, smear samples, environmental samples, or culture samples. The input nucleic acid can be isolated from any organ, including the head, neck, brain, breast, ovary, cervix, colon, rectum, endometrium, gallbladder, intestine, bladder, prostate, testis, liver, lung, kidney, esophagus, pancreas, thyroid gland, pituitary gland, thymus, skin, heart, larynx, or other organs.

[0240] In some embodiments, the input nucleic acid may be prepared using recombinant nucleic acid technology, including but not limited to any combination of vector cloning, transgenic host cell preparation, host cell culture and / or PCR amplification.

[0241] Preparation of library molecules

[0242] In some aspects, this disclosure provides methods for improving sequencing quality scores, comprising a library preparation workflow including the preparation of fragmented input nucleic acids that have undergone methods for reducing / removing deaminonucleotide bases and / or have undergone end-repair methods for reducing introduced nucleotide base errors as described above. These fragmented input nucleic acids may be further processed to generate multiple library molecules, including reactions for phosphorylation, A-tailing, and / or adaptor attachment. Exemplary non-limiting methods for library preparation are described in US2022 / 0403463 and US 2023 / 0203564, the contents of which are incorporated herein by reference in their entirety. In some embodiments, the library molecules comprise fragmented input nucleic acid molecules attached to at least one adaptor.

[0243] Phosphorylation

[0244] In some embodiments, nucleic acid libraries can be prepared by phosphorylating or removing the 5' or 3' phosphate ester from the 5' end of a fragmented input nucleic acid. For example, the fragmented input nucleic acid can be treated with T4 polynucleotide kinase to phosphorylate the 5' end of at least one strand of the duplex DNA. In some embodiments, the fragmented input nucleic acid can be treated with a phosphatase to remove the 5' or 3' phosphate ester, using shrimp alkaline phosphatase, calf intestinal alkaline phosphatase, bacterial alkaline phosphatase, thermosensitive phosphatase, and / or placental alkaline phosphatase.

[0245] Non-template tail

[0246] In some embodiments, a nucleic acid library can be prepared by adding a non-template tail to the 3' end of a fragmented input nucleic acid. In some embodiments, a plurality of dATP and a DNA polymerase, such as Taq DNA polymerase (or a derivative thereof), Tfi (exo-minus) DNA polymerase, large fragment Klenow (e.g., 3' to 5' exo-minus), T4 DNA polymerase, or Hemo KlenTaq polymerase (e.g., from New England Biolabs, catalog number M0332S), can be used to attach a single non-template A tail to the 3' end of the fragmented input nucleic acid in the presence of dATP. In some embodiments, a terminal transferase and a plurality of dATP can be used to attach a non-template A tail to the 3' end of the fragmented input nucleic acid.

[0247] connector

[0248] In some embodiments, a nucleic acid library can be prepared by attaching at least one adaptor to one end of each fragmented input nucleic acid. In some embodiments, the adaptor comprises an oligonucleotide that can be operatively linked (attached) to one or both ends of the fragmented input nucleic acid, wherein the adaptor confers function to the co-conjugated adaptor-fragment molecule. The adaptor includes DNA, RNA, chimeric DNA / RNA, or the like. The adaptor may contain at least one ribonucleoside residue. The adaptor may be single-stranded, double-stranded, or have single-stranded and / or double-stranded portions. The adaptor may be configured in a linear, stem-loop, hairpin, or Y-shaped form. The adaptor may be of any length, including 4 to 100 nucleotides or longer. The adaptor may have blunt ends, overhanging ends, or a combination of both. Overhanging ends include 5' overhanging ends and 3' overhanging ends. The 5' end of a single-stranded adaptor or one strand of a double-stranded adaptor may have a 5' phosphate group or lack a 5' phosphate group. The adaptor may contain a 5' tail (e.g., a tailed adaptor) capable of hybridizing with a tailed fragmented input nucleic acid, or the adaptor may be tailless. At least a portion of the adaptor contains a known and predetermined sequence. The adaptor may contain a sequence complementary to at least a portion of a primer (such as an amplification primer, sequencing primer, or capture primer (e.g., a soluble or immobilized capture primer)). The adaptor may contain a random or degenerate sequence. The adaptor may contain at least one inosine residue. The adaptor may contain at least one thiophosphate, thiophosphate, and / or phosphoramide bond. The adaptor may contain at least one sample barcode / index sequence that can be used to distinguish polynucleotides (e.g., insert sequences) from different sample sources in multiplex assays. The adaptor may contain at least one unique identification sequence (e.g., a molecular identifier) ​​that can be used to uniquely identify the nucleic acid molecule to which the adaptor is appended. In some embodiments, the unique identification sequence comprises 2 to 20 or more nucleotides having a known sequence. For example, the unique identifying sequence comprises a known random sequence in which the nucleotides at each position are randomly selected from nucleotides having the bases A, G, C, T, or U. The adaptor may contain at least one restriction enzyme recognition sequence, including any combination of any one or more of the groups consisting of types I, II, III, IV, Hs, or IIB. The adaptor may contain at least one cleavable portion that can be cleaved to produce a base-free site, or the adaptor may lack an cleavable portion. Exemplary cleavable portions include uridine, 8-oxo-7,8-dihydroguanine (e.g., 8oxoG), and deoxyinosine.

[0249] In some embodiments, the adaptor contains a universal sequence. In some embodiments, the universal sequence and related terms refer to a sequence common to two or more polynucleotide molecules in a nucleic acid molecule (e.g., an adaptor). For example, an adaptor having a universal sequence can be operatively conjugated to multiple polynucleotides such that a population of co-conjugated molecules carries the same universal adaptor sequence. Examples of universal adaptor sequences include amplification primer sequences, sequencing primer sequences, capture primer sequences (e.g., soluble or immobilized capture primers), and compressed oligonucleotide binding sequences.

[0250] Y-shaped connector

[0251] In some embodiments, the adapter includes a double-stranded nucleic acid Y-shaped adapter, wherein each double-stranded adapter comprises a first oligonucleotide chain and a second oligonucleotide chain hybridized together, wherein both the first oligonucleotide chain and the second oligonucleotide chain contain complementary regions and mismatched regions, thereby forming a Y-shaped adapter having a double-stranded annealed portion and a mismatched portion having two single strands.

[0252] In some embodiments, the 5' ends of the first and / or second oligonucleotide chains forming the Y-shaped adaptor may be phosphorylated or unphosphorylated. In some embodiments, the first oligonucleotide chain comprises a first universal adaptor sequence containing a binding sequence for a first sequencing primer or its complementary sequence. In some embodiments, the second oligonucleotide chain comprises a second universal adaptor sequence containing a binding sequence for a second sequencing primer or its complementary sequence. In some embodiments, the binding sequences for the first and second sequencing primers comprise different sequences. In some embodiments, in a population of Y-shaped adaptors, the respective first oligonucleotide chains forming the Y-shaped adaptor have the same sequence. In some embodiments, in a population of Y-shaped adaptors, the respective second oligonucleotide chains forming the Y-shaped adaptor have the same sequence. In some embodiments, the double-stranded annealing region of the Y-shaped adaptor comprises at least four consecutive base-paired nucleotides. In some embodiments, the double-stranded annealing region comprises an end capable of joining to a nucleic acid fragment having a target sequence, wherein joining can be performed via an enzymatic ligation reaction. In some embodiments, the double-stranded annealing region comprises a blunt end, or the end may have a 5' or 3' overhang. In some embodiments, the first and second oligonucleotide chains of the mismatched portion may be of the same length or of different lengths.

[0253] In some embodiments, the first strand of the double-stranded annealed region of the Y-shaped adaptor contains at least a portion of a binding sequence for a first sequencing primer (e.g., a reverse sequencing primer or a forward sequencing primer) or its complementary sequence. In some embodiments, the second strand of the double-stranded annealed region of the Y-shaped adaptor contains at least a portion of a binding sequence for a second sequencing primer (e.g., a forward sequencing primer or a reverse sequencing primer) or its complementary sequence.

[0254] In some embodiments, the first strand of the mismatch region contains at least a portion of a binding sequence for a first sequencing primer (e.g., a reverse sequencing primer or a forward sequencing primer) or a complementary sequence thereof. In some embodiments, the first strand of the mismatch region further contains at least a portion of a binding sequence for a first surface primer or a complementary sequence thereof. In some embodiments, the first strand of the mismatch region contains a universal adaptor sequence that includes a first sample index sequence.

[0255] In some embodiments, the second strand of the mismatch region contains at least a portion of a binding sequence for a second sequencing primer (e.g., a forward sequencing primer or a reverse sequencing primer) or its complementary sequence. In some embodiments, the second strand of the mismatch region further contains at least a portion of a binding sequence for a second surface primer or its complementary sequence. In some embodiments, the second strand of the mismatch region further contains a universal adaptor sequence that includes a second sample index sequence.

[0256] In some embodiments, only the first chain of the mismatch region contains a universal connector, which contains a first sample index sequence. In some embodiments, only the second chain of the mismatch region contains a universal connector, which contains a second sample index sequence. In some embodiments, the first chain of the mismatch region contains the first sample index sequence, and the second chain of the mismatch region contains the second sample index sequence.

[0257] Connector attachment

[0258] In some embodiments, a ligation reaction may be used to attach one or both ends of a fragmented input nucleic acid to at least one adaptor, wherein the fragmented input nucleic acid comprises at least one blunt end, at least one 5' overhanging end, or at least one 3' overhanging end. The adaptor ligation reaction may include a linear double-stranded adaptor and / or a double-stranded Y-shaped adaptor. In some embodiments, T4 DNA ligase, T3 DNA ligase, or T7 DNA ligase may be used for the ligation reaction.

[0259] In some embodiments, single-stranded tailed primers can be used to attach an adaptor sequence to one or both ends of a fragmented input nucleic acid using at least one primer extension reaction or PCR. In some embodiments, the 5' end of the tailed primer contains the adaptor sequence to be attached to the fragmented input nucleic acid. In some embodiments, the 5' end of the tailed primer does not hybridize with the fragmented input nucleic acid. In some embodiments, the 3' end of the tailed primer contains a sequence capable of hybridizing with at least a portion of the fragmented input nucleic acid. In some embodiments, the adaptor sequence can be attached to the fragmented input nucleic acid by performing at least one primer extension reaction using a single-stranded tailed primer, a polymerase, and multiple nucleotides. In some embodiments, the primer extension reaction may employ one type of tailed primer to attach the adaptor sequence to one end of the fragmented input nucleic acid. In some embodiments, the primer extension reaction may employ two types of tailed primers to attach the adaptor sequence to both ends of the fragmented input nucleic acid. In some embodiments, PCR can be used to employ a multi-primer extension reaction. In some embodiments, the heat from a PCR reaction using tailed primers can generate a nucleic acid library molecule containing at least one deaminonucleotide base. In some embodiments, the library preparation workflow may be PCR-free.

[0260] Preparation of cyclized library molecules with reduced deaminated nucleotide bases

[0261] In some aspects, this disclosure provides methods for improving sequencing quality scoring, which include generating a plurality of circularized library molecules. In some embodiments, the plurality of linear library molecules may be subjected to any of the workflows described herein for generating a plurality of circularized library molecules, including an intramolecular linking workflow, a telomerase workflow, or a workflow employing single-stranded oligonucleotides or double-stranded linkers.

[0262] In some embodiments, the library molecule includes a fragmented input nucleic acid molecule attached to at least one adaptor. In some embodiments, the linear library molecule includes a double-stranded fragmented input nucleic acid molecule attached to at least one double-stranded adaptor. In some embodiments, the double-stranded library molecule may be denatured using heat or an alkaline reagent (e.g., NaOH or KOH) to generate two single-stranded library molecules. In some embodiments, one or both of the single-stranded library molecules may be cyclized.

[0263] In some embodiments, in any of the cyclization workflows, fragmented input nucleic acids may be treated with a reagent that removes deaminonucleotide bases. In some embodiments, in any of the cyclization workflows, library molecules may be treated with a reagent that removes deaminonucleotide bases. In some embodiments, any of the intermediate nucleic acid molecules generated in any of the cyclization workflows may be treated with a reagent that removes deaminonucleotide bases. In some embodiments, covalently closed circular library molecules generated through any of the cyclization workflows may be treated with a reagent that removes deaminonucleotide bases.

[0264] Cyclic library molecules were generated using CircLigase.

[0265] In some embodiments, the ends of single-stranded library molecules may undergo intramolecular ligation using a single-stranded ligase (e.g., CircLigase from Epicentre or Lucigen) to generate covalently closed circular library molecules. These covalently closed circular library molecules can then be subjected to rolling circle amplification. In some embodiments, the covalently closed circular library molecules generated with CircLigase can be treated with any reagent as described herein for removing deaminonucleotide bases.

[0266] Generating cyclized library molecules using telomerase

[0267] In some embodiments, circular DNA molecules can be generated without a nuclease ligase. A protoplast identifies a target enzyme recognition sequence within a nucleic acid molecule (e.g., a linear library molecule), cleaves this enzyme recognition sequence to generate ends with exposed 5' and 3' cleavage ends, and re-attaches the single exposed 5' and 3' cleavage ends at the target site to form a single linear molecule from the cleaved 5' and 3' ends. When this reaction is performed on both ends of a double-stranded nucleic acid molecule (e.g., a double-stranded library molecule) having a target enzyme recognition sequence appended to each end, the result is a circularized nucleic acid molecule. An adaptor carrying the enzyme recognition sequence can be attached to the double-stranded library molecule via ligation or PCR using tailed PCR primers. Many enzymes or combinations of enzymes are compatible with this reaction, including protoplasts. An exemplary type of protoplast is the TelN protoplast, such as the protoplast from *E. coli* phage N1. Covalently closed circular library molecules can be subjected to rolling circle amplification. In some embodiments, covalently closed circular library molecules generated by front-end granzyme can be treated with any reagent as described herein for removing deaminonucleotide bases.

[0268] Cyclic library molecules were generated using nucleic acid clips.

[0269] In some embodiments, any of the linkers described herein and any of the linker attachment methods may be used to generate linear library molecules. In some embodiments, a single-stranded or double-stranded linker may be used to circulate the linear library molecule. For example, a linear library molecule (100) may hybridize with a double-stranded linker (200), each having a short and a long linker chain. The long linker chain holds the linear library molecule in a circumscribed form, and the ends of the short linker chain are juxtaposed with the ends of the linear library molecule for connection (e.g., Figure 15 Linear library molecules can hybridize with double-stranded splints to form library splint complexes (500) with two nicks (e.g., Figure 15 In this method, two nicks can be enzymatically linked to form a covalently closed circular molecule. In another example, a linear library molecule (700) can hybridize with a single-stranded clamp (800) that allows the ends of the linear molecule to be juxtaposed for ligation (e.g., Figure 18 Linear library molecules can hybridize with single-stranded clips to form a library-scraper complex (900) with a nick, wherein the nick can be enzymatically ligated to form a covalently closed circular molecule. In some embodiments, covalently closed circular library molecules generated with double-stranded or single-stranded clips can be treated with any reagent as described herein for removing deaminonucleotide bases.

[0270] Removal of deamino bases from covalently closed cyclic library molecules

[0271] In some embodiments, any of the methods described above can be used to generate multiple covalently closed circular library molecules. In some embodiments, each covalently closed circular library molecule contains a target sequence (insertion region) operatively linked to both sides by at least one nucleic acid adaptor sequence.

[0272] In some embodiments, the plurality of covalently closed cyclic libraries comprises a mixture of a first subgroup and a second subgroup of covalently closed cyclic libraries. In some embodiments, each covalently closed cyclic library molecule in the first subgroup carries at least one deaminated nucleotide base. In some embodiments, each covalently closed cyclic library molecule in the second subgroup lacks a deaminated nucleotide base.

[0273] In some embodiments, a method for preparing a plurality of library molecules having reduced deaminated nucleotide bases includes contacting the plurality of covalently closed circular library molecules with a deaminating agent, thereby generating a plurality of library molecules, wherein each covalently closed circular library molecule contains at least one base-free site. In some embodiments, the deaminating agent comprises at least one enzyme having glycosylation activity, including any combination of any two or more of the following: formamidopyrimidine DNA glycosylase (fpg); uracil N-glycosylase (UNG); uracil DNA glycosylase (UDG); 8-oxoguanine glycosylase (OGG, including thermostable OGG); DNA (purine-free) lyase; DNA (pyrimidine-free) lyase; and / or endonuclease III. In some embodiments, the deaminating agent may be washed away or inactivated after the glycosylation reaction is complete.

[0274] In some embodiments, the reagent for removing deaminated bases from the plurality of covalently closed circular library molecules comprises at least one enzyme with lysin activity, capable of cleaving the phosphodiester backbone at the 5' and 3' sides of the base-free site to release the base-free deoxyribose and create a nick. The enzyme with lysin activity comprises any combination of any two or more of the following: AP lyase, Endo IV endonuclease, FPG glycosylase / AP lyase (formamidopyrimidine DNA glycosylase), endonuclease VIII glycosylase / AP lyase, and / or endonuclease III. In some embodiments, the reagent for removing deaminated bases may be washed away or inactivated after the lysin reaction is complete.

[0275] In some embodiments, the reagent for removing deamination bases from the plurality of covalently closed circular library molecules comprises at least one enzyme that generates base-free sites in the nucleic acid strand and at least one enzyme with lysin activity. In some embodiments, the reagent for removing deamination bases comprises a mixture of uracil DNA glycosylase and DNA glycosylase-lysin endonuclease VIII, for example, USER (uracil-specific excision reagent enzyme, such as from New England Biolabs) or heat-sensitive USER (e.g., from New England Biolabs). In some embodiments, the reagent for removing deamination bases may be washed away or inactivated after the glycosylase and lysin reaction is complete.

[0276] Methods for forming multiple cyclic library molecules

[0277] Use double-chain clamp connector

[0278] In some aspects, this disclosure provides compositions and methods for improving sequencing quality scores, comprising preparing a plurality of linear library molecules using any of the methods described herein and circularizing the linear library molecules. In some embodiments, a plurality of covalently closed circularized library molecules can be generated by hybridizing the plurality of linear library molecules with a plurality of double-stranded adapters as described herein. Exemplary, non-limiting double-stranded adapters and associated methods are described in WO 2023 / 168443, WO 2024 / 011145, WO 2024 / 059550 and PCT / US2024 / 39186, the contents of which are incorporated herein by reference in their entirety. In some embodiments, the covalently closed circularized library molecules can be amplified by rolling circle amplification. In some embodiments, rolling circle amplification can be performed on a support, or in solution and on a support.

[0279] In some embodiments, a method for generating a plurality of covalently closed cyclic library molecules includes step (a): providing a plurality of double-stranded splint linkers (200), wherein each of the plurality of double-stranded splint linkers (200) comprises a first splint linker (300) hybridizing with a second splint linker (400), wherein the double-stranded splint linker comprises a double-stranded region and two side-attached single-stranded regions, wherein the first splint linker comprises a first region (320), an inner region (310), and a second region (330), and wherein the inner region (310) of the first splint linker hybridizes with the second splint linker (400). In some embodiments, the 5' end of the first splint linker (300) is phosphorylated or lacks a phosphate ester group. In some embodiments, the 3' end of the first splint linker (300) comprises a 3' end OH group or a 3' end blocking group. An exemplary double-stranded splint linker (200) in Figures 15 to 17 As shown in the image.

[0280] In some embodiments, a method for generating a plurality of covalently closed circular library molecules includes step (b): hybridizing the plurality of double-stranded splint adapters (200) with a plurality of single-stranded nucleic acid library molecules (100) to form a plurality of library-sponge complexes (500). In some embodiments, each single-stranded library molecule (100) comprises: (i) a universal adaptor sequence (120) having a binding sequence for a first surface primer (e.g., the P5 surface primer or its complementary sequence); (ii) a left sample index sequence (160); (iii) a universal adaptor sequence (140) having a binding sequence for a first sequencing primer (e.g., a reverse sequencing primer); (iv) a target sequence (110); (v) a universal adaptor sequence (150) having a binding sequence for a second sequencing primer (e.g., a forward sequencing primer); (vi) a right sample index sequence (170); and (vii) a universal adaptor sequence (130) having a binding sequence for a second surface primer (e.g., the P7 surface primer or its complementary sequence) (e.g., Figures 15 to 16 In some embodiments, any of the universal adaptor sequences (including (120), (140), (150), or (130)) may hybridize with a portion of the compressed oligonucleotide. In some embodiments, the single-stranded library molecule optionally includes a unique identification sequence (180) comprising a sequence segment used to uniquely identify, within a population of other target molecular sequences (e.g., molecular identifiers), each to which the unique identification sequence (180) is attached. In some embodiments, the unique identification sequence (180) may be located to the left or right of the insertion region. In some embodiments, the unique identification sequence comprises 2 to 12 or more nucleotides having known sequences. For example, the unique identification sequence includes a known random sequence, wherein the nucleotides at each position are randomly selected from nucleotides having bases A, G, C, T, or U. The unique identification sequence (180) may be used in a molecular identification procedure.

[0281] In some embodiments, the hybridization in step (b) is performed under conditions suitable for hybridizing the first region (320) of the first splint chain with a universal adaptor sequence (120) having a binding sequence for a first surface primer against a library molecule, and these conditions are also suitable for hybridizing the second region (330) of the first splint chain with a universal adaptor sequence (130) having a binding sequence for a second surface primer against a library molecule, thereby circularizing the plurality of library molecules to form a plurality of library-splice complexes (500) with two nicks (e.g., Figure 15 In some embodiments, the library-sandwich complex (500) includes a first slit between the 5' end of the library molecule and the 3' end of the second sandwich chain (e.g., Figures 15 to 16In some embodiments, the library-sandwich complex (500) further comprises a second nick between the 5' end of the second sandwich chain and the 3' end of the library molecule (e.g., Figures 15 to 16 In some embodiments, the first and second incisions are enzymatically fused.

[0282] In some embodiments, in step (b), the first region (320) of the first splint chain may hybridize with the sense or antisense strand of the double-stranded library molecule. In some embodiments, the second region (330) of the first splint chain may hybridize with the sense or antisense strand of the double-stranded library molecule. The double-stranded library molecule may be denatured to generate single-stranded sense and antisense library chains. In some embodiments, the double-stranded library molecule may be denatured using heat or an alkaline reagent (e.g., NaOH or KOH) to generate sense and antisense library chains.

[0283] In some embodiments, in step (b), the second clamp chain (400) does not hybridize with the target sequence (110), and the internal region (310) of the first clamp chain does not hybridize with the target sequence (110).

[0284] In some embodiments, in step (b), the first region (320) of the first clamp chain does not hybridize with the target sequence (110), and the second region (330) of the first clamp chain does not hybridize with the target sequence (110).

[0285] In some embodiments, in step (b), the 5' end of the single-chain library molecule (100) is phosphorylated or lacks a phosphate ester group. In some embodiments, the 3' end of the single-chain library molecule includes a 3' OH group or a 3' blocking group.

[0286] In some embodiments, in step (b), the sample index sequences (160) and (170) can be used to distinguish target sequences obtained from different sample sources in a multi-process workflow. In some embodiments, the left index sequence (160) may include a random sequence (e.g., NNN) or lack a random sequence. In some embodiments, the right index sequence (170) may include a random sequence (e.g., NNN) or lack a random sequence.

[0287] The left sample index sequence (160) can be 3 to 20 nucleotides in length. The right sample index sequence (170) can be 3 to 20 nucleotides in length. The sequences of the left and right sample index sequences (e.g., (160) and (170)) can be the same as or different from each other.

[0288] A multiplexing workflow is initiated by preparing sample-indexed libraries using one or two sample index sequences (e.g., a left sample index sequence and / or a right sample index sequence). Individual sample-indexed libraries can be prepared using the left index sequence (160) and / or the right index sequence (170) with input nucleic acids isolated from different sources. Sample-indexed libraries can be pooled together to generate a multiplex library mixture, and the pooled libraries can be amplified and / or sequenced. The sequence of the insert region, along with the left index sequence (160) and / or the right index sequence (170), can be used to identify the origin of the input nucleic acid. In some embodiments, any number of sample-indexed libraries can be pooled together, for example, 2 to 10, or 10 to 50, or 50 to 100, or 100 to 200, or more than 200 sample-indexed libraries can be pooled. Exemplary nucleic acid sources include naturally occurring, recombinant, or chemically synthesized sources. Exemplary nucleic acid sources include single cells, multiple cells, tissues, biological fluids, environmental samples, or whole organisms. Exemplary sources of nucleic acids include fresh, frozen, fresh-frozen, or archived sources (e.g., formalin-fixed paraffin-embedded; FFPE). Those skilled in the art will recognize that nucleic acids can be isolated from many other sources. Nucleic acid libraries can be prepared in single-stranded or double-stranded form.

[0289] In some embodiments, in step (b), the second clamp chain (400) includes at least two sub-regions, including a first sub-region and a second sub-region (e.g., Figure 15 The first subregion contains a universal binding sequence for the third surface primer, and the second subregion contains a universal binding sequence for the fourth surface primer, wherein the first and second subregions do not hybridize with the first and second surface primers (or at least show very little hybridization).

[0290] In some embodiments, in step (b), the second splint chain (400) carries a new linker sequence and / or a new index sequence to be introduced into the covalently closed circular library molecule. In some embodiments, a first and / or second subregion of the second splint chain (400) introduces a universal sequence to allow each covalently closed circular library molecule to hybridize with a third surface primer (e.g., a capture primer). In some embodiments, a first and / or second subregion of the second splint chain (400) introduces a universal sequence to allow at least a portion of the multiply molecules to hybridize with a fourth surface primer (e.g., a stapled primer). For example, the covalently closed circular library molecules may be distributed onto a support lacking fixed first and second capture primers, but the support includes a plurality of fixed third capture primers and optionally a plurality of fixed stapled primers.

[0291] In some embodiments, in step (b), the second clamp chain (400) further includes an optional third subregion containing a sample index sequence having 5 to 20 bases and / or a unique identification sequence (e.g., UMI) having 2 to 10 or more bases (e.g., NN). Figure 15 In some embodiments, the second splint chain (400) contains only a first subregion and lacks a second and third subregion, wherein the first subregion contains a sample index sequence having 5 to 20 bases. In some embodiments, the sample index sequence can be used to distinguish target sequences obtained from different sample sources in multiplex assays. In some embodiments, the unique identification sequence comprises a random sequence. The unique identification sequence may be designed to exhibit reduced hybridization or no hybridization with the first, second, third, and fourth surface primers. An exemplary arrangement of the subregions in the second splint chain (400) in the 5' to 3' direction includes: 5'-[second subregion]–[first subregion]–3'. Another exemplary arrangement of the subregions in the second splint chain (400) in the 5' to 3' direction includes: 5'-[third subregion]–[second subregion]–[first subregion]–3'. In some embodiments, the second splint chain (400) may be 20 to 100 nucleotides long, or 30 to 80 nucleotides long, or 40 to 60 nucleotides long. In some embodiments, the second splint chain (400) includes one or more thiophosphate bonds at the 5' end and / or 3' end to confer exonuclease resistance. In some embodiments, the second splint chain (400) includes one or more thiophosphate bonds at an internal location to confer endonuclease resistance. In some embodiments, the second splint chain (400) includes one or more 2'-O-methylcytosine bases at the 5' end and / or 3' end or at an internal location. In some embodiments, the 5' end of the second splint chain (400) is phosphorylated or non-phosphorylated. In some embodiments, the 3' end of the second splint chain (400) includes a terminal 3' OH group or a terminal 3' blocking group.

[0292] In some embodiments, in step (b), the first clamp chain (300) includes an inner region (310) containing at least two sub-regions, including a fourth sub-region and a fifth sub-region (e.g., Figure 15 The fourth subregion hybridizes with the first subregion of the second splint chain (400). The fifth subregion hybridizes with the second subregion of the second splint chain (400). The fourth and fifth subregions do not hybridize with the first and second surface primers (or at least show very little hybridization). In some embodiments, the inner region (310) of the first splint chain further includes an optional sixth subregion that hybridizes with the third subregion of the second splint chain (400) (e.g., Figure 15An exemplary arrangement of the subregions of the first splint chain (300) in the 5' to 3' direction comprises: 5' – [fourth subregion] – [fifth subregion] – 3'. Another exemplary arrangement of the subregions of the first splint chain (300) in the 5' to 3' direction comprises: 5' – [fourth subregion] – [fifth subregion] – [sixth subregion] – 3'. In some embodiments, the first splint chain (300) may be 50 to 150 nucleotides long, or 60 to 100 nucleotides long, or 70 to 90 nucleotides long. In some embodiments, the first splint chain (300) includes one or more phosphate thioester bonds at the 5' end and / or the 3' end to confer exonuclease resistance. In some embodiments, the first splint chain (300) includes one or more phosphate thioester bonds at an internal location to confer endonuclease resistance. In some embodiments, the first splint chain (300) includes one or more 2'-O-methylcytosine bases at the 5' end and / or the 3' end or at an internal location.

[0293] In some embodiments, the plurality of library-sandwich complexes (500) formed in step (b) may be subjected to at least one enzymatic reaction, including phosphorylation, ligation, and / or exonuclease reaction. The enzymatic reactions may be performed sequentially or substantially simultaneously. The enzymatic reactions may be performed in a single reaction vessel. Alternatively, the first enzymatic reaction may be performed in a first reaction vessel, then transferred to a second reaction vessel for a second enzymatic reaction, and then to a third reaction vessel for a third enzymatic reaction.

[0294] In some embodiments, the method for generating a plurality of covalently closed circular library molecules further includes performing separate and sequential phosphorylation and ligation reactions in separate reaction vessels. In some embodiments, the method for generating a plurality of covalently closed circular library molecules further includes step (c1): in a first reaction vessel, contacting a plurality of double-stranded splice initiators (200) and a plurality of single-stranded nucleic acid library molecules (100) with T4 polynucleotide kinase under conditions suitable for phosphorylating the 5' ends of a plurality of double-stranded splice initiators (200) and / or a plurality of single-stranded nucleic acid library molecules (100); and transferring the phosphorylation reaction to a second reaction vessel. In some embodiments, the method for forming a plurality of library-sandwich complexes (500) further includes step (d1): in a second reaction vessel, under conditions suitable for enzymatic ligation of a first and a second nick, contacting a plurality of phosphorylated double-stranded sandwich adaptors (200) and a plurality of phosphorylated single-stranded nucleic acid library molecules (100) with a ligase, thereby generating a plurality of covalently closed circular library molecules (600), each covalently closed circular library molecule hybridizing with a first sandwich strand (300). In some embodiments, the ligase includes T7 DNA ligase, T3 ligase, T4 ligase, or Taq ligase.

[0295] In some embodiments, the method for generating a plurality of covalently closed circular library molecules further includes performing sequential phosphorylation and ligation reactions, which are carried out sequentially in the same reaction vessel. In some embodiments, the method for generating a plurality of covalently closed circular library molecules further includes step (c2): in a first reaction vessel, contacting the plurality of double-stranded splice initiators (200) and the plurality of single-stranded nucleic acid library molecules (100) with T4 polynucleotide kinase under conditions suitable for phosphorylating the 5' ends of the plurality of double-stranded splice initiators (200) and the plurality of single-stranded nucleic acid library molecules (100). In some embodiments, the method for forming a plurality of library-sandwich complexes (500) further includes step (d2): in the same first reaction vessel, under conditions suitable for enzymatic ligation of a first and a second nick, contacting a phosphorylated double-stranded sandwich adaptor (200) and a phosphorylated single-stranded nucleic acid library molecule (100) with a ligase, thereby generating a plurality of covalently closed circular library molecules (600), each covalently closed circular library molecule hybridizing with a first sandwich strand (300). In some embodiments, the ligase includes T7 DNA ligase, T3 ligase, T4 ligase, or Taq ligase.

[0296] In some embodiments, the method for generating a plurality of covalently closed circular library molecules further includes performing substantially simultaneous phosphorylation and ligation reactions together in a reaction vessel. In some embodiments, the method for generating a plurality of covalently closed circular library molecules further includes step (c3): in a first reaction vessel, under conditions suitable for phosphorylating the 5' ends of a plurality of double-stranded splint initiators (200) and a plurality of single-stranded nucleic acid library molecules (100), and conditions suitable for enzymatically ligating a first nick and a second nick, contacting the plurality of double-stranded splint initiators (200) and the plurality of single-stranded nucleic acid library molecules (100) with (i) a T4 polynucleotide kinase and (ii) a ligase, thereby generating a plurality of covalently closed circular library molecules (600), each covalently closed circular library molecule hybridizing with a first splint strand (300). In some embodiments, the ligase includes a T7 DNA ligase, a T3 ligase, a T4 ligase, or a Taq ligase.

[0297] In some embodiments, in any of steps (c1)(d1), (c2)(d2), or (c3), the completion of the phosphorylation and linkage reaction generates a plurality of covalently closed cyclic library molecules (600) (e.g., Figure 16In some embodiments, the ligase may be inactivated using heat or an alkaline reagent after the ligase reaction is complete. In some embodiments, ligase inactivation includes contacting the ligase with an alkaline reagent. In some embodiments, the alkaline reagent includes NaOH and / or KOH. In some embodiments, the ligase is not inactivated using heat. In some embodiments, a plurality of covalently closed circular library molecules (600) are retained. In some embodiments, inactivation of the ligase with an alkaline reagent reduces the formation of deaminated nucleotide bases in the plurality of covalently closed circular library molecules (600) compared to heat-inactivated covalently closed circular library molecules.

[0298] In some embodiments, the method for generating a plurality of covalently closed circular library molecules further includes an optional step (e): enzymatically removing a plurality of first splint chains (300) from the plurality of covalently closed circular library molecules (600). In some embodiments, the optional step (e): contacting the plurality of covalently closed circular library molecules (600) and the plurality of first splint chains with at least one exonuclease to remove / degrade the plurality of first splint chains (300) and retain the plurality of covalently closed circular library molecules (600). In some embodiments, the exonuclease reaction may be performed in the same reaction buffer used for phosphorylation and / or ligation reactions, or in different reaction buffers. In some embodiments, the exonuclease reaction may be performed in a third reaction container after phosphorylation (c1) in a first reaction container and ligation (d1) in a second reaction container. In some embodiments, the exonuclease reaction may be performed in a first reaction container after phosphorylation (c2) in a first reaction container and sequential ligation (d2) in a first reaction container. In some embodiments, the exonuclease reaction may be performed in the first reaction vessel after a substantially simultaneous phosphorylation and ligation reaction (c3). In some embodiments, the at least one exonuclease comprises any combination of two or more of exonuclease I, thermostable exonuclease I, and / or T7 exonuclease.

[0299] In some embodiments, after step (e), the completion of the exonuclease reaction generates individual covalently closed circular library molecules (600) and a degraded first splint chain (300). In some embodiments, after the exonuclease reaction is completed, the exonuclease can be inactivated using heat or an alkaline reagent. In some embodiments, exonuclease inactivation includes contacting the exonuclease with an alkaline reagent. In some embodiments, the alkaline reagent includes NaOH and / or KOH. In some embodiments, the exonuclease is not inactivated using heat. In some embodiments, multiple covalently closed circular library molecules (600) are retained. In some embodiments, inactivation of the exonuclease with an alkaline reagent reduces the formation of deaminated nucleotide bases in the multiple covalently closed circular library molecules (600) compared to exonuclease-inactivated covalently closed circular library molecules.

[0300] In some embodiments, any of steps (a) to (e) of the method for generating a plurality of covalently closed circular library molecules (600) may include applying a deamination agent and / or a basic agent to any of the linear library molecules and / or cyclizing any of the cyclized library molecules, thereby generating a plurality of covalently closed circular library molecules with reduced C:G to T:A base transitions, which may generate higher quality base interpretations during downstream sequencing workflows. In some embodiments, applying a deamination agent and / or a basic agent may increase the sequencing quality score from Q30 to Q40, Q45, Q50, Q55, Q60 or higher.

[0301] In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid handling workflow can achieve a sequencing quality score (Q40) of about 80% to 90%, or about 90% to 95%, or about 95% to 100%. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid handling workflow can achieve a sequencing quality score (Q45) of about 75% to 85%, or about 85% to 90%, or about 90% to 95%, or about 95% to 100%. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid handling workflow can achieve a sequencing quality score (Q50) of about 65% to 75%, or about 75% to 85%, or about 85% to 95%, or about 95% to 100%. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid handling workflow can achieve a sequencing quality score (Q55) of approximately 60% to 70%, or approximately 70% to 80%, or approximately 80% to 85%, or approximately 85% to 90%, or approximately 90% to 100%. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid handling workflow can achieve a sequencing quality score (Q60) of approximately 60% to 70%, or approximately 70% to 80%, or approximately 80% to 85%, or approximately 85% to 90%, or approximately 90% to 100%. See, for example, [link to documentation]. Figure 65 , Figure 66 , Figures 67A to 67D , Figures 68A to 68D , Figure 69 and Figure 70 , and see Figure 73 Tables A and B are located at [location].

[0302] In some embodiments, in any of the methods for generating the plurality of covalently closed circular library molecules described herein, a first subregion of the second splint chain (400) comprises the sequence 5'-CATGTAATGCACGTACTTTCAGGGT-3' (SEQ ID NO: 30) (or its complementary sequence). In some embodiments, a second subregion of the second splint chain (400) comprises the sequence 5'-AGTCGTCGCAGCCTCACCTGATC-3' (SEQ ID NO: 31) (or its complementary sequence). In some embodiments, the second splint chain (400) comprises first and second subregions comprising the sequence 5'-AGTCGTCGCAGCCTCACCTGATCCATGTAATGCACGTACTTTCAGGGT-3' (SEQ ID NO: 32) (or its complementary sequence). See also Figure 17 In some embodiments, the 5' end of the second clamp chain (400) may be phosphorylated or unphosphorylated.

[0303] In some embodiments, in any of the methods for generating the plurality of covalently closed circular library molecules described herein, the first region (320) of the first splint chain includes a first universal adaptor sequence containing a binding sequence (or its complementary sequence) against a first surface primer, wherein the first region (320) contains the sequence 5'-TCGGTGGTCGCCGTATCATT-3' (SEQ ID NO: 33) (or its complementary sequence). For example, the first region (320) of the first splint chain may hybridize with a P5 surface primer or a complementary sequence of a P5 surface primer. For example, the P5 surface primer contains the sequence 5'-AATGATACGGCGACCACCGA-3' (SEQ ID NO: 34; short P5) (or its complementary sequence), or the P5 surface primer contains the sequence 5'-AATGATACGGCGACCACCGAGATC-3' (SEQ ID NO: 35; long P5) (or its complementary sequence). In some embodiments, the second region (330) of the first splint chain includes a second universal connector sequence containing a universal binding sequence for the second surface primer, wherein the second region (330) contains the sequence 5'-CAAGCAGAAGACGGCATACGA-3' (SEQ ID NO: 36) (or its complementary sequence). For example, the second region (330) of the first splint chain may hybridize with a P7 surface primer or a complementary sequence of a P7 surface primer. For example, the P7 surface primer contains the sequence 5'-CAAGCAGAAGACGGCATACGA-3' (SEQ ID NO: 36; short P7) (or its complementary sequence), or the P7 surface primer contains the sequence 5'-CAAGCAGAAGACGGCATACGAGAT-3' (SEQ ID NO: 37; long P7) (or its complementary sequence). In some embodiments, the first clamping chain (300) includes an inner region (310) comprising a fourth sub-region 5'-ACCCTGAAAGTACGTGCATTACATG-3' (SEQ ID NO: 38) (or its complementary sequence) having the following sequence. In some embodiments, the first clamping chain (300) includes an inner region (310) comprising a fifth sub-region 5'-GATCAGGTGAGGCTGCGACGACT-3' (SEQ ID NO: 39) (or its complementary sequence) having the following sequence.In some embodiments, the first clamp chain (300) includes a first region (320); an inner region (310) having a fourth sub-region and a fifth sub-region; and a second region (330) having the following sequence: 5'-TCGGTGGTCGCCGTATCATTACCCTGAAAGTACGTGCATTACATGGATCAGGTGAGGCTGCGACGACTCAAGCAGAAGACGGCATACGA-3' (SEQ ID NO: 40) (or its complementary sequence). See also. Figure 17 In some embodiments, the 5' end of the first splint chain (300) may be phosphorylated or unphosphorylated. In some embodiments, a first subregion of the second splint chain (400) may hybridize with a fourth subregion of the first splint chain (300). In some embodiments, a second subregion of the second splint chain (400) may hybridize with a fifth subregion of the first splint chain (300).

[0304] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, a first region (320) of a first sandwich chain includes a sequence of a universal linker sequence (120) capable of binding library molecules, wherein the first region (320) of the first sandwich chain includes the sequence 5'-ACCCTGAAAGTACGTGCATTACATG-3' (SEQ ID NO: 38) (or its complementary sequence).

[0305] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, a second region (330) of the first sandwich chain contains a sequence of a universal linker sequence (130) capable of binding library molecules, wherein the second region (330) of the first sandwich chain contains the sequence 5'-GATCAGGTGAGGCTGCGACGACT-3' (SEQ ID NO: 39) (or its complementary sequence).

[0306] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule comprises a universal binding sequence (120) that binds to a first region (320) of a first sandwich chain, wherein the universal binding sequence (120) comprises sequence 5'-AATGATACGGCGACCACCGA-3' (SEQ ID NO: 34) (or its complementary sequence).

[0307] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule comprises a universal binding sequence (120) that binds to a first region (320) of a first sandwich chain, wherein the left universal binding sequence (120) comprises the sequence 5'-CATGTAATGCACGTACTTTCAGGGT-3' (SEQ ID NO: 30) (or its complementary sequence).

[0308] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule comprises a universal binding sequence (120) that binds to a first region (320) of a first sandwich chain, wherein the left universal binding sequence (120) comprises the sequence 5'-GAACGACATGGCTACGATCC-3' (SEQ ID NO: 41) (or its complementary sequence).

[0309] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule comprises a universal binding sequence (120) that binds to a first region (320) of a first sandwich chain, wherein the left universal binding sequence (120) comprises the sequence 5'-CTCTCAGTACGTCAGCAGTT-3' (SEQ ID NO: 42) (or its complementary sequence).

[0310] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule contains a universal binding sequence (140) for sequencing primers, wherein the left universal binding sequence contains sequence 5'-ACACTCTTTCCCTACACGACGCTCTTCCGATCT-3' (SEQ ID NO: 43) (or its complementary sequence).

[0311] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule contains a universal binding sequence (140) for sequencing primers, wherein the left universal binding sequence contains sequence 5'-TCGTCGGCAGCGTCAGATGTGTATAAGAGACAG-3' (SEQ ID NO: 44) (or its complementary sequence).

[0312] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule contains a universal binding sequence (140) for sequencing primers, wherein the left universal binding sequence contains sequence 5'-CGTGCTGGATTGGCTCACCAGACACCTTCCGACAT-3' (SEQ ID NO: 45) (or its complementary sequence).

[0313] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule contains a universal binding sequence (140) for sequencing primers, wherein the left universal binding sequence contains sequence 5'-GAACGACATGGCTACGATCCGACTT-3' (SEQ ID NO: 46) (or its complementary sequence).

[0314] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule contains a universal binding sequence (140) for sequencing primers, wherein the left universal binding sequence contains sequence 5'-GCTCACAGAACGACATGGCTACGATCCGACTT-3' (SEQ ID NO: 47) (or its complementary sequence).

[0315] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule contains a universal binding sequence (150) for sequencing primers, wherein the left universal binding sequence contains sequence 5'-AGATCGGAAGAGCACACGTCTGAACTCCAGTCAC-3' (SEQ ID NO: 48) (or its complementary sequence).

[0316] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule contains a universal binding sequence (150) for sequencing primers, wherein the left universal binding sequence contains sequence 5'-CTGTCTCTTATACACATCTCCGAGCCCACGAGAC-3' (SEQ ID NO: 49) (or its complementary sequence).

[0317] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule contains a universal binding sequence (150) for sequencing primers, wherein the left universal binding sequence contains sequence 5'-ATGTCGGAAGGTGTGCAGGCTACCGCTTGTCAACT-3' (SEQ ID NO: 50) (or its complementary sequence).

[0318] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule contains a universal binding sequence (150) for sequencing primers, wherein the left universal binding sequence contains the sequence 5'-TTTGTCTTCCTAAGACCGCTTGGCCTCCGACTT-3' (SEQ ID NO: 51) (or its complementary sequence).

[0319] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule comprises a universal binding sequence (130) that binds to a first region (330) of a first sandwich chain, wherein the right universal binding sequence (130) comprises the sequence 5'-TCGTATGCCGTCTTCTGCTTG-3' (SEQ ID NO: 52) (or its complementary sequence).

[0320] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule comprises a universal binding sequence (130) that binds to a first region (330) of a first sandwich chain, wherein the right universal binding sequence (130) comprises the sequence 5'-AGTGCGTCGCAGCCTCACCTGATC-3' (SEQ ID NO: 31) (or its complementary sequence).

[0321] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule comprises a universal binding sequence (130) that binds to a first region (330) of a first sandwich chain, wherein the right universal binding sequence (130) comprises the sequence 5'-GTTGAGGAACCGAGTGT-3' (SEQ ID NO: 53) (or its complementary sequence).

[0322] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule comprises a universal binding sequence (130) that binds to a first region (330) of a first sandwich chain, wherein the right universal binding sequence (130) comprises the sequence 5'-GACTATTCCAGCGGTACG-3' (SEQ ID NO: 54) (or its complementary sequence).

[0323] In some embodiments, in any of the methods for forming the plurality of library-sandwich complexes (500) described herein, the library molecule comprises a universal binding sequence (130) that binds to a first region (330) of a first sandwich chain, wherein the right universal binding sequence (130) comprises the sequence 5'-CTGATAAGGTCGCCATGC-3' (SEQ ID NO: 55) (or its complementary sequence).

[0324] Methods for Rolling Circle Amplification

[0325] Cyclic library molecules generated via ds-clamp linker

[0326] In some aspects, this disclosure provides methods for improving sequencing quality scoring, comprising performing rolling circle amplification (ROA) on a covalently closed circular library molecule (600) to generate a plurality of fixed multiply molecules. The ROA may be performed after phosphorylation and ligation reactions, or after ligation reactions. In some embodiments, the ROA may be performed after an exonuclease reaction, at which point the covalently closed circular library molecule (600) no longer hybridizes with the first splint strand (300). In some embodiments, the ROA may be performed on the covalently closed circular library molecule (600) hybridized with the first splint strand (300). In some embodiments, the covalently closed circular library molecule (600) may be distributed on a support and then subjected to the ROA. In some embodiments, the covalently closed circular library molecule (600) may be subjected to the ROA in solution and then distributed onto a support. In some embodiments, the rolling circle amplification reaction may use the retained first splint chain (300) as the amplification primer, or the first splint chain (300) may be removed (e.g., by digestion with an exonuclease) and replaced with a soluble amplification primer.

[0327] Support for rolling circle amplification

[0328] Cyclic library molecules generated via ds-clamp linker

[0329] In some embodiments, a method for rolling circle amplification of a plurality of covalently closed circular library molecules (600) lacking a first splint chain (300), wherein each of the plurality of covalently closed circular library molecules (600) includes a second splint chain region (400) comprising a universal binding sequence for a third surface primer (e.g., a fixed capture primer), the method comprising the step (a): distributing the plurality of covalently closed circular library molecules (600) onto a support having a plurality of third surface primers fixed thereon, under conditions suitable for hybridizing the respective covalently closed circular library molecules (600) with the respective fixed third surface primers, thereby fixing the plurality of covalently closed circular library molecules (600). In some embodiments, the support further includes a plurality of fourth surface primers (e.g., a plurality of fixed stapled primers). In some embodiments, multiple covalently closed cyclic library molecules (600) are distributed onto a support to fix the multiple covalently closed cyclic library molecules (600) onto the support.

[0330] In some embodiments, in step (a), the immobilized third surface primer comprises a single-stranded oligonucleotide comprising DNA, RNA, or a combination of DNA and RNA. The third surface primer contains a sequence along its length that is fully or partially complementary to at least a portion of a nucleic acid library molecule (e.g., a linear or circular library molecule). The third surface primer may contain a terminal 3' nucleotide having a sugar 3' OH moiety that can be extended for nucleotide polymerization (e.g., polymerase-catalyzed polymerization).

[0331] In some embodiments, in step (a), the fixed third surface primer may be fixed to a support or a coating on the support. In some embodiments, the coating comprises a hydrophilic polymer coating. The fixed third surface primer may be embedded in and attached (e.g., coupled) to the coating on the support. In some embodiments, the 5' end of the fixed third surface primer may be fixed to the support or a coating on the support. Alternatively, the inner portion or the 3' end of the fixed third surface primer may be fixed to the support or a coating on the support. The support comprises a plurality of fixed third surface primers having the same sequence. The fixed third surface primer may be of any length, such as 4 to 50 nucleotides, or 50 to 100 nucleotides, or 100 to 150 nucleotides or longer.

[0332] In some embodiments, in step (a), the purpose of each third surface primer is to hybridize with a portion of a covalently closed circular library molecule, thereby immobilizing the library molecule to a support or a coating on the support. In some embodiments, each third surface primer may hybridize with a universal binding sequence of the third surface primer in the covalently closed circular library molecule. In some embodiments, the plurality of immobilized third surface primers act as a plurality of immobilized capture primers. In some embodiments, the 3' ends of the third surface primers may initiate a rolling circle amplification reaction to generate multiply molecules immobilized to the support (e.g., Figure 33 and Figure 34 ).

[0333] In some embodiments, in step (a), the plurality of immobilized third surface primers contain at least one phosphate-thioester diester bond at their 5' ends, which makes the third surface primers resistant to exonuclease degradation. In some embodiments, the plurality of immobilized third surface primers contain 2 to 5 or more consecutive phosphate-thioester diester bonds at their 5' ends. In some embodiments, the plurality of immobilized third surface primers contain at least one ribonucleotide and / or at least one 2'-O-methyl or 2'-O-methoxyethyl (MOE) nucleotide, which makes the third surface primers resistant to exonuclease degradation.

[0334] In some embodiments, in step (a), the immobilized third surface primer contains at least one locked nucleic acid (LNA) comprising a methylene bridge between the 2' oxygen and 4' carbon of the pentose ring. The immobilized third surface primer containing at least one LNA is resistant to nuclease digestion and exhibits an increased melting temperature when hybridized with the forward extension strand.

[0335] In some embodiments, in step (a), the fixed third surface primer includes at least one spacer arm at its 5' end. In some embodiments, the 5' end of each fixed third surface primer includes 1 to 10 consecutive spacer arms. In some embodiments, the spacer arms comprise hexaethylene glycol phosphorimide. For example, the spacer arms comprise 18 atoms of hexaethylene glycol spacers.

[0336] In some embodiments, in step (a), the support further includes a plurality of fourth surface primers immobilized thereon. In some embodiments, the sequences of the third and fourth surface primers are different. In some embodiments, the fourth primer comprises a single-stranded oligonucleotide comprising DNA, RNA, or a combination of DNA and RNA. In some embodiments, the fourth surface primer contains a sequence along its length that is completely or partially complementary to at least a portion of the multiply template molecule (e.g., Figure 46In some embodiments, the plurality of fourth surface primers may be fixed to a support or a coating on the support. In some embodiments, the fixed fourth surface primers may be embedded in and attached (coupled) to a coating on the support. In some embodiments, the 5' end of the fourth surface primer may be fixed to a support or a coating on the support. Alternatively, the inner portion or 3' end of the fourth surface primer may be fixed to a support or a coating on the support. In some embodiments, the support comprises a plurality of fixed fourth surface primers having the same sequence. The fixed fourth surface primers may be of any length, such as 4 to 50 nucleotides, or 50 to 100 nucleotides, or 100 to 150 nucleotides or longer.

[0337] In some embodiments, in step (a), the purpose of each fourth surface primer is to hybridize with a portion of the nucleic acid multiplicon molecule, thereby pinning a portion of the multiplicon molecule downward to the support or downward to a coating on the support (e.g., Figure 46 In some embodiments, each fourth surface primer may hybridize with a universal binding sequence for the fourth surface primer in the multiply molecule. In some embodiments, the plurality of fixed fourth surface primers act as a plurality of fixed pinning primers. In some embodiments, the 3' end of the fourth surface primer includes a blocking portion that prevents the fourth surface primer from extending. Therefore, the fourth surface primer cannot initiate a primer extension reaction. In some embodiments, a fixed third surface primer may hybridize / capture a covalently closed circular library molecule and initiate a rolling circle amplification reaction to generate a fixed multiply molecule, and a fixed fourth surface primer may hybridize with a portion of the fixed multiply molecule to pin down a portion of the multiply molecule (e.g., Figure 46 ).

[0338] In some embodiments, in step (a), the 3' end of the fixed fourth surface primer includes an extendable 3' OH portion. In some embodiments, the 3' end of the fixed fourth surface primer includes a non-extendable 3' portion. The 3' end of the fixed fourth surface primer includes a portion that blocks primer extension, such as, for example, a phosphate group, a dideoxycytidine group, a reverse dT group, or an amino group. The fixed fourth surface primer is non-extendable in the primer extension reaction. The fixed fourth surface primer lacks nucleotides with easily cleavable portions. For example, the fourth surface primer lacks uridine, 8-oxo-7,8-dihydroguanine (e.g., 8oxoG), and deoxyinosine.

[0339] In some embodiments, in step (a), the plurality of immobilized fourth surface primers contain at least one phosphate-thioester diester bond at their 5' ends, which makes the fourth surface primers resistant to exonuclease degradation. In some embodiments, the plurality of immobilized fourth surface primers contain 2 to 5 or more consecutive phosphate-thioester diester bonds at their 5' ends. In some embodiments, the plurality of immobilized fourth surface primers contain at least one ribonucleotide and / or at least one 2'-O-methyl or 2'-O-methoxyethyl (MOE) nucleotide, which makes the fourth surface primers resistant to exonuclease degradation.

[0340] In some embodiments, in step (a), the immobilized fourth surface primer contains at least one locked nucleic acid (LNA) comprising a methylene bridge between the 2' oxygen and the 4' carbon of the pentose ring. The immobilized fourth surface primer containing at least one LNA is resistant to nuclease digestion and exhibits an increased melting temperature when hybridized to a portion of a multiply molecule.

[0341] In some embodiments, in step (a), the fixed fourth surface primer includes at least one spacer arm at its 5' end. In some embodiments, the 5' end of each fixed fourth surface includes 1 to 10 consecutive spacer arms. In some embodiments, the spacer arms comprise hexaethylene glycol phosphorimide. For example, the spacer arms comprise 18-atom hexaethylene glycol spacers.

[0342] In some embodiments, the support includes per mm 2 Approximately 10 2 Up to 10 15 A fixed surface capture primer. In some embodiments, the support comprises per mm 2 Approximately 10 2 Up to 10 15 A fixed surface anchoring primer. In some embodiments, the support comprises per mm 2 Approximately 10 2 Up to 10 15 A fixed surface capture primer and a fixed surface stapled primer. In some embodiments, the fixed surface capture primer and the fixed surface stapled primer are fluidly connected to each other to allow various solutions of linear or circular nucleic acid template molecules, soluble primers, enzymes, nucleotides, divalent cations, buffers, reagents, etc., to flow onto the support, such that the plurality of fixed surface capture primers and fixed surface stapled primers can react with the solution in a large-scale parallel manner.

[0343] In some embodiments, the method for performing rolling circle amplification includes step (b): contacting the plurality of covalently closed circular library molecules immobilized on a support with a reagent for removing deaminated bases. In some embodiments, the plurality of covalently closed circular library molecules (600) comprises a mixture of a first subgroup and a second subgroup of covalently closed circular library molecules. In some embodiments, each covalently closed circular library molecule in the first subgroup carries at least one deaminated nucleotide base. In some embodiments, each covalently closed circular library molecule in the second subgroup lacks a deaminated nucleotide base.

[0344] In some embodiments, the contacting in step (b) comprises contacting the plurality of covalently closed circular library molecules (e.g., a first subgroup and a second subgroup) immobilized on a support with a deamination-removing reagent, thereby generating a plurality of immobilized covalently closed circular library molecules, wherein the subgroups of the covalently closed circular library molecules contain at least one base-free site. In some embodiments, the deamination-removing reagent comprises at least one enzyme having glycosylation activity, including any combination of any two or more of the following: formamidopyrimidine DNA glycosylation enzyme (fpg); uracil N-glycosylation enzyme (UNG); uracil DNA glycosylation enzyme (UDG); DNA (purine-free) lyase; DNA (pyrimidine-free) lyase; and / or endonuclease III.

[0345] In some embodiments, in step (b), the reagent for removing deaminated bases includes at least one enzyme with lysin activity, which is capable of cleaving the phosphodiester backbone on the 5' and 3' sides of the baseless site to release the baseless deoxyribose and create a gap, wherein the enzyme with lysin activity includes any one or any combination of two or more of the following: AP lyase, Endo IV endonuclease, FPG glycosylationase / AP lyase (formamidopyrimidine DNA glycosylationase), endonuclease VIII glycosylationase / AP lyase and / or endonuclease III.

[0346] In some embodiments, in step (b), the reagent for removing deaminated bases comprises at least one enzyme that produces a base-free site in the nucleic acid chain and at least one enzyme with lysin activity. In some embodiments, the reagent for removing deaminated bases comprises a mixture of uracil DNA glycosylase and DNA glycosylase-lysin endonuclease VIII, such as USER (uracil-specific excision reagent enzyme, such as from New England Biolabs) or thermosensitive USER (e.g., from New England Biolabs).

[0347] In some embodiments, in step (b), the reagent for removing deaminated bases may be washed away or inactivated after the glycosylation enzyme reaction is completed. In some embodiments, the reagent for removing deaminated bases may be washed away or inactivated after the lyase reaction is completed. In some embodiments, the reagent for removing deaminated bases may be washed away or inactivated after both the glycosylation enzyme and lyase reactions are completed.

[0348] In some embodiments, the method for performing rolling circle amplification further includes step (c): under conditions suitable for performing rolling circle amplification on a support using a plurality of third surface primers as immobilized amplification primers and a plurality of covalently closed circular library molecules (600) as template molecules, contacting the plurality of covalently closed circular library molecules (600) with a plurality of strand displacement polymerases and a plurality of nucleotides (e.g., containing bases A, G, C, T, and / or U), thereby generating a plurality of nucleic acid polynucleotide template molecules immobilized to the third surface primers. In some embodiments, the plurality of nucleotides includes any combination of two or more of dATP, dGTP, dCTP, dTTP, and / or dUTP. In some embodiments, rolling circle amplification generates a plurality of polynucleotide molecules, wherein each nucleic acid polynucleotide template molecule comprises a plurality of tandemly repeated polynucleotide units, wherein each polynucleotide unit comprises a target sequence, a binding site for the third surface primer, and a binding site for the fourth surface primer. In some embodiments, each nucleic acid polynucleotide template molecule is covalently bound to a respective third surface primer (e.g., an immobilized nucleic acid polynucleotide template molecule). In some embodiments, each of the plurality of covalently closed circular library molecules (600) includes a second splint region (400) that further includes a universal binding sequence for a fourth surface primer, such that rolling circle amplification generates a multiply molecule having multiple copies of the universal binding sequences for the third and fourth surface primers. In some embodiments, the method includes: distributing the covalently closed circular library molecule (600) onto a support comprising a plurality of fixed third and fourth surface primers; performing rolling circle amplification under conditions suitable for hybridizing at least a portion of the second splint region (400) of the multiply molecule with the fixed fourth surface primer to generate the multiply molecule, thereby pinning at least a portion of the multiply molecule downward to the support. In some embodiments, the fixed multiply may be subjected to a sequencing reaction.

[0349] In some embodiments, the rolling circle amplification reaction in step (c) can be performed using a nucleotide mixture containing dATP, dCTP, dGTP, dTTP, and a nucleotide having a cleavable moiety to generate a fixed polynucleotide template molecule containing at least one nucleotide having a cleavable moiety. The cleavable moiety in the fixed polynucleotide template molecule can be converted to a base-free site. In some embodiments, the nucleotide having a cleavable moiety in the nucleotide mixture includes uridine, 8-oxo-7,8-dihydroguanine (e.g., 8oxoG), or deoxyinosine. In the fixed polynucleotide template molecule, uridine can be converted to a base-free site using uracil DNA glycosylase (UDG), 8oxoG can be converted to a base-free site using FPG glycosylase, and deoxyinosine can be converted to a base-free site using AlkA glycosylase.

[0350] In some embodiments, the nucleotide mixture may contain a certain amount of dUTP such that a target percentage of thymidine in the resulting polypeptide molecule is replaced with dUTP. For example, when 30% of the dTTP in the polypeptide molecule is to be replaced with dUTP (e.g., 30% is the target percentage), the nucleotide mixture may contain 7.5% dUTP (e.g., 30 / 4 = 7.5%), 17.5% dTTP, and 25% each of dATP, dCTP, and dGTP. The target percentage of dTTP to be replaced with dUTP may be about 0.1% to 1%, or about 1% to 5%, or about 5% to 10%, or about 10% to 20%, or about 20% to 30%, or about 30% to 45%, or about 45% to 50%, or a higher percentage of dTTP in the fixed polypeptide template molecule, replaced with nucleotides having cleavable moieties.

[0351] In some embodiments, the nucleotide mixture may contain a amount of deoxyinosine such that a target percentage of guanosine in the resulting polymer molecule is replaced with deoxyinosine. For example, when 30% of the dGTP in the polymer molecule is to be replaced with deoxyinosine (e.g., 30% is the target percentage), the nucleotide mixture may contain 7.5% deoxyinosine (e.g., 30 / 4 = 7.5%), 17.5% dGTP, and 25% each of dATP, dCTP, and dTTP. The target percentage of dGTP to be replaced with deoxyinosine may be about 0.1% to 1%, or about 1% to 5%, or about 5% to 10%, or about 10% to 20%, or about 20% to 30%, or about 30% to 45%, or about 45% to 50%, or a higher percentage of dGTP in the fixed polymer template molecule, replaced with nucleotides having easily cleavable moieties.

[0352] In some embodiments, the nucleotide mixture may contain an amount of 8oxoG such that a target percentage of guanosine in the resulting polymer molecule is replaced with 8oxoG. For example, when 30% of dGTP in the polymer molecule is to be replaced with 8oxoG (e.g., 30% is the target percentage), the nucleotide mixture may contain 7.5% 8oxoG (e.g., 30 / 4 = 7.5%), 17.5% dGTP, and 25% each of dATP, dCTP, and dTTP. The target percentage of dGTP to be replaced with 8oxoG may be about 0.1% to 1%, or about 1% to 5%, or about 5% to 10%, or about 10% to 20%, or about 20% to 30%, or about 30% to 45%, or about 45% to 50%, or a higher percentage of dGTP in the fixed polymer template molecule, replaced with nucleotides having cleavable moieties.

[0353] In some embodiments, rolling circle amplification (RBA) generates immobilized nucleic acid multiplicand template molecules, which contain incorporated nucleotides with cleavable moieties distributed at random positions along the various immobilized nucleic acid multiplicand template molecules. In some embodiments, the cleavable nucleotides are distributed at different positions within different immobilized nucleic acid multiplicand template molecules.

[0354] In some embodiments, rolling circle amplification (RCA) can generate multiple copies of a single-stranded nucleic acid multinucleotide molecule having tandemly arranged polynucleotide units, each polynucleotide unit containing a target sequence and at least one binding site for a compressed oligonucleotide. In some embodiments, the rolling circle amplification reaction in step (c) can be performed with or without multiple compressed oligonucleotides. In some embodiments, the compressed oligonucleotide comprises a 5' region, an optional internal region (insertion region), and a 3' region. The 5' and 3' regions of the compressed oligonucleotide can hybridize with the binding site of the nucleic acid multinucleotide template molecule to pull the distal portions of the nucleic acid multinucleotide template molecule together, thereby causing compression of the nucleic acid multinucleotide template molecule to form DNA nanospheres. For example, the 5' region of the compressed oligonucleotide is designed to hybridize with a first portion of the nucleic acid multinucleotide template molecule, and the 3' region of the compressed oligonucleotide is designed to hybridize with a second portion of the nucleic acid multinucleotide template molecule. In some embodiments, the 3' ends of the compressed oligonucleotides are non-elongating, which inhibits their elongation during rolling circle amplification. Compared to nucleic acid multiply template molecules generated in the absence of compressed oligonucleotides, including compressed oligonucleotides during RCA promotes the formation of DNA nanospheres with a more compact size and shape. The compact and stable properties of the DNA nanospheres improve sequencing accuracy by increasing signal intensity, and the DNA nanospheres maintain their shape and size during multiple sequencing cycles.

[0355] In some embodiments, the method for performing rolling circle amplification further includes step (d): sequencing the plurality of nucleic acid polymorphic template molecules (immobilized nucleic acid polymorphic template molecules) immobilized on a support. In some embodiments, the immobilized nucleic acid polymorphic template molecules include nucleic acid template molecules to be sequenced. In some embodiments, the sequencing in step (d) can be performed by contacting the immobilized nucleic acid polymorphic template molecules with a plurality of sequencing primers, a plurality of sequencing polymerases, and a plurality of nucleotide reagents, and performing at least two sequencing reaction cycles. In some embodiments, the nucleotide reagents include nucleotides, nucleotide analogs, and / or multivalent molecules. In some embodiments, the sequencing reaction employs nucleotide reagents containing detectably labeled nucleotide analogs. In some embodiments, the sequencing reaction employs nucleotide reagents containing detectably labeled multivalent molecules. In some embodiments, the sequencing reaction employs a two-stage sequencing reaction comprising binding a detectably labeled multivalent molecule and incorporating a nucleotide analog as described herein. In some embodiments, the sequencing reaction employs labeled or unlabeled nucleotide analogs as described herein. In some embodiments, the sequencing reaction employs a binding sequencing reaction as described herein. In some embodiments, step (d) includes pairwise sequencing, wherein 2 to 30 consecutive bases in the initial portion of read 2 (R2) are sequenced using an unlabeled nucleotide analogue (e.g., dark sequencing).

[0356] In some embodiments, any of steps (a) to (d) of the method for rolling circle amplification of a plurality of covalently closed circular library molecules (600) may include applying a deamination reagent and / or a basic reagent to any of the covalently closed circular library molecules (600), thereby generating a plurality of covalently closed circular library molecules with reduced C:G to T:A base transitions, which can generate higher quality base interpretation during downstream sequencing workflows. In some embodiments, applying a deamination reagent and / or a basic reagent can increase the sequencing quality score from Q30 to Q40, Q45, Q50, Q55, Q60 or higher. In some embodiments, applying a deamination reagent and / or a basic reagent to a nucleic acid manipulation workflow can achieve a sequencing quality score of approximately 80% to 90%, or approximately 90% to 95%, or approximately 95% to 100% of Q40. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid handling workflow can achieve a sequencing quality score Q45 of about 75% to 85%, or about 85% to 90%, or about 90% to 95%, or about 95% to 100%. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid handling workflow can achieve a sequencing quality score Q50 of about 65% to 75%, or about 75% to 85%, or about 85% to 95%, or about 95% to 100%. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid handling workflow can achieve a sequencing quality score Q55 of about 60% to 70%, or about 70% to 80%, or about 80% to 85%, or about 85% to 90%, or about 90% to 100%. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid manipulation workflow can achieve sequencing quality scores (Q60) of approximately 60% to 70%, approximately 70% to 80%, approximately 80% to 85%, approximately 85% to 90%, or approximately 90% to 100%. See, for example, [link to documentation]. Figure 65 , Figure 66 , Figures 67A to 67D , Figures 68A to 68D , Figure 69 and Figure 70 , and see Figure 73 Tables A and B are located at [location].

[0357] In some embodiments, in step (a), a plurality of covalently closed cyclic library molecules (600) may be distributed onto a support coated with one or more compounds to create a passivation layer on the support (e.g., Figure 1In some embodiments, the passivation layer forms a porous or semi-porous layer. In some embodiments, a third surface primer (e.g., a surface-capturing primer), a fourth surface primer (e.g., a surface-stacking primer), a multiplicon template molecule, and / or a polymerase may be attached to the passivation layer for immobilization to a support. In some embodiments, the support includes a low-nonspecific binding surface that can improve nucleic acid hybridization and amplification performance on the support. Generally, the support may include one or more covalently or non-covalently attached low-binding chemically modified layers, such as silane layers, polymer films, and one or more covalently or non-covalently attached oligonucleotides for immobilizing multiple nucleic acid multiplicon template molecules to the support. In some embodiments, the support may include a functionalized polymer coating covalently bound to at least a portion of the support via chemical groups on the support, primers grafted to the functionalized polymer coating, and a water-soluble protective coating on the primers and the functionalized polymer coating. In some embodiments, the functionalized polymer coating comprises poly(N-(5-azidoacetamidopentyl)acrylamide-co-acrylamide (PAZAM). In some embodiments, the support comprises a surface coating having at least one hydrophilic polymer coating and at least one layer of multiple oligonucleotides. The hydrophilic polymer coating may comprise polyethylene glycol (PEG). The hydrophilic polymer coating may comprise branched PEG having at least four branches. In some embodiments, the low nonspecific binding coating has a degree of hydrophilicity that can be measured as a water contact angle, wherein the water contact angle does not exceed 45 degrees. In some embodiments, the density of covalently closed cyclic library molecules (600) fixed to or on the support is about 10. 2 -10 6 pcs / mm 2 or about 10 6 -10 9 pcs / mm 2 or about 10 9 -10 12 pcs / mm 2 In some embodiments, a plurality of covalently closed circular library molecules (600) are fixed to the support or the coating on the support at predetermined sites on the support (or the coating on the support), or fixed to the coating on the support at random sites on the support (or the coating on the support).

[0358] In some embodiments, the distribution in step (a) may be performed in the presence of a high-efficiency hybridization buffer comprising: (i) a first polar aprotic solvent having a dielectric constant of not more than 40 and a polarity index of 4 to 9; (ii) a second polar aprotic solvent having a dielectric constant of not more than 115 and present in the hybridization buffer formulation in an amount capable of effectively denaturing double-stranded nucleic acids; (iii) a pH buffer system that maintains the pH of the hybridization buffer formulation in the range of about 4 to 8; and (iv) a crowding agent in an amount sufficient to enhance or promote molecular crowding. In some embodiments, the high-efficiency hybridization buffer comprises: (i) a first polar aprotic solvent comprising acetonitrile at 25% to 50% by volume of the hybridization buffer; (ii) a second polar aprotic solvent comprising formamide at 5% to 10% by volume of the hybridization buffer; (iii) a pH buffer system comprising 2-(N-morpholino)ethanesulfonic acid (MES) at a pH of 5 to 6.5; and (iv) a congesting agent comprising polyethylene glycol (PEG) at 5% to 35% by volume of the hybridization buffer. In some embodiments, the high-efficiency hybridization buffer further comprises betaine.

[0359] In some embodiments, in step (a), the plurality of third surface primers (e.g., capture primers) immobilized on the support comprise the sequence 5'-GATCAGGTGAGGCTGCGACGACT-3' (SEQ ID NO: 39) (or its complementary sequence). Each third surface primer (e.g., capture primer) may hybridize with a covalently closed circular library molecule (600) having a second splint chain region (400) comprising a universal binding sequence for the third surface primer, wherein the universal binding sequence for the third surface primer comprises a second subregion comprising the sequence 5'-AGTCGTCGCAGCCTCACCTGATC-3' (SEQ ID NO: 31) (or its complementary sequence).

[0360] In some embodiments, in step (a), the plurality of third surface primers (e.g., capture primers) fixed to the support contain the sequence 5'-CAAGCAGAAGACGGCATACGA-3' (SEQ ID NO: 36) (or its complementary sequence).

[0361] In some embodiments, in step (c), the plurality of fourth surface primers (e.g., stapled primers) fixed to the support comprise the sequence 5'-CATGTAATGCACGTACTTTCAGGGT-3' (SEQ ID NO: 30) (or its complementary sequence). In some embodiments, in step (c), the plurality of fourth surface primers (e.g., stapled primers) fixed to the support comprise the sequence 5'-AATGCACGTACTTTCAGGGT-3' (SEQ ID NO: 56) (or its complementary sequence). Each fourth surface primer (e.g., stapled primer) may hybridize with a portion of a multiply molecule having a second splint chain region (400) comprising a universal binding sequence for the fourth surface primer, wherein the universal binding sequence for the fourth surface primer comprises a first subregion comprising the sequence 5'-CATGTAATGCACGTACTTTCAGGGT-3' (SEQ ID NO: 30) (or its complementary sequence).

[0362] In some embodiments, in step (a), the plurality of fourth surface primers (e.g., stapled primers) fixed to the support contain the sequence 5'-AATGATACGGCGACCACCGA-3' (SEQ ID NO: 34) (or its complementary sequence).

[0363] In-solution rolling circle amplification was performed using soluble amplification primers.

[0364] Cyclic library molecules generated via ds-clamp linker

[0365] In some embodiments, a method for performing rolling circle amplification on a plurality of covalently closed circular library molecules (600), wherein each of the plurality of covalently closed circular library molecules (600) includes a second splint chain region (400) comprising universal binding sequences for a third surface primer and a fourth surface primer, the method comprising the step (a): hybridizing the plurality of soluble amplification primers to the plurality of covalently closed circular library molecules in solution (e.g., Figure 47A In some embodiments, the plurality of soluble amplification primers comprise a plurality of first splint chains (300), each first splint chain having an extendable 3' end (e.g., Figure 16(Bottom). In some embodiments, the plurality of first splint chains (300) have been degraded or removed and replaced with a plurality of soluble amplification primers that can hybridize with a universal adaptor sequence (120) having a binding sequence for a first surface primer. In some embodiments, the plurality of first splint chains (300) have been degraded or removed and replaced with a plurality of soluble amplification primers that can hybridize with a universal adaptor sequence (130) having a binding sequence for a second surface primer.

[0366] In some embodiments, the method for performing rolling circle amplification further includes step (b): performing a first rolling circle amplification reaction by contacting multiple covalently closed circular library molecules (600) and multiple soluble amplification primers with multiple strand displacement polymerases and multiple nucleotides (e.g., containing bases A, G, C, T and / or U) under conditions suitable for initiating primer extension using multiple soluble amplification primers and using multiple covalently closed circular library molecules (600) as template molecules, thereby generating multiple nascent nucleic acid polymorph template molecules (e.g., still hybridized with their homologous covalently closed circular library molecules (600)). Figure 47A In some embodiments, rolling circle amplification in solution generates multiple nascent multiply molecules, wherein each nascent nucleic acid multiply template molecule contains multiple tandemly repeated polynucleotide units, wherein each polynucleotide unit contains a target sequence, a binding site for a third surface primer, and a binding site for a fourth surface primer.

[0367] In some embodiments, the first rolling circle amplification reaction in step (b) may be performed with or without multiple compressed oligonucleotides. In some embodiments, the compressed oligonucleotides comprise a 5' region, an optional internal region (insertion region), and a 3' region. The 5' and 3' regions of the compressed oligonucleotides may hybridize with the binding site of a nascent nucleic acid polyp template molecule to pull the distal portions of the nascent nucleic acid polyp template molecule together, thereby causing compression of the nascent nucleic acid polyp template molecule to form DNA nanospheres. For example, the 5' region of the compressed oligonucleotide is designed to hybridize with a first portion of the nascent nucleic acid polyp template molecule, and the 3' region of the compressed oligonucleotide is designed to hybridize with a second portion of the nascent nucleic acid polyp template molecule. In some embodiments, the 3' ends of the compressed oligonucleotides are non-elongating, which inhibits their elongation during the first rolling circle amplification reaction. Including compressed oligonucleotides during RCA promotes the formation of DNA nanospheres with a more compact size and shape compared to polyps generated in the absence of compressed oligonucleotides.

[0368] In some embodiments, the method for performing rolling circle amplification further includes step (c): distributing a plurality of newly formed nucleic acid multiply template molecules onto a support on which a plurality of third surface primers (e.g., fixed capture primers) are fixed, under conditions suitable for hybridizing at least a portion of each newly formed nucleic acid multiply template molecule with fixed third surface primers (e.g., fixed capture primers), thereby fixing a plurality of newly formed nucleic acid multiply template molecules (fixed newly formed nucleic acid multiply template molecules) (e.g., Figure 47B In some embodiments, each fixed, newly formed nucleic acid polymorph template molecule still hybridizes with its homologous covalently closed circular library molecule (600). In some embodiments, the support further comprises a plurality of fixed fourth primers (e.g., fixed pinning primers) that can hybridize with at least a portion of the fixed nucleic acid polymorph template molecule, thereby pinning down a portion of the fixed, newly formed nucleic acid polymorph template molecule.

[0369] In some embodiments, in step (c), the immobilized third surface primer comprises a single-stranded oligonucleotide comprising DNA, RNA, or a combination of DNA and RNA. The third surface primer includes a sequence along its length that is completely or partially complementary to at least a portion of the nascent nucleic acid polynucleotide template molecule. In some embodiments, the third surface primer includes a 3' end portion containing a blocking portion that prevents the third surface primer from extending. In some embodiments, the third surface primer includes a 3' end nucleotide containing a 3' OH portion that can extend for nucleotide polymerization (e.g., polymerase-catalyzed polymerization).

[0370] In some embodiments, in step (c), the fixed third surface primer may be fixed to a support or a coating on the support. The fixed third surface primer may be embedded in and attached (e.g., coupled) to a coating on the support. In some embodiments, the 5' end of the fixed third surface primer may be fixed to a support or a coating on the support. Alternatively, the inner portion or the 3' end of the fixed third surface primer may be fixed to a support or a coating on the support. The support comprises a plurality of fixed third surface primers having the same sequence. The fixed third surface primer may be of any length, such as 4 to 50 nucleotides, or 50 to 100 nucleotides, or 100 to 150 nucleotides or longer.

[0371] In some embodiments, in step (c), the purpose of each third surface primer is to hybridize with a portion of the nascent multiply molecules, thereby immobilizing the nascent multiply molecules to a support or a coating on the support (e.g., Figure 47BIn some embodiments, each third surface primer may hybridize with a universal binding sequence for the third surface primer in the nascent multiply molecule. In some embodiments, the plurality of fixed third surface primers act as a plurality of fixed capture primers.

[0372] In some embodiments, in step (c), the plurality of immobilized third surface primers contain at least one phosphate-thioester diester bond at their 5' ends, which makes the third surface primers resistant to exonuclease degradation. In some embodiments, the plurality of immobilized third surface primers contain 2 to 5 or more consecutive phosphate-thioester diester bonds at their 5' ends. In some embodiments, the plurality of immobilized third surface primers contain at least one ribonucleotide and / or at least one 2'-O-methyl or 2'-O-methoxyethyl (MOE) nucleotide, which makes the third surface primers resistant to exonuclease degradation.

[0373] In some embodiments, in step (c), the immobilized third surface primer contains at least one locked nucleic acid (LNA) containing a methylene bridge between the 2' oxygen and the 4' carbon of the pentose ring. The immobilized third surface primer containing at least one LNA is resistant to nuclease digestion and exhibits an increased melting temperature when hybridized with the forward extension strand.

[0374] In some embodiments, in step (c), the fixed third surface primer includes at least one spacer arm at its 5' end. In some embodiments, the 5' end of each fixed third surface primer includes 1 to 10 consecutive spacer arms. In some embodiments, the spacer arms comprise hexaethylene glycol phosphorimide. For example, the spacer arms comprise 18 atoms of hexaethylene glycol spacers.

[0375] In some embodiments, in step (c), the support further includes a plurality of fourth surface primers immobilized thereon. In some embodiments, the sequences of the third and fourth surface primers are different. In some embodiments, the fourth primer comprises a single-stranded oligonucleotide comprising DNA, RNA, or a combination of DNA and RNA. In some embodiments, the fourth surface primer contains a sequence along its length that is completely or partially complementary to at least a portion of the multiply template molecule (e.g., Figure 47CIn some embodiments, the plurality of fourth surface primers may be fixed to a support or a coating on the support. In some embodiments, the fixed fourth surface primers may be embedded in and attached (coupled) to a coating on the support. In some embodiments, the 5' end of the fourth surface primer may be fixed to a support or a coating on the support. Alternatively, the inner portion or 3' end of the fourth surface primer may be fixed to a support or a coating on the support. In some embodiments, the support comprises a plurality of fixed fourth surface primers having the same sequence. The fixed fourth surface primers may be of any length, such as 4 to 50 nucleotides, or 50 to 100 nucleotides, or 100 to 150 nucleotides or longer.

[0376] In some embodiments, in step (c), the purpose of each fourth surface primer is to hybridize with a portion of the nucleic acid multiplicity template molecule, thereby pinning that portion of the nucleic acid multiplicity template molecule downward to the support or downward to a coating on the support (e.g., Figure 47C In some embodiments, each fourth surface primer may hybridize with a universal binding sequence for the fourth surface primer in the multiplex molecule. In some embodiments, the plurality of fixed fourth surface primers act as a plurality of fixed pinning primers. In some embodiments, the 3' end of the fourth surface primer includes a blocking portion that prevents the fourth surface primer from extending. Therefore, the fourth surface primer cannot initiate a primer extension reaction. In some embodiments, a fixed third surface primer may hybridize / capture a covalently closed circular library molecule and initiate a rolling circle amplification reaction to generate a fixed multiplex molecule, and a fixed fourth surface primer may hybridize with a portion of a fixed nucleic acid multiplex template molecule to pin down a portion of the nucleic acid multiplex template molecule (e.g., Figure 47C ).

[0377] In some embodiments, in step (c), the 3' end of the fixed fourth surface primer includes an extendable 3' OH portion. In some embodiments, the 3' end of the fixed fourth surface primer includes a non-extendable 3' portion. The 3' end of the fixed fourth surface primer includes a portion that blocks primer extension, such as, for example, a phosphate group, a dideoxycytidine group, a reverse dT group, or an amino group. The fixed fourth surface primer is non-extendable in the primer extension reaction. The fixed fourth surface primer lacks nucleotides with easily cleavable portions. For example, the fourth surface primer lacks uridine, 8-oxo-7,8-dihydroguanine (e.g., 8oxoG), and deoxyinosine.

[0378] In some embodiments, in step (c), the plurality of immobilized fourth surface primers contain at least one phosphate-thioester diester bond at their 5' ends, which makes the fourth surface primers resistant to exonuclease degradation. In some embodiments, the plurality of immobilized fourth surface primers contain 2 to 5 or more consecutive phosphate-thioester diester bonds at their 5' ends. In some embodiments, the plurality of immobilized fourth surface primers contain at least one ribonucleotide and / or at least one 2'-O-methyl or 2'-O-methoxyethyl (MOE) nucleotide, which makes the fourth surface primers resistant to exonuclease degradation.

[0379] In some embodiments, in step (c), the immobilized fourth surface primer contains at least one locked nucleic acid (LNA) comprising a methylene bridge between the 2' oxygen and the 4' carbon of the pentose ring. The immobilized fourth surface primer containing at least one LNA is resistant to nuclease digestion and exhibits an increased melting temperature when hybridizing with a portion of a nucleic acid multiplicon template molecule.

[0380] In some embodiments, in step (c), the fixed fourth surface primer includes at least one spacer arm at its 5' end. In some embodiments, the 5' end of each fixed fourth surface includes 1 to 10 consecutive spacer arms. In some embodiments, the spacer arms comprise hexaethylene glycol phosphorimide. For example, the spacer arms comprise 18-atom hexaethylene glycol spacers.

[0381] In some embodiments, the support includes per mm 2 Approximately 10 2 Up to 10 15 A fixed surface capture primer. In some embodiments, the support comprises per mm 2 Approximately 10 2 Up to 10 15 A fixed surface anchoring primer. In some embodiments, the support comprises per mm 2 Approximately 10 2 Up to 10 15 A fixed surface capture primer and a fixed surface stapled primer. In some embodiments, the fixed surface capture primer and the fixed surface stapled primer are fluidly connected to each other to allow various solutions of linear or circular nucleic acid template molecules, soluble primers, enzymes, nucleotides, divalent cations, buffers, reagents, etc., to flow onto the support, such that the plurality of fixed surface capture primers and fixed surface stapled primers can react with the solution in a large-scale parallel manner.

[0382] In some embodiments, in step (c), the method includes contacting a plurality of newly formed nucleic acid polymer template molecules with a reagent for removing deaminated bases. In some embodiments, the plurality of newly formed nucleic acid polymer template molecules comprises a mixture of a first subgroup and a second subgroup of newly formed nucleic acid polymer template molecules. In some embodiments, each newly formed polymer molecule in the first subgroup carries at least one deaminated nucleotide base. In some embodiments, each newly formed nucleic acid polymer template molecule in the second subgroup lacks a deaminated nucleotide base.

[0383] In some embodiments, the contacting in step (c) comprises contacting the plurality of newly formed nucleic acid polymer template molecules (e.g., a first subgroup and a second subgroup) with a deamination-removing agent, thereby generating a plurality of immobilized newly formed nucleic acid polymer template molecules, wherein the subgroups of the plurality of newly formed nucleic acid polymer template molecules contain at least one base-free site. In some embodiments, the deamination-removing agent comprises at least one enzyme having glycosylation activity, including any combination of any two or more of the following: formamidopyrimidine DNA glycosylase (fpg); uracil N-glycosylase (UNG); uracil DNA glycosylase (UDG); DNA (purine-free) lyase; DNA (pyrimidine-free) lyase; and / or endonuclease III.

[0384] In some embodiments, in step (c), the reagent for removing deaminated bases includes at least one enzyme with lysin activity, which is capable of cleaving the phosphodiester backbone on the 5' and 3' sides of the baseless site to release the baseless deoxyribose and create a gap, wherein the enzyme with lysin activity includes any combination of any two or more of the following: AP lyase, Endo IV endonuclease, FPG glycosylase / AP lyase (formamidopyrimidine DNA glycosylase), endonuclease VIII glycosylase / AP lyase and / or endonuclease III.

[0385] In some embodiments, in step (c), the reagent for removing deaminated bases includes at least one enzyme that produces a base-free site in the nucleic acid chain and at least one enzyme with lysin activity. In some embodiments, the reagent for removing deaminated bases includes a mixture of uracil DNA glycosylase and DNA glycosylase-lysin endonuclease VIII, such as USER (uracil-specific excision reagent enzyme, such as from New England Biolabs) or thermosensitive USER (e.g., from New England Biolabs).

[0386] In some embodiments, in step (c), the reagent for removing deaminated bases may be washed away or inactivated after the glycosylation enzyme reaction is complete. In some embodiments, the reagent for removing deaminated bases may be washed away or inactivated after the lyase reaction is complete. In some embodiments, the reagent for removing deaminated bases may be washed away or inactivated after both the glycosylation enzyme and lyase reactions are complete.

[0387] In some embodiments, the method for performing rolling circle amplification further includes step (d): under conditions suitable for performing a second rolling circle amplification reaction on a support using a plurality of covalently closed circular library molecules (600) as template molecules, contacting the plurality of nascent nucleic acid polymer template molecules (fixed nascent nucleic acid polymer template molecules) with a plurality of chain displacement polymerases and a plurality of nucleotides (e.g., including bases A, G, C, T and / or U), thereby further extending the plurality of fixed nascent nucleic acid polymer template molecules (e.g., Figure 47B In some embodiments, the first rolling circle amplification reaction and / or the second rolling circle amplification reaction may be performed using a plurality of nucleotides including any combination of two or more of dATP, dGTP, dCTP, dTTP and / or dUTP. In some embodiments, the second rolling circle amplification generates a plurality of immobilized nucleic acid polynucleotide template molecules, wherein each immobilized nucleic acid polynucleotide template molecule comprises a plurality of tandem repeat polynucleotide units, wherein each polynucleotide unit comprises a target sequence, a binding site for a third surface primer and a binding site for a fourth surface primer. In some embodiments, each immobilized nucleic acid polynucleotide template molecule hybridizes with a respective third surface primer. In some embodiments, each covalently closed circular library molecule (600) in the plurality of covalently closed circular library molecules comprises a second splint chain region (400), the second splint chain region further comprising a universal binding sequence for the fourth surface primer, such that the first rolling circle amplification reaction in solution generates a plurality of copies of nucleic acid polynucleotide template molecules having the universal binding sequences for the third and fourth surface primers (i.e., unimmobilized nucleic acid polynucleotide template molecules). In some embodiments, the method includes distributing a nucleic acid polyp template molecule onto a support lacking fixed first and second capture primers, and the support comprising a plurality of fixed third and fourth surface primers. In some embodiments, the method includes incubating the nucleic acid polyp template molecule under conditions suitable for hybridizing a first and / or second subregion of a second splint chain region (400) of the polyp molecule with the fixed third and fourth surface primers, thereby pinning at least a portion of the nucleic acid polyp template molecule downward to the support (and generating a fixed nucleic acid polyp template molecule). In some embodiments, the fixed polyp may be subjected to a sequencing reaction.

[0388] In some embodiments, the covalently closed circular library molecule of step (a) includes a second splint chain (400) region carrying a new adaptor sequence and / or a new index sequence. In some embodiments, the first and / or second subregions of the second splint chain (400) introduce universal sequences to allow each covalently closed circular library molecule to hybridize with a third surface primer (e.g., a third capture primer). In some embodiments, the first and / or second subregions of the second splint chain (400) introduce universal sequences to allow at least a portion of the multiply template molecule to hybridize with a fourth surface primer (e.g., a stapled primer). For example, the covalently closed circular library molecule may be distributed onto a support lacking fixed first and second capture primers, but the support includes a plurality of fixed third capture primers and optionally a plurality of fixed stapled primers.

[0389] In some embodiments, the first and / or second subregions of the second splint chain (400) introduce universal sequences to allow each covalently closed circular library molecule to hybridize with a third surface primer (e.g., a capture primer). In some embodiments, the first and / or second subregions of the second splint chain (400) introduce universal sequences to allow at least a portion of the polyp template molecule to hybridize with a fourth surface primer (e.g., a stapled primer). For example, in step (c), the nascent nucleic acid polyp template molecule (e.g., hybridizing with its homologous covalently closed circular library molecule) may be distributed onto a support lacking fixed first and second capture primers, but the support includes multiple fixed third capture primers and multiple stapled primers.

[0390] In some embodiments, the support-based rolling circle amplification reaction in step (d) can be performed using a nucleotide mixture containing dATP, dCTP, dGTP, dTTP, and a nucleotide with a cleavable moiety to generate a fixed nucleic acid polymer template molecule containing at least one nucleotide with a cleavable moiety. The cleavable moiety in the fixed nucleic acid polymer template molecule can be converted to a base-free site. In some embodiments, the nucleotide with the cleavable moiety in the nucleotide mixture includes uridine, 8-oxo-7,8-dihydroguanine (e.g., 8oxoG), or deoxyinosine. In the fixed polymer template molecule, uridine can be converted to a base-free site using uracil DNA glycosylase (UDG), 8oxoG can be converted to a base-free site using FPG glycosylase, and deoxyinosine can be converted to a base-free site using AlkA glycosylase.

[0391] In some embodiments, the nucleotide mixture of step (d) may contain a certain amount of dUTP such that a target percentage of thymidine in the resulting nucleic acid multiplex template molecule is replaced with dUTP. For example, when 30% of the dTTP in the nucleic acid multiplex template molecule is to be replaced with dUTP (e.g., 30% is the target percentage), the nucleotide mixture may contain 7.5% dUTP (e.g., 30 / 4 = 7.5%), 17.5% dTTP, and 25% each of dATP, dCTP, and dGTP. The target percentage of dTTP to be replaced by dUTP may be about 0.1% to 1%, or about 1% to 5%, or about 5% to 10%, or about 10% to 20%, or about 20% to 30%, or about 30% to 45%, or about 45% to 50%, or a higher percentage of dTTP in the nucleic acid multiplex template molecule replaced with nucleotides having cleavable moieties.

[0392] In some embodiments, the nucleotide mixture of step (d) may contain a certain amount of deoxyinosine such that a target percentage of guanosine in the resulting polymer molecule is replaced with deoxyinosine. For example, when 30% of dGTP in the polymer molecule is to be replaced with deoxyinosine (e.g., 30% is the target percentage), the nucleotide mixture may contain 7.5% deoxyinosine (e.g., 30 / 4 = 7.5%), 17.5% dGTP, and 25% each of dATP, dCTP, and dTTP. The target percentage of dGTP to be replaced with deoxyinosine may be about 0.1% to 1%, or about 1% to 5%, or about 5% to 10%, or about 10% to 20%, or about 20% to 30%, or about 30% to 45%, or about 45% to 50%, or a higher percentage of dGTP in the nucleic acid polymer template molecule replaced with nucleotides having cleavable moieties.

[0393] In some embodiments, the nucleotide mixture of step (d) may contain an amount of 8oxoG such that a target percentage of guanosine in the resulting nucleic acid polymer template molecule is replaced with 8oxoG. For example, when 30% of dGTP in the nucleic acid polymer template molecule is to be replaced with 8oxoG (e.g., 30% is the target percentage), the nucleotide mixture may contain 7.5% 8oxoG (e.g., 30 / 4 = 7.5%), 17.5% dGTP, and 25% each of dATP, dCTP, and dTTP. The target percentage of dGTP to be replaced by 8oxoG may be about 0.1% to 1%, or about 1% to 5%, or about 5% to 10%, or about 10% to 20%, or about 20% to 30%, or about 30% to 45%, or about 45% to 50%, or a higher percentage of dGTP in the nucleic acid polymer template molecule replaced with nucleotides having cleavable moieties.

[0394] In some embodiments, the rolling circle amplification reaction in step (d) can generate a nucleic acid multiplicative template molecule with an incorporated nucleotide having a cleavable portion distributed at random positions along the various multiplicative template molecules. In some embodiments, the nucleotide with the cleavable portion is distributed at different positions in different fixed multiplicative template molecules. In some embodiments, the nucleic acid multiplicative template molecules are fixed.

[0395] In some embodiments, the rolling circle amplification (RCA) of step (d) can generate multiple copies of a nucleic acid polynucleotide template molecule having tandemly arranged polynucleotide units, each polynucleotide unit containing a target sequence and at least one binding site for a compressed oligonucleotide. In some embodiments, the second rolling circle amplification reaction of step (d) can be performed with or without multiple compressed oligonucleotides. In some embodiments, the compressed oligonucleotide comprises a 5' region, an optional internal region (insertion region), and a 3' region. The 5' and 3' regions of the compressed oligonucleotide can hybridize with the binding site of the polynucleotide molecule to pull the distal portions of the nucleic acid polynucleotide molecule together, thereby causing compression of the nucleic acid polynucleotide template molecule to form DNA nanospheres. For example, the 5' region of the compressed oligonucleotide is designed to hybridize with a first portion of the nucleic acid polynucleotide template molecule, and the 3' region of the compressed oligonucleotide is designed to hybridize with a second portion of the nucleic acid polynucleotide template molecule. In some embodiments, the 3' ends of the compressed oligonucleotides are non-elongating, which inhibits their elongation during rolling circle amplification. Compared to multiplexes generated in the absence of compressed oligonucleotides, including compressed oligonucleotides during RCA promotes the formation of DNA nanospheres with a more compact size and shape. The compact and stable properties of the DNA nanospheres improve sequencing accuracy by increasing signal intensity, and the DNA nanospheres maintain their shape and size during multiple sequencing cycles. In some embodiments, the nucleic acid multiplex template molecule is single-stranded.

[0396] In some embodiments, the method for performing rolling circle amplification further includes step (e): sequencing the plurality of polyp molecules. In some embodiments, the nucleic acid polyp template molecule is immobilized (immobilized nucleic acid polyp template molecule). In some embodiments, the nucleic acid polyp template molecule includes a nucleic acid template molecule to be sequenced. In some embodiments, the sequencing in step (e) can be performed by contacting the nucleic acid polyp template molecule with a plurality of sequencing primers, a plurality of sequencing polymerases, and a plurality of nucleotide reagents, and performing at least two sequencing reaction cycles. In some embodiments, the nucleotide reagent includes nucleotides, nucleotide analogs, and / or multivalent molecules. In some embodiments, the sequencing reaction employs a nucleotide reagent containing a detectably labeled nucleotide analog. In some embodiments, the sequencing reaction employs a nucleotide reagent containing a detectably labeled multivalent molecule. In some embodiments, the sequencing reaction employs a two-stage sequencing reaction comprising binding a detectably labeled multivalent molecule and incorporating a nucleotide analog as described herein. In some embodiments, the sequencing reaction employs labeled or unlabeled nucleotide analogs as described herein. In some embodiments, the sequencing reaction employs a binding sequencing reaction as described herein. In some embodiments, step (e) includes pairwise sequencing, wherein 2 to 30 consecutive bases in the initial portion of read 2 (R2) are sequenced using unlabeled nucleotide analogs (e.g., dark sequencing).

[0397] In some embodiments, any of steps (a) to (e) of the method for rolling circle amplification of a plurality of covalently closed circular library molecules (600) may include applying a deamination reagent and / or a basic reagent to any of the covalently closed circular library molecules (600), thereby generating a plurality of covalently closed circular library molecules with reduced C:G to T:A base transitions, which can generate higher quality base interpretation during downstream sequencing workflows. In some embodiments, applying a deamination reagent and / or a basic reagent can increase the sequencing quality score from Q30 to Q40, Q45, Q50, Q55, Q60 or higher. In some embodiments, applying a deamination reagent and / or a basic reagent to a nucleic acid manipulation workflow can achieve a sequencing quality score of approximately 80% to 90%, or approximately 90% to 95%, or approximately 95% to 100% of Q40. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid handling workflow can achieve a sequencing quality score Q45 of about 75% to 85%, or about 85% to 90%, or about 90% to 95%, or about 95% to 100%. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid handling workflow can achieve a sequencing quality score Q50 of about 65% to 75%, or about 75% to 85%, or about 85% to 95%, or about 95% to 100%. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid handling workflow can achieve a sequencing quality score Q55 of about 60% to 70%, or about 70% to 80%, or about 80% to 85%, or about 85% to 90%, or about 90% to 100%. In some embodiments, applying deamination reagents and / or basic reagents to a nucleic acid manipulation workflow can achieve sequencing quality scores (Q60) of approximately 60% to 70%, approximately 70% to 80%, approximately 80% to 85%, approximately 85% to 90%, or approximately 90% to 100%. See, for example, [link to documentation]. Figure 65 , Figure 66 , Figures 67A to 67D , Figures 68A to 68D , Figure 69 and Figure 70 , and see Figure 73 Tables A and B are located at [location].

[0398] In some embodiments, in step (c), the plurality of newly generated nucleic acid multiply template molecules and their homologous covalently closed circular library molecules (600) may be distributed onto a support coated with one or more compounds to create a passivation layer on the support (e.g., Figure 1In some embodiments, the passivation layer forms a porous or semi-porous layer. In some embodiments, the first surface primer and / or the second surface primer, the nucleic acid multiplicon template molecule and / or the polymerase may be attached to the passivation layer to immobilize it to the support. In some embodiments, the support includes a low nonspecific binding surface that can improve the nucleic acid hybridization and amplification performance on the support. Generally, the support may include one or more covalently or non-covalently attached low-binding chemical modification layers, such as silane layers, polymer films, and one or more covalently or non-covalently attached oligonucleotides for immobilizing multiple nucleic acid multiplicon template molecules to the support. In some embodiments, the support may include a functionalized polymer coating covalently bound to at least a portion of the support via chemical groups on the support, primers grafted to the functionalized polymer coating, and a water-soluble protective coating on the primers and the functionalized polymer coating. In some embodiments, the functionalized polymer coating comprises poly(N-(5-azidoacetamidopentyl)acrylamide-co-acrylamide (PAZAM). In some embodiments, the support comprises a surface coating having at least one hydrophilic polymer coating and at least one layer of multiple oligonucleotides. The hydrophilic polymer coating may comprise polyethylene glycol (PEG). The hydrophilic polymer coating may comprise branched PEG having at least four branches. In some embodiments, the low nonspecific binding coating has a degree of hydrophilicity, which can be measured as a water contact angle, wherein the water contact angle does not exceed 45 degrees. In some embodiments, the density of newly generated polynucleotide molecules attached to or attached to the support is about 10. 2 Up to 10 6 / mm 2 or about 10 6 Up to 10 9 / mm 2 or about 10 9 Up to 10 12 / mm 2 In some embodiments, the plurality of newly formed polymolecules are fixed to the support or the coating on the support at predetermined sites on the support (or the coating on the support); or fixed to the coating on the support at random sites on the support (or the coating on the support).

[0399] In some embodiments, the distribution in step (c) may be performed in the presence of a high-efficiency hybridization buffer comprising: (i) a first polar aprotic solvent having a dielectric constant of not more than 40 and a polarity index of 4 to 9; (ii) a second polar aprotic solvent having a dielectric constant of not more than 115 and present in the hybridization buffer formulation in an amount capable of effectively denaturing double-stranded nucleic acids; (iii) a pH buffer system that maintains the pH of the hybridization buffer formulation in the range of about 4 to 8; and (iv) a crowding agent in an amount sufficient to enhance or promote molecular crowding. In some embodiments, the high-efficiency hybridization buffer comprises: (i) a first polar aprotic solvent comprising acetonitrile at 25% to 50% by volume of the hybridization buffer; (ii) a second polar aprotic solvent comprising formamide at 5% to 10% by volume of the hybridization buffer; (iii) a pH buffer system comprising 2-(N-morpholino)ethanesulfonic acid (MES) at a pH of 5 to 6.5; and (iv) a congesting agent comprising polyethylene glycol (PEG) at 5% to 35% by volume of the hybridization buffer. In some embodiments, the high-efficiency hybridization buffer further comprises betaine.

[0400] In some embodiments, in step (c), the plurality of third surface primers (e.g., capture primers) immobilized on the support comprise the sequence 5'-GATCAGGTGAGGCTGCGACGACT-3' (SEQ ID NO: 39) (or its complementary sequence). Each third surface primer (e.g., capture primer) may hybridize with a covalently closed circular library molecule (600) having a second splint chain region (400) comprising a universal binding sequence for the third surface primer, wherein the universal binding sequence for the third surface primer comprises a second subregion comprising the sequence 5'-AGTCGTCGCAGCCTCACCTGATC-3' (SEQ ID NO: 31) (or its complementary sequence).

[0401] In some embodiments, in step (c), the plurality of third surface primers (e.g., capture primers) fixed to the support contain the sequence 5'-CAAGCAGAAGACGGCATACGA-3' (SEQ ID NO: 36) (or its complementary sequence).

[0402] In some embodiments, in step (c), the plurality of fourth surface primers (e.g., stapled primers) fixed to the support comprise the sequence 5'-CATGTAATGCACGTACTTTCAGGGT-3' (SEQ ID NO: 30) (or its complementary sequence). In some embodiments, in step (c), the plurality of fourth surface primers (e.g., stapled primers) fixed to the support comprise the sequence 5'-AATGCACGTACTTTCAGGGT-3' (SEQ ID NO: 56) (or its complementary sequence). Each fourth surface primer (e.g., stapled primer) may hybridize with a portion of a multiply molecule having a second splint chain region (400) comprising a universal binding sequence (or its complementary sequence) for the fourth surface primer, wherein the universal binding sequence for the fourth surface primer comprises a first subregion comprising the sequence 5'-CATGTAATGCACGTACTTTCAGGGT-3' (SEQ ID NO: 30).

[0403] In some embodiments, in step (c), the plurality of fourth surface primers (e.g., stapled primers) fixed to the support contain the sequence 5'-AATGATACGGCGACCACCGA-3' (SEQ ID NO: 34 or its complementary sequence).

[0404] Reagent kit including double-stranded splint connector

[0405] In some aspects, this disclosure provides a kit for introducing one or more novel adapter sequences into a linear nucleic acid library molecule using any of the double-stranded clip adapters described herein. In some embodiments, the kit can be used to circularize a single-stranded nucleic acid library molecule having a target sequence (110) flanked by universal adapter sequences (e.g., see...). Figure 15 In some embodiments, the cyclized library molecule can be converted into a covalently closed cyclic molecule (e.g., Figures 15 to 16 This can undergo rolling circle amplification (RCA) to generate nucleic acid polymers. The polymers can be immobilized onto supports for massively parallel sequencing.

[0406] This disclosure provides a kit comprising a double-stranded nucleic acid splint adaptor (200), comprising: (i) a first splint strand (long splint strand (300)) hybridized with (ii) a second splint strand (short splint strand (400)). The first splint strand comprises a first region (320), an inner region (310), and a second region (330). The inner region (310) of the first splint strand hybridizes with the second splint strand (400) to form a double-stranded splint adaptor (200) having a double-stranded region and two side-attached single-stranded regions. The second splint strand (400) comprises a novel adaptor sequence for incorporating linear nucleic acid library molecules. An exemplary double-stranded splint adaptor is described in... Figure 15 and Figure 17 As shown in the diagram. The kit may include a container containing a first splint chain (300) hybridizing with a second splint chain (400). The kit may include a first container containing the first splint chain (300) and a second container containing the second splint chain (400).

[0407] In some embodiments, in the kit, the second splint chain (400) comprises at least two sub-regions, including a first sub-region and a second sub-region (e.g., see...). Figure 15 and Figure 17 The first subregion contains a universal binding sequence for the third surface primer, and the second subregion contains a universal binding sequence for the fourth surface primer, wherein the first and second subregions do not hybridize with the first and second surface primers (or at least show very little hybridization). In some embodiments, the second splint chain (400) further includes an optional third subregion containing a sample index sequence having 5 to 20 bases and / or a unique identification sequence (180) having 2 to 10 or more bases (e.g., NN) (e.g., see [link to relevant documentation]). Figure 15 In some embodiments, the second splint chain (400) contains only one subregion and lacks a second and third subregion, wherein the first subregion contains a sample index sequence having 5 to 20 bases. In some embodiments, the sample index sequence can be used to distinguish target sequences obtained from different sample sources in multiple assays. In some embodiments, the unique identification sequence contains a random sequence. The unique identification sequence may be designed to exhibit reduced or no hybridization with the first, second, third, and fourth surface primers. An exemplary arrangement of the subregions in the second splint chain (400) in the 5' to 3' direction includes: 5'-[second subregion]–[first subregion]–3'. Another exemplary arrangement of the subregions in the second splint chain (400) in the 5' to 3' direction includes: 5'-[third subregion]–[second subregion]–[first subregion]–3'. An exemplary first splint chain (300) and second splint chain (400) in Figure 15 and Figure 17As shown in the figure. In some embodiments, the second splint chain (400) may be 20 to 100 nucleotides long, or 30 to 80 nucleotides long, or 40 to 60 nucleotides long.

[0408] In some embodiments, in the kit, the second splint chain (400) includes one or more thiophosphate bonds at the 5' end and / or 3' end to confer exonuclease resistance. In some embodiments, the second splint chain (400) includes one or more thiophosphate bonds at an internal location to confer endonuclease resistance. In some embodiments, the second splint chain (400) includes one or more 2'-O-methylcytosine bases at the 5' end and / or 3' end or at an internal location. In some embodiments, the 5' end of the second splint chain (400) is phosphorylated or non-phosphorylated. In some embodiments, the 3' end of the second splint chain (400) includes a terminal 3' OH group or a terminal 3' blocking group.

[0409] In some embodiments, in the kit, the first splint chain (300) comprises a first region (320), a second region (330), and an inner region (310). The first region (320) comprises a first universal adaptor sequence that is hybridizable to a first universal binding sequence located at one end of a linear nucleic acid library molecule (e.g., Figure 15 The second region (330) contains a second universal adaptor sequence that can hybridize with a second universal binding sequence located at the other end of the linear nucleic acid library molecule (e.g., Figure 15In some embodiments, the first region (320) of the first splint chain includes a first universal adaptor sequence comprising a universal binding sequence for a forward or reverse sequencing primer, a universal binding sequence for a first or second surface primer, a universal binding sequence for a forward or reverse amplification primer, or a universal binding sequence for a compressed oligonucleotide. In some embodiments, the second region (330) of the first splint chain includes a second universal adaptor sequence comprising a universal binding sequence for a forward or reverse sequencing primer, a universal binding sequence for a first or second surface primer, a universal binding sequence for a forward or reverse amplification primer, or a universal binding sequence for a compressed oligonucleotide. In some embodiments, the first splint chain (300) may be 50 to 150 nucleotides long, 60 to 100 nucleotides long, or 70 to 90 nucleotides long. In some embodiments, the first splint chain (300) includes one or more phosphate thioester bonds at the 5' end and / or the 3' end to confer exonuclease resistance. In some embodiments, the first splint chain (300) contains one or more phosphate thioester bonds at an internal location to confer endonuclease resistance. In some embodiments, the first splint chain (300) contains one or more 2'-O-methylcytosine bases at the 5' end and / or the 3' end or at an internal location. In some embodiments, the 5' end of the first splint chain (300) is phosphorylated or non-phosphorylated. In some embodiments, the 3' end of the first splint chain (300) contains a terminal 3' OH group or a terminal 3' blocking group.

[0410] In some embodiments, in the kit, the first clamp chain (300) includes an inner region (310) containing at least two sub-regions, including a fourth and a fifth sub-region (e.g., Figure 15 and Figure 17 The fourth subregion hybridizes with the first subregion of the second splint chain (400). The fifth subregion hybridizes with the second subregion of the second splint chain (400). The fourth and fifth subregions do not hybridize with the first and second surface primers (or at least show very little hybridization). In some embodiments, the inner region (310) of the first splint chain further includes an optional sixth subregion that hybridizes with the third subregion of the second splint chain (400). An exemplary arrangement of the subregions of the first splint chain (300) in the 5' to 3' direction includes: 3' – [fourth subregion] – [fifth subregion] – 5'. Another exemplary arrangement of the subregions of the first splint chain (300) in the 5' to 3' direction includes: 3' – [fourth subregion] – [fifth subregion] – [sixth subregion] – 5'.

[0411] In some embodiments, the kit includes a plurality of first splint chains (300) having a first region (320) capable of hybridizing to one end of a linear library molecule, the linear library molecule containing a universal adaptor sequence (120) having a binding sequence for a first surface primer (see, for example, see...). Figure 15 The above lists an exemplary sequence of a universal linker sequence (120) having a binding sequence for the first surface primer.

[0412] In some embodiments, the kit includes a plurality of first splint chains (300) having a second region (330) capable of hybridizing to the other end of the same linear library molecule, the linear library molecule containing a universal adaptor sequence (130) having a binding sequence for a second surface primer (see, for example, see...). Figure 15 The above lists an exemplary sequence of a universal linker sequence (130) having a binding sequence for the second surface primer.

[0413] In some embodiments, the kit includes a plurality of second splint chains (400) having a first subregion containing a universal binding sequence for a third surface primer (e.g., a universal binding sequence for a surface capture primer). Figure 15 ).

[0414] In some embodiments, the kit includes a plurality of second splint chains (400) having a second subregion containing a universal binding sequence for a fourth surface primer (e.g., a universal binding sequence for a surface-stapled primer). Figure 15 The above lists exemplary sequences of the first and second sub-regions of the second clamp chain (400).

[0415] In some embodiments, the sequence of the first clamping chain (300) and the sequence of the second clamping chain (400) are in Figure 17 As shown in the image.

[0416] Methods for forming multiple cyclic library molecules

[0417] Use a single-chain clamp chain

[0418] In some aspects, this disclosure provides compositions and methods for improving sequencing quality scores, comprising preparing a plurality of linear library molecules using any of the methods described herein and circularizing the linear library molecules. In some embodiments, a plurality of covalently closed circularized library molecules can be generated by hybridizing the plurality of linear library molecules with a plurality of single-stranded splint chains as described herein. In some embodiments, the covalently closed circularized library molecules can be amplified by rolling circle amplification. In some embodiments, rolling circle amplification can be performed on a support, or in solution and on a support. Exemplary, non-limiting single-stranded splint chains and double-stranded splint connectors, and related methods, are described in WO 2023 / 168444, the contents of which are incorporated herein by reference in their entirety.

[0419] In some embodiments, a method for generating a plurality of covalently closed circular library molecules includes step (a): providing a plurality of library molecules (700), wherein each library molecule (700) comprises: (i) a universal adaptor sequence (720) having a binding sequence for a second surface primer (e.g., a stapled primer); (ii) a left sample index sequence (760); (iii) a universal adaptor sequence (740) having a binding sequence for a first sequencing primer (e.g., a reverse sequencing primer); (iv) a target sequence (710); (v) a universal adaptor sequence (750) having a binding sequence for a second sequencing primer (e.g., a forward sequencing primer); (vi) a right sample index sequence (770); and (vii) a universal adaptor sequence (730) having a binding sequence for a first surface primer (e.g., a capture primer) (e.g., Figures 18 to 19 In some embodiments, any of the universal adaptor sequences (including (720), (740), (750), or (730)) may hybridize with a portion of the compressed oligonucleotide. In some embodiments, the single-stranded library molecule further includes a unique identification sequence (780) comprising a sequence segment used to uniquely identify, within a population of other target molecular sequences (e.g., molecular identifiers), each to which the unique identification sequence (780) is attached. In some embodiments, the unique identification sequence (780) may be located to the left or right of the insertion region. In some embodiments, the unique identification sequence comprises 2 to 12 or more nucleotides having known sequences. For example, the unique identification sequence includes a known random sequence, wherein the nucleotides at each position are randomly selected from nucleotides having bases A, G, C, T, or U. The unique identification sequence (780) may be used in a molecular identification procedure.

[0420] In some embodiments, the method for generating a plurality of covalently closed circular library molecules further includes step (b): hybridizing a plurality of single-stranded splint chains (800) with a plurality of library molecules (700), wherein each of the plurality of single-stranded splint chains (800) comprises: (i) a first region (810) capable of hybridizing with a universal linker sequence (720) of each library molecule, and (ii) a second region (820) capable of hybridizing with a universal linker sequence (730) of each library molecule. In some embodiments, the 5' end of the single-stranded splint chain (800) is phosphorylated or lacks a phosphate ester group. In some embodiments, the 3' end of the single-stranded splint chain (800) comprises a 3' end OH group or a 3' end blocking group. An exemplary single-stranded splint chain (800) in Figures 18 to 19 As shown in the figure. In some embodiments, the single-stranded splint chain (800) may be 20 to 150 nucleotides long, or 60 to 100 nucleotides long, or 70 to 90 nucleotides long, or 60 to 80 nucleotides long.

[0421] In some embodiments, the hybridization in step (b) is performed under conditions suitable for hybridizing the first region (810) of the single-stranded splint chain with a universal adaptor sequence (720) having a binding sequence for a second surface primer (e.g., a stapled primer) targeting the library molecule, and these conditions are suitable for hybridizing the second region (820) of the single-stranded splint chain with a universal adaptor sequence (730) having a binding sequence for a first surface primer (e.g., a capture primer) targeting the library molecule, thereby circularizing the plurality of library molecules to form a plurality of library-splice complexes (900) with a nick (e.g., Figure 18 In some embodiments, the library-splice complex (900) includes a cut between the 5' and 3' ends of the library molecule (e.g., Figures 18 to 19 In some embodiments, the incision is enzymatically fused.

[0422] In some embodiments, in step (b), the first region (810) of the single-stranded splint chain may hybridize with the sense or antisense strand of the double-stranded library molecule (700). In some embodiments, the second region (820) of the single-stranded splint chain may hybridize with the sense or antisense strand of the double-stranded library molecule (700). The double-stranded library molecule may be denatured to generate single-stranded sense and antisense library chains. In some embodiments, the double-stranded library molecule may be denatured using heat or an alkaline reagent (e.g., NaOH or KOH) to generate sense and antisense library chains.

[0423] In some embodiments, in step (b), the first region (810) of the single-stranded cladding chain does not hybridize with the target sequence (710), and the second region (820) of the single-stranded cladding chain does not hybridize with the target sequence (710).

[0424] In some embodiments, in step (b), the sample index sequences (760) and (770) can be used to distinguish target sequences obtained from different sample sources in a multi-process workflow. In some embodiments, the left index sequence (760) may include a random sequence (e.g., NNN) or lack a random sequence. In some embodiments, the right index sequence (770) may include a random sequence (e.g., NNN) or lack a random sequence. The left sample index sequence (760) may be 3 to 20 nucleotides in length. The right sample index sequence (770) may be 3 to 20 nucleotides in length. The sequences of the left and right sample index sequences (e.g., (760) and (770)) may be the same as or different from each other.

[0425] A multiplexing workflow can be initiated by preparing sample-indexed libraries using one or two sample index sequences (e.g., a left sample index sequence and / or a right sample index sequence). Individual sample-indexed libraries can be prepared using the left index sequence (760) and / or the right index sequence (770) with input nucleic acids isolated from different sources. Sample-indexed libraries can be pooled together to generate a multiplex library mixture, and the pooled libraries can be amplified and / or sequenced. The sequence of the insert region, along with the left index sequence (760) and / or the right index sequence (770), can be used to identify the origin of the input nucleic acid. In some embodiments, any number of sample-indexed libraries can be pooled together, for example, 2 to 10, or 10 to 50, or 50 to 100, or 100 to 200, or more than 200 sample-indexed libraries can be pooled. Exemplary nucleic acid sources include naturally occurring, recombinant, or chemically synthesized sources. Exemplary nucleic acid sources include single cells, multiple cells, tissues, biological fluids, environmental samples, or whole organisms. Exemplary sources of nucleic acids include fresh, frozen, fresh-frozen, or archived sources (e.g., formalin-fixed paraffin-embedded; FFPE). Those skilled in the art will recognize that nucleic acids can be isolated from many other sources. Nucleic acid libraries can be prepared in single-stranded or double-stranded form.

[0426] In some embodiments, in step (b), the single-stranded splint chain (800) contains one or more thiophosphate bonds at its 5' end and / or 3' end to confer exonuclease resistance. In some embodiments, the single-stranded splint chain (800) contains one or more thiophosphate bonds at an internal location to confer endonuclease resistance. In some embodiments, the single-stranded splint chain (800) contains one or more 2'-O-methylcytosine bases at its 5' end and / or 3' end or at an internal location. In some embodiments, the 5' end of the single-stranded splint chain (800) is phosphorylated or unphosphorylated. In some embodiments, the 3' end of the single-stranded splint chain (800) contains a 3' OH group or a 3' blocking group.

[0427] In some embodiments, the plurality of library-sandwich complexes (900) formed in step (b) may be subjected to at least one enzymatic reaction, including phosphorylation, ligation, and / or exonuclease reaction. The enzymatic reactions may be performed sequentially or substantially simultaneously. The enzymatic reactions may be performed in a single reaction vessel. Alternatively, the first enzymatic reaction may be performed in a first reaction vessel, then transferred to a second reaction vessel for a second enzymatic reaction, and then to a third reaction vessel for a third enzymatic reaction.

[0428] In some embodiments, any of the methods for forming the plurality of library-sandwich complexes (900) described herein further includes performing separate and sequential phosphorylation and ligation reactions in separate reaction vessels. In some embodiments, the method for forming the plurality of library-sandwich complexes (900) further includes step (c1): contacting the plurality of single-stranded sandwich chains (800) and the plurality of single-stranded nucleic acid library molecules (700) with T4 polynucleotide kinase in a first reaction vessel under conditions suitable for phosphorylating the 5' ends of the plurality of single-stranded sandwich chains (800) and / or the plurality of single-stranded nucleic acid library molecules (700); and transferring the phosphorylation reaction to a second reaction vessel. In some embodiments, the method for forming a plurality of library-sandwich complexes (900) further includes step (d1): in a second reaction vessel, under conditions suitable for enzymatic ligation nicks, contacting a plurality of phosphorylated single-stranded sandwich strands (800) and a plurality of phosphorylated single-stranded nucleic acid library molecules (700) with a ligase, thereby generating a plurality of covalently closed circular library molecules (1000), each hybridized to a single-stranded sandwich strand (800). In some embodiments, the ligase includes T7 DNA ligase, T3 ligase, T4 ligase, or Taq ligase.

[0429] In some embodiments, any of the methods for forming the plurality of library-splice complexes (900) described herein further comprises performing sequential phosphorylation and ligation reactions, which are carried out sequentially in the same reaction vessel. In some embodiments, the method for forming the plurality of library-splice complexes (900) further comprises step (c2): in a first reaction vessel, contacting the plurality of single-stranded splint chains (800) and the plurality of single-stranded nucleic acid library molecules (700) with T4 polynucleotide kinase under conditions suitable for phosphorylation of the 5' ends of the plurality of single-stranded splint chains (800) and the plurality of single-stranded nucleic acid library molecules (700). In some embodiments, the method for forming the plurality of library-splice complexes (900) further comprises step (d2): in the same first reaction vessel, contacting the phosphorylated single-stranded splint chains (800) and the phosphorylated single-stranded nucleic acid library molecules (700) with a ligase under conditions suitable for enzymatic ligation nicks, thereby producing a plurality of covalently closed circular library molecules (1000), each hybridized with a single-stranded splint chain (800). In some embodiments, the ligase includes T7 DNA ligase, T3 ligase, T4 ligase, or Taq ligase.

[0430] In some embodiments, any of the methods for forming the plurality of library-sandwich complexes (900) described herein further comprises performing substantially simultaneous phosphorylation and ligation reactions together in the same reaction vessel. In some embodiments, the method for forming the plurality of library-sandwich complexes (900) further comprises step (c3): under conditions suitable for phosphorylating the 5' ends of the plurality of single-stranded sandwich strands (800) and the plurality of single-stranded nucleic acid library molecules (700), and conditions suitable for enzymatic ligation nicks, in a first reaction vessel, contacting the plurality of single-stranded sandwich strands (800) and the plurality of single-stranded nucleic acid library molecules (700) with (i) a T4 polynucleotide kinase and (ii) a ligase, thereby producing a plurality of covalently closed circular library molecules (1000), each hybridized to the single-stranded sandwich strand (800). In some embodiments, the ligase comprises a T7 DNA ligase, a T3 ligase, a T4 ligase, or a Taq ligase.

[0431] In some embodiments, in any of steps (c1)(d1), (c2)(d2), or (c3), the completion of the phosphorylation and linkage reaction generates a plurality of covalently closed cyclic library molecules (1000) (e.g., Figure 19In some embodiments, the ligase may be inactivated using heat or an alkaline reagent after the ligase reaction is complete. In some embodiments, ligase inactivation includes contacting the ligase with an alkaline reagent. In some embodiments, the alkaline reagent includes NaOH and / or KOH. In some embodiments, the ligase is not inactivated using heat. In some embodiments, a plurality of covalently closed circular library molecules (1000) are retained. In some embodiments, inactivation of the ligase with an alkaline reagent reduces the formation of deaminated nucleotide bases in the plurality of covalently closed circular library molecules (1000) compared to heat-inactivated covalently closed circular library molecules.

[0432] In some embodiments, any of the methods for forming the plurality of library-sandwich complexes (900) described herein further includes the optional step of enzymatically removing a plurality of single-stranded sandwich chains (800) from a plurality of covalently closed circular library molecules (1000), which includes the optional step (e): contacting the plurality of covalently closed circular library molecules (1000) with at least one exonuclease to remove the plurality of single-stranded sandwich chains (800) and retain the plurality of covalently closed circular library molecules (1000). In some embodiments, the exonuclease reaction may be performed in the same reaction buffer used for phosphorylation and / or ligation reactions, or in different reaction buffers. In some embodiments, the exonuclease reaction may be performed in a third reaction container after phosphorylation (step c1, see above) in a first reaction container and ligation (step d1, see above) in a second reaction container. In some embodiments, a phosphorylation reaction (step c2, see above) and a sequential ligation reaction (step d2, see above) may be performed in the first reaction vessel, followed by an exonuclease reaction in the fi...

Claims

1. A method for reducing the number of nucleic acid library molecules carrying at least one deaminonucleotide base in a plurality of library molecules, the method comprising: a) Provide a plurality of clip-on trapping primers fixed to a support, wherein each clip-on trapping primer comprises a first portion and a second portion, wherein the plurality of clip-on trapping primers have the same sequence, and wherein the density of the plurality of clip-on trapping primers is 10. 2 Up to 10 15 / mm 2 between; b) Contact the plurality of clamp-on trapping primers with a plurality of linear nucleic acid libraries comprising a first subgroup and a second subgroup of linear library molecules, wherein the linear library molecules of the first subgroup carry at least one deaminated nucleotide base, and wherein the linear library molecules of the second subgroup lack deaminated bases, and wherein each of the plurality of library molecules is single-stranded and comprises: (i) A universal linker sequence having a binding sequence for the first part of a given clip-capture primer. (ii) It has a universal adaptor sequence that binds to the binding sequence of forward sequencing primers. (iii) Target sequence, (iv) Possesses a universal adaptor sequence that binds to reverse sequencing primers. (v) Possesses a universal adaptor sequence for binding sequences to compressed oligonucleotides, and (vi) A universal linker sequence having a binding sequence for the second part of the primer that captures the same given clip; The contact is performed under conditions suitable for generating a plurality of fixed open-ring libraries from the linear library molecule, wherein each fixed open-ring library molecule contains a nick between the 5' and 3' ends of the respective library molecule, wherein the nick is enzymatically ligated, and wherein each fixed open-ring library molecule contains a first portion of a clip-capture primer and a second portion of the same clip-capture primer, the first portion hybridizing with a universal adaptor sequence having a binding sequence for the first portion of the clip-capture primer, and the second portion hybridizing with a universal adaptor sequence having a binding sequence for the second portion of the clip-capture primer, wherein the plurality of fixed open-ring libraries comprises a first subgroup and a second subgroup, the first subgroup comprising fixed open-ring libraries having at least one deaminated base, and the second subgroup comprising fixed open-ring libraries lacking a deaminated base; c) Contact the plurality of fixed open-loop library molecules with a ligase to generate a plurality of fixed covalently closed circular library molecules, wherein each covalently closed circular library molecule hybridizes with a fixed clip-on capture primer. d) Contact the plurality of fixed covalently closed cyclic library molecules with a deamination reagent, the deamination reagent comprising: (vii)(i) at least one enzyme with glycosylation activity, which generates one or more base-free sites in a covalently closed circular library molecule, and (ii) at least one enzyme having lysinic activity, which releases the base-free site One or more gaps are generated in the covalently closed cyclic library molecules, thereby generating a first subgroup of fixed covalently closed cyclic library molecules carrying one or more gaps and a second subgroup of fixed covalently closed cyclic library molecules having complete covalently closed cyclic library molecules. This generates a plurality of fixed linearized library molecules from the second subgroup of fixed covalently closed cyclic library molecules, while retaining the second subgroup of fixed covalently closed cyclic library molecules having complete covalently closed cyclic library molecules. This reduces the number of nucleic acid library molecules that carry at least one deaminonucleotide base in multiple library molecules.

2. The method according to claim 1, further comprising (e) contacting the plurality of immobilized covalently closed circular library molecules with rolling circle amplification reagent to generate a plurality of immobilized nucleic acid multiply template molecules immobilized to the support.

3. The method according to claim 1 or 2, further comprising (f) sequencing the plurality of fixed nucleic acid multiply template molecules to determine the sequence of at least a portion of the fixed nucleic acid multiply template molecules.

4. The method of claim 3, wherein the sequencing in step (f) comprises performing pairwise sequencing, which includes: Sequencing of the multiple fixed multiply template molecules generates multiple first-strand reads (R1). Multiple second multiply molecules are generated by replacing the plurality of fixed multiply molecules through a primer extension reaction, each second multiply chain having a sequence complementary to the sequence of the fixed multiply template molecule. The plurality of fixed polyp template molecules are removed while the plurality of second polyp strands are retained; and the plurality of second polyp strands are sequenced to generate a plurality of second strand reads (R2).

5. The method of claim 4, wherein sequencing the plurality of second multiply strands comprises dark sequencing using a plurality of reverse sequencing primers, a plurality of unlabeled nucleotide reagents and a plurality of sequencing polymerases, wherein the unlabeled nucleotide reagents may be incorporated into the 3' end of the reverse sequencing primers, thereby extending the reverse sequencing primers, and wherein the incorporation of the unlabeled nucleotide reagents is not detected.

6. The method of claim 5, wherein the dark sequencing is performed for 2 to 30 consecutive cycles.

7. The method according to any one of claims 4 to 6, wherein sequencing the plurality of second multiply strands comprises dark sequencing of the initial portion of the second multiply strand for 2 to 30 consecutive sequencing cycles.

8. The method according to any one of claims 1 to 7, wherein the at least one enzyme having glycosylation activity comprises any one or any combination of the following: formamidopyrimidine DNA glycosylation enzyme (fpg); uracil N-glycosylation enzyme (UNG); uracil DNA glycosylation enzyme (UDG); 8-oxoguanine glycosylation enzyme (OGG, including thermostable OGG); DNA (purine-free) lyase; DNA (pyrimidine-free) lyase; and / or endonuclease III.

9. The method according to any one of claims 1 to 8, wherein the at least one enzyme having lysin activity comprises any one or any combination of the following: AP lyase, Endo IV endonuclease, FPG glycosylation enzyme / AP lyase (formamidopyrimidine DNA glycosylation enzyme), endonuclease VIII glycosylation enzyme / AP lyase and / or endonuclease III.

10. The method according to any one of claims 2 to 9, wherein the rolling circle amplification reagent in step (e) comprises a chain displacement polymerase and a plurality of nucleotides, said plurality of nucleotides including dATP, dGTP, dCTP, dTTP and dUTP.

11. The method of claim 10, wherein the rolling circle amplification reagent generates a plurality of fixed polymers carrying at least one uracil.

12. The method of claim 11, wherein the at least one uracil is distributed at random positions along the plurality of fixed polymolecules.

13. The method according to any one of claims 2 to 12, wherein the rolling circle amplification reagent in step (e) comprises a plurality of compressed oligonucleotides, wherein each compressed oligonucleotide contains a 5' region and a 3' region, and wherein the 5' and 3' regions of a given compressed oligonucleotide are hybridizable to binding sites in a given fixed nucleic acid multiply template molecule to pull together the distal portions of the given fixed nucleic acid multiply template molecule, thereby causing compression of the fixed nucleic acid multiply template molecule to form DNA nanospheres.

14. The method of claim 13, wherein each compressed oligonucleotide is contained in an inner region between the 5' region and the 3' region.

15. The method according to any one of claims 3 to 14, wherein sequencing the plurality of fixed nucleic acid polymorph template molecules comprises: a) Contacting the plurality of immobilized nucleic acid multiply template molecules with (i) a plurality of sequencing polymerases and (ii) a plurality of soluble sequencing primers, wherein the contact is performed under conditions suitable for forming a plurality of complex sequencing polymerases, each complex sequencing polymerase comprising a sequencing polymerase that binds to a nucleic acid duplex, wherein the nucleic acid duplex comprises an immobilized nucleic acid multiply template molecule, the immobilized nucleic acid multiply template molecule hybridizing with soluble sequencing primers, thereby providing hybridization sequencing primers; b) Contact the plurality of complex sequencing polymerases with a plurality of nucleotides under conditions suitable for binding at least one nucleotide to the complex sequencing polymerases, wherein the plurality of nucleotides includes at least one nucleotide analog labeled with a fluorophore and having a removable chain termination portion at the sugar 3' position. c) Incorporate at least one nucleotide into the 3' end of the hybridized sequencing primer, thereby generating a plurality of newly formed extended sequencing primers; as well as d) Detect the incorporated nucleotides and identify the nucleobases of the incorporated nucleotides. The identification of the nucleobases mentioned therein includes base interpretation.

16. The method of claim 15, wherein each of the plurality of nucleotides comprises a removable chain termination portion at a 3' sugar group, optionally wherein the removable chain termination portion comprises an alkyl group, an alkenyl group, an alkynyl group, an allyl group, an aryl group, a benzyl group, an azide group, an azidoyl group, an O-azidomethyl group, an amine group, an amide group, a ketone group, an isocyanate group, a phosphate group, a thio group, a disulfide group, a carbonate group, a urea group, an acetal group, or a silyl group, and wherein the removable chain termination portion can be cleaved with a chemical compound to generate an extendable 3'OH moiety on the sugar group.

17. The method of claim 15 or 16, wherein the plurality of nucleotides comprises a type of nucleotide selected from the group consisting of dATP, dGTP, dCTP, dTTP, and dUTP.

18. The method of claim 15 or 16, wherein the plurality of nucleotides comprises a mixture of any two or more types of nucleotides selected from the group consisting of dATP, dGTP, dCTP, dTTP, and dUTP.

19. The method according to any one of claims 3 to 14, wherein sequencing the plurality of fixed nucleic acid polymorph template molecules comprises: a) Contact the plurality of immobilized nucleic acid multiply template molecules with (i) a plurality of sequencing polymerases and (ii) a plurality of soluble sequencing primers, wherein the contact is performed under conditions suitable for forming a plurality of first complex sequencing polymerases, each of the first complex sequencing polymerases comprising a sequencing polymerase that binds to a nucleic acid duplex, wherein the nucleic acid duplex comprises an immobilized nucleic acid multiply molecule that has hybridized with the soluble sequencing primers. b) Under conditions suitable for binding the complementary nucleotide portion of the multivalent molecule to at least two of the plurality of first complex sequencing polymerases, the plurality of first complex sequencing polymerases are contacted with a plurality of detectably labeled multivalent molecules to form a plurality of multivalent complex polymerases, thereby forming a plurality of multivalent complex polymerases, wherein the suitable conditions inhibit the incorporation of the complementary nucleotide portion into the soluble sequencing primers of the plurality of multivalent complex polymerases, wherein each of the plurality of multivalent molecules comprises a core attached to a plurality of nucleotide arms, and each nucleotide arm is attached to a nucleotide portion; c) Detect the plurality of multivalent complex polymerases; as well as d) Identify the nucleobases of the complementary nucleotide moieties that bind to the plurality of first complex sequencing polymerases among the plurality of multivalent complex polymerases, thereby determining the sequence of the nucleic acid template. The identification of the nucleobases mentioned therein includes base interpretation.

20. The method of claim 19, further comprising: e) Dissociate the plurality of multivalent complex polymerases and remove the plurality of first sequencing polymerases and the multivalent molecules they bind, while retaining the plurality of nucleic acid duplexes; f) Contact the plurality of nucleic acid duplexes retained in step (e) with a plurality of second sequencing polymerases, wherein the contact is performed under conditions suitable for binding the plurality of second sequencing polymerases with the plurality of nucleic acid duplexes, thereby forming a plurality of second complex sequencing polymerases, each of the second complex sequencing polymerases containing a second sequencing polymerase bound to a nucleic acid duplex. g) Contacting the plurality of second complex sequencing polymerases with a plurality of nucleotides, the plurality of nucleotides comprising at least one unlabeled nucleotide analog having a removable chain termination portion at the 3' position of the sugar, wherein the contact is performed under conditions suitable for: i. Combining complementary nucleotides from the plurality of nucleotides with at least two of the second complex sequencing polymerases from step (f), thereby forming a plurality of nucleotide complex polymerases; and ii. To facilitate the incorporation of the bound complementary nucleotide into the sequencing primer of the nucleotide complex polymerase.

21. The method according to any one of claims 15 to 20, wherein the soluble sequencing primer comprises a soluble universal sequencing primer.

22. A method for sequencing by forming at least one affinity complex, comprising: a) A first universal sequencing primer, a first sequencing polymerase, and a first detectably labeled multivalent molecule are combined with a first portion of the immobilized nucleic acid multivalent template molecule generated by the method according to claim 19, thereby forming a first binding complex, wherein a first nucleotide portion of the first multivalent molecule is bound to the first sequencing polymerase. b) A second universal sequencing primer, a second sequencing polymerase, and the first detectably labeled multivalent molecule are bound to a second portion of the same immobilized nucleic acid multivalent template molecule, thereby forming a second binding complex, wherein the second nucleotide portion of the first multivalent molecule is bound to the second sequencing polymerase, wherein the first binding complex and the second binding complex bound to the same multivalent molecule form an affinity complex, wherein the first detectably labeled multivalent molecule comprises a core attached to a plurality of nucleotide arms, and each nucleotide arm is attached to a nucleotide portion, wherein the immobilized nucleic acid multivalent template molecule comprises two or more tandem repeat sequences of the target sequence (110) and universal primer binding sites for binding the first universal sequencing primer and the second universal sequencing primer, and wherein the contact is performed under conditions suitable for inhibiting polymerase-catalyzed incorporation of the first and second nucleotide portions bound in the first binding complex and the second binding complex; c) Detect the first and second binding complexes on the same fixed nucleic acid multiplex template molecule, and d) Identify the first nucleotide moiety in the first binding complex, thereby determining the sequence of the first portion of the immobilized multiply template molecule, and identify the second nucleotide moiety in the second binding complex, thereby determining the sequence of the second portion of the immobilized multiply template molecule. The identification of the first nucleotide portion and the identification of the second nucleotide portion include base interpretation.

23. The method of any one of claims 19 or 22, wherein the plurality of nucleotide arms attached to the core of the respective multivalent molecules have the same type of nucleotide moiety, and wherein the type of nucleotide moiety is selected from the group consisting of dATP, dGTP, dCTP, dTTP, and dUTP.

24. The method according to any one of claims 19 or 22, wherein the plurality of multivalent molecules comprises a mixture of any combination of two or more types of multivalent molecules, each type having a nucleotide moiety selected from the group consisting of dATP, dGTP, dCTP, dTTP, and dUTP.

25. The method according to any one of claims 15 to 18, wherein each nucleotide in the plurality of nucleotides comprises a removable chain termination portion at a 3' sugar group, wherein the removable chain termination portion comprises an alkyl group, an alkenyl group, an alkynyl group, an allyl group, an aryl group, a benzyl group, an azide group, an azidoyl group, an O-azidomethyl group, an amine group, an amide group, a ketone group, an isocyanate group, a phosphate group, a thio group, a disulfide group, a carbonate group, a urea group, or a silyl group, and wherein the removable chain termination portion can be cleaved with a chemical compound to generate an extendable 3'OH moiety on the sugar group.

26. The method according to any one of claims 15 to 18, wherein the plurality of nucleotides comprises a type of nucleotide selected from the group consisting of dATP, dGTP, dCTP, dTTP, and dUTP.

27. The method according to any one of claims 15 to 18, wherein the plurality of nucleotides comprises a mixture of any combination of two or more types of nucleotides selected from the group consisting of: dATP, dGTP, dCTP, dTTP, and dUTP.

28. The method according to any one of claims 1 to 27, wherein the support comprises a glass or plastic substrate.

29. The method according to any one of claims 1 to 28, wherein the support is passivated with at least one hydrophilic polymer coating having a water contact angle of not more than 45 degrees.

30. The method of claim 29, wherein the at least one hydrophilic polymer coating comprises molecules selected from the group consisting of: polyethylene glycol (PEG), poly(vinyl alcohol) (PVA), poly(vinylpyridine), poly(vinylpyrrolidone) (PVP), poly(acrylic acid) (PAA), polyacrylamide, poly(N-isopropylacrylamide) (PNIPAM), poly(methyl methacrylate) (PMA), poly(2-hydroxyethyl methacrylate) (PHEMA), poly(oligomeric (ethylene glycol) methyl ether methacrylate) (POEGMA), polyglutamic acid (PGA), polylysine, polyglucoside, streptavidin, and dextran.

31. The method according to any one of claims 1 to 30, wherein the plurality of fixed clamps capture primers are located at predetermined positions on the polymer-coated support.

32. The method according to any one of claims 1 to 30, wherein the plurality of fixed clamps trap primers are located at random positions on the polymer-coated support.

33. The method according to any one of claims 1 to 32, wherein the plurality of immobilized nucleic acid multiply template molecules on the support are in fluid communication with each other to allow the reagent solution to flow onto the support, such that the plurality of immobilized nucleic acid multiply template molecules can react with the reagent substantially simultaneously in a large-scale parallel manner.

34. The method of claim 33, wherein the reagent comprises one or more enzymes, nucleotides, divalent cations, or combinations thereof.

35. The method according to any one of claims 3 to 34, further comprising: The percentage of base misreadings is determined based on the sequencing described in step (f).

36. The method of claim 35, further comprising determining a quality score of the sequencing data based on the percentage of base misreadings.

37. The method of claim 36, wherein when a deamination agent is used in step (c), the quality score increases from Q30 to Q40 or Q50 compared to a method in which no deamination agent is used in step (c).

38. The method according to claim 36 or 37, wherein when a deamination agent is used in step (c), the quality score of the first chain read (R1) increases from Q30 to Q40 or Q50 compared to the same method without a deamination agent in step (c).

39. The method according to any one of claims 36 to 38, wherein when a deamination agent is used in step (c) compared to the same method without the use of a deamination agent, the quality score of the second chain reading segment (R2) increases from Q30 to Q40 or Q50.

Citation Information

Patent Citations

  • Method and system for sequencing nucleic acids

    US10246744B2

  • Engineered polymerases for improved sequencing

    US10731141B2

  • Engineered polymerases with reduced sequence-specific errors

    US11788075B2

  • Compositions and methods for pairwise sequencing

    US11859241B2

  • Compositions and methods for pairwise sequencing

    US20220403463A1